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Abstract 
In this study, we explore the molecular mechanisms linking amino acid (leucine) 
deprivation to IGFBP-1 hyperphosphorylation in vitro. During pregnancy, a maladaptive 
fetal response to in utero amino acid deprivation leads toFetal Growth Restriction (FGR). 
FGR infants display elevated phosphorylatedIGFBP-1, which is associated with 
decreased IGF-I bioavailability. Leucine deprivation inhibits mechanistic target of 
rapamycin (mTOR) signaling and stimulates the amino acid response (AAR). Using 
HepG2 cells, a model for fetal hepatocytes, we demonstrate that in leucine deprivation, 
the AAR modulates total and phosphorylated IGFBP-1 while mTOR mediates total 
IGFBP-1 secretion only. We also reveal that protein kinases CK2 and PKC mediate 
IGFBP-1 phosphorylation and subsequent IGF-I bioactivity in leucine deprivation. 
Together, our findings implicate fetal hepatic AAR and CK2 activation as key 
mechanistic links between amino acid deprivation and decreased IGF-I bioavailability in 
FGR and suggest a novel role for PKC in modulating IGFBP-1 phosphorylation in vitro. 
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1 Introduction 
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1.1 Fetal Growth Restriction (FGR) 
1.1.1 Definition, diagnosis and outcomes 
Fetal Growth Restriction (FGR) is a perigestational growth disorder whereby the fetus 
fails to achieve its full, genetically-determined growth potential, and is linked to an 
increased risk of neonatal death as well as several perinatal and adult morbidities1,2. 
Affecting 5-7% of pregnancies3, FGR infants are born under the 10th percentile birth-
weight expected for gestational age4, though some more stringent definitions classify 
FGR infants as those born under the 5th or 3rd percentiles5 of expected birth-weight. FGR 
infants are notoriously difficult to identify among small for gestational age (SGA) babies 
– a classification accorded to all neonates born under the 10th percentile expected birth-
weight, including those who are healthy and constitutively small due to factors such as 
ethnicity, sex, and body/mass index and those infants affected by other growth-restricting 
pathologies. In fact, 70% of SGA infants are at no increased risk for perinatal or adult 
morbidity6. There are presently no reliable tools for the diagnosis and management of 
FGR7 among SGA infants. Currently, likelihood of FGR onset is determined prenatally 
based on suspicion of maternal risk factors, followed by clinical assessments of various 
maternal aspects (e.g. maternal abdominal circumference, amniotic fluid volume, and 
estimated fetal weight) as well as sonographic screening of the fetus7,8. Uterine arterial 
Doppler velocimetry is a useful measure of placental function, as it indicates blood flow 
between the fetus and placenta9, and Doppler values of the umbilical artery, in addition to 
fetal heart rate, are useful in detecting the fetal cardiac manifestations of FGR7,10. 
However, clinically, these tools have been proven to be highly unreliable in consistently 
predicting FGR7, 9, 11 and therapeutic strategies against FGR have also been ineffective12.   
The importance of perigestational influences on the development of adult diseases is 
becoming increasingly recognized in a paradigm known as the “developmental origins of 
health and disease” or “fetal programming”13,14. Indeed, FGR is associated with perinatal 
mortality and morbidity1,15 as well as severe adult neurological, metabolic, and 
cardiovascular complications1,2,15-17, even for infants who have achieved post-natal 
“catch-up growth”18. The lifetime implications of FGR for the individual patient, and the 
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subsequent implications of the disorder on public health system, make it an important 
area for investigation. 
1.1.2 Insufficient placental nutrient (amino acid) transfer in FGR 
The underlying etiologies of FGR are diverse: fetal genetics, perigestational viral 
infections, and disturbances in maternal health account for 30-50% of FGR cases19-21. 
However, the majority of FGR incidences are attributed to placental factors which 
compromise the ability of the placenta to adequately transfer nutrients from the mother to 
the fetus during pregnancy4,22,23. Perigestational nutritional supply is a dominant 
influence on the fetal programming of adult diseases387,388. The adequate availability of 
nutrients to the fetus is directly linked to fetal growth and is dependant on adequate 
placental function389.  
As the feto-maternal interface, adequate placental function is essential in controlling 
appropriate resource allocation between mother and fetus, which is integral to 
reproductive success. The placenta matures during pregnancy to meet increasing fetal 
nutritional demands10, which intensify as fetal growth rate increases over the course of 
gestation with the fetus experiencing maximum overall growth during the third 
trimester24. Pathological placental function, such as due to abnormal placental 
angiogenesis leading to decreased utero-placental blood flow, decreases placental 
capacity for nutrient transfer25,26. Both mother and fetus physiologically adapt to 
fluctuations in nutrient availability based on nutritional cues derived from the placenta13, 
and placental function itself is metabolically consuming and dependent on hormonal cues 
from both the mother and fetus27,28. Evidence is emerging for placental nutrient sensing 
as a key factor in healthy fetal growth13, suggesting that the placenta serves as much more 
than a passive conduit for nutrients from the mother to fetus. Placental nutrient sensing 
involves a complex of signaling mechanisms which serve to integrate nutritional cues 
from both mother29-34 and fetus27,35-38 to regulate nutrient transportin an effort to optimize 
both maternal and fetal outcomes13,39. Insufficiency in any aspect of this process which 
results in the fetus not receiving the appropriate quantity of nutrients, such as essential 
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amino acids, necessary for its healthy development can trigger a maladaptive fetal 
response leading to FGR40,41. 
Excess amino acids are not stored in humans54, so the developing fetus requires a 
constant, reliable supply of essential amino acids (EAAs) from the placenta in order to 
sustain fetogenesis. Of the 20 amino acids, nine (leucine, isoleucine, valine, lysine, 
threonine, tryptophan, phenylalanine, methionine, histidine) are considered “essential” as 
they are not internally synthesized54. Decreased fetal/maternal “enrichment” ratios of 
various EAAs – which areindicative of reduced trans-placental EAA transport – have 
been detected in FGR pregnancies46-48. This is largely due to the down-regulated 
expression of placental amino acid transporters (System L (leucine) transporter, Taurine 
transporter (TAUT), and System A transporter) in FGR22,49-52. Inadequate placental 
function leads to increased amino acid concentrations in the maternal circulation and 
decreased circulating amino acids in the fetuses of FGR pregnancies42. Induced FGR via 
placental embolization in an ovine model reduced fetal plasma and amniotic fluid 
concentrations of all amino acids by 15%43, and altered amino acid profiles are observed 
in the plasma of women who experience FGR versus healthy 
pregnancies44.Maladaptative responses by the fetus to perigestational amino acid 
deficiency likely induce a host of developmental complications, including FGR53. 
1.1.3 Fetal response to deficient nutrient (amino acid) supply 
Decreased fetal amino acid uptake is characteristic of FGR55 and fetal circulating EAAs 
are decreased in growth-restricted fetuses4. The ability of a single EAA, leucine, to 
attenuate induced FGR45 suggests that amino acid availability is implicated in FGR 
pathogenesis. Bajoria et. al. assessed amino acid plasma concentrations at birth in human 
twins who experienced discordant growth, where one infant was FGR and one was 
appropriate for gestational age (AGA)56. The FGR twin demonstrated decreased plasma 
venous EAAs, especially the branched-chain amino acids (BCAAs – leucine, isoleucine, 
valinel) compared to the AGA twin56. Teodoro et. al. demonstrated that amino acid 
supplementation of maternal-protein-restricted rats restored growth and organ mass in 
offspring45, which were otherwise reduced by restricted maternal diets.  
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In the fetus, an intrinsic maladaptive response after suffering amino acid deprivation 
likely manifests in FGR53. Fetuses are highly sensitive to fluctuations in circulating 
maternal amino acid availability – in fact, 48 hours of restricted maternal protein intake 
was sufficient to produce growth-restricted offspring in a mouse model57. Maternal 
fasting led to decreased insulin, increased glucagon and potentiated activity of key 
gluconeogenic factors in the livers of growth-restricted rats57. Girard et. al. demonstrated 
that decreased nutrient supply from the mother during the third trimester induces 
premature fetal gluconeogenesis, likely leading to impaired fetal growth at the cost of 
endogenous fuel provision57. The need for the fetus to endogenously provide energy in 
amino acid-restricted conditions is further demonstrated by the observation that 
diminished placental amino acid transfer elicits increased fetal protein catabolism, as 
observed via increased concentrations of certain fetal tissue amino acids, and concomitant 
placental dysfunction, in human FGR28,58,59.  
There is strong evidence that the fetal response to amino acid unavailability in 
uteroinflicts long term repercussions on offspring health in addition to confining fetal 
growth7,45,56,60. In an experimental model for FGR, pregnant rats fed nutrient restricted 
diets exhibited significantly decreased circulating levels of the three essential BCAAs, 
which led to FGR in off-springs and correlated to severe glucose intolerance and 
atherosclerosis in adult life60. In approximately 70-80% of human FGR infants61,62, the 
metabolic stress due to amino acid insufficiency causes the fetus to prioritize its limited 
energy supply towards preserving the functions of vital organs such as the heart, brain 
and placenta at the compromise of the full maturation of remaining fetal organs63-67, 
which frequently leads to asymmetrical fetal growth61,62. These FGR infants are typically 
born with larger head:body mass ratios7, and compromised maturation of fetal organs – 
including the brain68 – which likely manifests in its compromised function later in life. 
The specific signaling pathways triggered in the fetus upon amino acid restriction which 
serve to link amino acid deprivation to decreased fetal growth in the FGR fetus remain 
largely elusive. Fetogenesis is a dynamic and molecularly complex phenomenon that 
involves the interaction of a variety of signaling pathways, abrogation of any of which 
may lead to deterred fetal growth and development. By elucidating the molecular 
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mechanisms linking amino acid deprivation to restricted fetal growth, we will further our 
understanding of FGR pathogenesis, which is quintessential in the future development of 
targeted therapies and diagnosis against the disorder that are currently lacking.  
1.2 The Insulin-like Growth Factors (IGFs) in Fetal 
Growth and Development 
To explore the mechanisms modulating fetal growth under amino acid restriction, we 
focused our attention on the key mediators of fetal growth and development. The Insulin-
like Growth Factor (IGF)/IGF-Binding Protein(IGFBP) axis is critically involved in fetal 
cell growth and proliferation. During human pregnancy, the two IGFs (IGF-I, IGF-II) 
are synthesized by most embryonic and fetal tissues and play important roles in fetal 
growth69-71. As gestation progresses, IGF production increases72 and as the fetal liver 
develops, the majority of IGF is hepatically synthesized73 and secreted into the fetal 
circulation74,75 where it contributes to systemic fetal growth and development76.  
The two IGFs have unique and shared functions in fetogenesis. Both IGFs are 
synthesized by in early gestation77 and are necessary for the migration of trophoblast cells 
in the maternal decidua78 which is crucial to healthy placental and fetal development. 
Fetal liver secretes IGF-II protein whose mRNA is transcribed from the paternally 
imprinted allele79with mRNA detection as early as 12-18 days gestation. Deficits in IGF-
II signaling during early embryo development typically result in irregular organogenesis 
and fetal demise80. For example, it has been shown that mice null for IGF-II displayed 
pathological placental and embryonic growth37. IGF-II exists in the fetal serum in far 
greater concentrations (3-10 fold) than IGF-I72,81, and this imbalance persists post-natally 
in humans where IGF-II is typically present in a 2.5-fold greater concentration in serum 
compared to IGF-I.  
However, as gestation progresses, fetal development becomes increasingly dependent on 
IGF-I82. Unlike IGF-II, which has been proposed to provide continuous stimulus for 
growth81, IGF-I activity is more sensitive to physiological and environmental cues, such 
as nutritional stress81,83. Fetal IGF-I secretion begins early in gestation (~6 weeks)72 by all 
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fetal tissues and at this time, functions primarily in an autocrine/paracrine manner84. IGF-
I secretion rises dramatically around 16-20 weeks gestation85 as the fetal liver matures, 
and continues to increase systemically throughout the remaining gestational 
period72,75,85,86. Both the endocrine and paracrine functions of IGF-I become increasingly 
critical to the development of fetal tissues as gestation progresses87. During this period, 
IGF-I levels in cord serum of healthy fetuses rise to 10-80 ug/L85, and only begin to 
decrease post-natally72. IGF-I is the key mediator of overall fetal growth88-91, particularly 
in the third trimester68,92,93 when it is the dominant regulator of organ maturation80,94. 
Fetal circulating IGF-I levels have been consistently and positively associated with infant 
birth-weight82,86. In the fetal brain, IGF-I signaling is critically involved in neurogenesis, 
synaptogenesis, and myelination66,67.  
Wang et. al. have suggested that IGF-I is synthesized separately in the mother and fetus 
and that the mitogen does not cross the placenta95. In concordance, Davenport et. al. 
reported a limited ability of IGF-I to transverse the placental barrier96. However, Bassett 
et. al. showed that the placenta expresses the cognate receptor of IGF-I (IGF-1 Receptor) 
and that fetal IGF-I levels are radically modulated by the placenta in late gestation97. 
Further, maternal and fetal IGF-I feedback to acutely influence placental function, as 
indicated by the ability of IGF-I to influence amino acid allocation between the maternal 
and fetal compartments via the placenta82,98,99. Together, these studies emphasize the 
importance of available IGF-I in the fetal compartment in regulating fetal development 
and illustrate the dynamic interplay between placental nutrient sensingand IGF signaling 
in influencing fetal growth. 
1.2.1 Structural basis of IGF-I function via its receptor (IGF-1R) 
The IGFs are mitogenic proteins that exist as single polypeptide chains, are highly 
conserved among species and are structurally and functionally homologous to insulin120-
122. The tertiary IGF-I molecule contains a hydrophobic core similar to insulin in addition 
to a 12-residue connecting peptide, and a carboxy-terminal extension123. The IGFs and 
insulin share common ancestral history124,125; however, their functions have largely 
diverged over the course of evolution124,125. Unlike insulin, whose primary function is 
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metabolic regulation, the key function of the IGFs is to modulate cell growth and 
proliferation126. The IGFs participate directly in cell growth, metabolism, and 
proliferation126,127 in both pre- and post-natal life by binding to their ubiquitinously-
expressed cell-surface receptor, IGF-1 Receptor (IGF-1R)122,126.  
IGF-1R is structurally homologous to the insulin receptor (IR) (58% sequence 
identity)128. However, unlike the IRwhich participates primarily in glucose and lipid 
metabolism, IGF-1R activity is primarily associated with cell growth and 
differentiation129. IGF-1R is a heterotetrameric protein that contains two α subunits 
containing the extracellular ligand-binding domain, and two disulfide bond-liked β 
subunits with tyrosine kinase activity130. The extra-cellular domain maintains IGF-1R in 
an inactive state until ligand binding131, upon which a conformational change induces 
IGF-1R autophosphorylation at the two β subunits (pTyr1135), thereby activating the 
receptor131. IGF-1R β phosphorylation is necessary and sufficient for its activation131 and 
subsequent initiation of secondary messenger cascades which stimulate downstream 
mitogenic responses such as increased protein translation, proliferation and anti-apoptotic 
activity122,130,132.  
IGF-1R is the primary receptor for IGF-I and its activity has been shown to be critically 
involved in fetal development105,136,137. Mice null for IGF-1R weigh 45% of control birth 
weight perinatally and experience a high mortality rate, supporting that IGF-1R activity is 
a key factor affecting fetal development105. To a lesser degree, IGF-I and IGF-II can also 
stimulate IR and IGF-I/insulinhybrid receptor (HR)138. IGF-II also binds to IGF-2R, 
which functions only to sequester IGF-II and attenuate its mitogenic effects. Expression 
of both receptors is regulated based on environmental stimuli and dependent on the 
immediate needs of the organism. 
1.2.2 IGF-I in FGR 
Although IGF-II is more abundant in fetal circulation72,100-102, only fluctuations in IGF-I 
bioavailability have been consistently associated with FGR101,102. In an experimental 
model, IGF-II overexpression in mice was unable to rescue stunted growth induced by 
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IGF-I depletion104. Analysis of human fetal cord blood demonstrates that FGR fetuses 
display decreased circulating, bioavailable IGF-I76,88,101-103. Further, knockdown mice 
deficient in IGF-I display decreased fetal weight and increased neonatal death in 
addition to aberrant post-natal development and cognitive deficits reminiscent of 
FGR91,105. Growth-restricted neonates in ovine and murine models of FGR demonstrate 
decreased placental and fetal sensitivity to IGF-I63,106,107. One study has demonstrated 
extremely stunted growth in a severe FGR human patient with a deletion in the gene 
encoding IGF-I115. 
Placental IGF-I expression is reduced in mouse models of FGR108 and in human FGR 
infants109,110. Further, IGF-I protein levels are decreased in the circulation of mothers 
delivering FGR babies compared to maternal plasma from healthy pregnancies111,112and 
in their FGR infants at term113.Conversely, malnourished human mothers who produce 
significantly more small for gestational age (SGA) and FGR neonates secrete higher 
levels of total IGF-I (free and bound), suggesting an adaptive maternal response to in 
utero nutrient restriction114. IGF-I levels are highly sensitive to nutrient 
availability83,97,116,117; in particular, it has been suggested that nutritional status in the 
second half of gestation affects fetal circulating IGF-I concentrations83,88 . Perigestational 
maternal under-nutrition leads to decreased IGF-I in the fetus in late gestation117.IGF-I 
levels, in turn, are positively correlated with infant birth-weight95,119.  
Although total IGF-I levels rise dramatically as gestation progresses72, its bioavailability 
is contingent on developmental period, subject to tissue specificity and is highly 
sensitive to nutrient status83. Modulation of IGF-I bioavailability rather than total 
endogenous levels is critical to the regulation of fetal growth. For example, increased 
methylation of the IGF-I gene correlated to decreased total plasma IGF-I, but this 
decrease in IGF-I expression was not correlated with the FGR phenotype in an ovine 
model86. Based on the evidence provided, it is ascertainable that reduced IGF-I 
bioactivity is a hallmark of FGR. 
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1.3 Regulation of IGF-I bioavailability by the IGF 
binding proteins (IGFBPs) 
Total IGF is abundant in circulation; however, its bioavailability is tightly regulated by 
the six IGF binding proteins (IGFBP-1-6)139,140. IGFBPs are secretory proteins that 
modulate IGF bioactivity by binding the mitogenic proteins in various extracellular 
compartments141. The six IGFBPs serve to regulate the distribution of IGFs between 
the circulation, tissue fluids, and cell surface binding sites, thereby tightly 
controlling IGF bioavailablity139. The majority of IGFs (>90%) typically exist in 
circulation bound to IGFBPs132,385,386. Each of the six binding proteins differently 
regulates IGF bioactivity, as they bind and sequester IGFs from their receptors with 
varying affinities and with varying functions such as to prolong their half-lives, attenuate 
their bioactivity, maintain them in circulation, or to target them to specific tissues142. 
1.3.1 IGFBP-3 is the general transport protein for IGF-I 
Most IGF protein exists in circulation bound to IGFBP-3 in a stable, ternary complex 
with acid labile subunit (ALS) glycoprotein143,144. IGFBP-3 actions are generally growth-
promoting, functioning to prolong the half-lives of and effectively transport both IGF-I 
and IGF-II throughout the circulation. The IGFBP-3:IGF-I:ALS complex has a half-life 
of 12 hours, which is significantly extended compared to free unbound IGF-I (t1/2 = 10 
minutes) or IGFBP-3 (t1/2 = 30-90 minutes)143. At any given time, IGFBP-3 is associated 
with approximately 75% of total IGF, maintaining a reservoir of IGFs within the 
circulation either free or bound to other IGFBPs, available for immediate metabolic 
demands143.  
IGFBP-3 is the predominant circulating IGFBP in post-natal life at approximately a 10-
time higher concentration than other IGFBPs145. Accordingly, IGFBP-3 serves as the 
major IGF transport protein while other IGFBPs are involved in more specific, acute 
regulation of IGF bioactivity145. Although IGFBP-3 sequesters the majority of total IGF-
I, the role of this binding protein is generic and generally stable in circulation. 
Fluctuations in IGFBP-3 levels have not been found to be consistently associated with 
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disease states. In contrast, the roles of other IGFBPs are more specific. IGFBP-1 plays a 
crucial role in mitogen signaling in ovarian, endometrial, trophoblast and fetal and 
placental tissues146 and is the key circulating IGFBP during gestation75. 
1.3.2 IGFBP-1 regulation of IGF-I during pregnancy 
Hepatically secreted IGFBP-1 is a potent inhibitor of the IGFs both in vitro147 and in 
vivo148-150,186,187. However, IGFBP-1 has a much greater affinity for IGF-I compared to 
IGF-II151, supporting its role as a potent, specific inhibitorof IGF-I bioavailability. 
IGFBP-1 regulates free serum IGF-I bioavailability154 by binding and sequestering IGF-I 
from IGF-1R, preventing it from transducing its growth-promoting effects155-159. IGFBP-
1 has been suggested to bind to IGF-I and block its receptor-binding site160.  
IGFBP-1 is the predominant circulating IGFBP in fetal circulation, fetal liver, placenta 
and amniotic fluid during pregnancy69,74,103,149,152,153. IGFBP-1 is significantly elevated in 
pregnant versus non-pregnant women (approx. 2-fold) and is present at even higher 
concentrations in amniotic fluid161. During pregnancy, decidual cells secrete IGFBP-1 
into the placenta162,163 where it functions primarily to inhibit trophoblast invasion at the 
placental barrier, which is involved in embryo implantation164. In the fetal compartment, 
IGF-I bioavailability is tightly regulating by fetal hepatic IGFBP-1 which is widely 
acknowledged as a critical factor in altered human fetal development12, 54, 66, 67, 175, 193. 
Fetal liver is the primary source of fetal IGFBP-1175 and fetal hepatic IGFBP-1 is the 
primary regulator of fetal IGF-I bioactivity76.  
Fetal IGFBP-1 levels rise dramatically around approximately 16-20 weeks gestation and 
rapidly reach their peak72. IGFBP-1/IGF-I binary complexes increase in tandem with fetal 
IGFBP-1 production at 16 weeks gestation72. Once the concentration of IGFBP-1 peaks, 
it remains at a steady concentration for the remaining gestational period in both the 
fetus72and maternal plasma176 in normal, non-growth restricted pregnancies. Langford et. 
al. determined a steady concentration of 300 +/- 25.1 ug/L IGFBP-1 in healthy fetuses, 
which remained consistent throughout gestation85. In the fetus, IGFBP-1 levels fall after 
33 weeks gestation and continue decreasing post-natally95. 
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1.3.3 IGFBP-1 structural elements 
The Igfbp1 gene is located adjacent to Igfbp3 on chromosome 7p12-p14177.The 
IGFBP-1 promoter contains the TATA element in addition to a cAMP response 
element (CRE), glucocorticoid response elements 1 (GRE1) and 2 (GRE2), and 
binding sites for hepatic nuclear factor 1(HNF1) and 3 (HNF3), the latter also known 
as the insulin-response element (IRE)154. Binding to the HNF1 motif on the IGFBP-1 
promoter contributes to tissue-specific expression of IGFBP-1 in the decidua, ovary, 
liver and kidney154. Systemically, insulin is the primary regulator of IGF-I 
transcription via binding to the IRE and subsequent inhibition of IGFBP-1 
transcription, whereas glucocorticoids and cAMP stimulate IGFBP-1 expression154. 
The six IGFBPs possess several structural and functional similarities particularly in their 
highly conserved, cysteine-rich, amino- and carboxy-terminal domains178. The primary 
IGFBP sequence contains a string of 12 N-terminal and six C-terminal cysteines, which 
have been demonstrated to be necessary for optimal IGF binding and are conserved 
among all IGFBPs in mammalian systems179. The di-sulfide bonds in these highly 
conserved N- and C- terminal cysteine residues form a highly specific IGF-binding 
pocket178,180. Conversely, the linker region between the two terminal domains is 
mobile and not well conserved among the IGFBPs. The linker region contains sites 
for post-translational modification, protein/protein interactions, and ubiquitination 
that are unique to each IGFBP139,156,181,182. This linker region is prone to 
phosphorylation in IGFBP-1, -3, and 5140, however, only phosphorylation of IGFBP-1 
in this region enhances its affinity for IGF-I166,183,184and its ability to inhibit IGF 
bioactivity155-158,185. 
1.3.4 IGFBP-1 phosphorylation 
Phosphorylation of IGFBP-1 dramatically increases its affinity for IGF-I73,151 and 
potentiates its bioinhibitory effect on the mitogen73,139,151,155. IGFBP-1 phosphorylation is 
associated with the inhibition of IGF-I-mediated cell proliferation, amino acid 
transport and apoptosis155. Phosphorylated IGFBP-1 has also been shown to inhibit 
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IGF-I-stimulated DNA synthesis in experimental animals156, smooth muscle cells185 
and fetal skin fibroblasts157. 
Previously, our team has demonstrated that IGFBP-1 hyperphosphorylation is associated 
with decreased IGF-I bioavailability in amniotic fluid from FGR pregnancies171and with 
decreased IGF-I bioactivity in vitro172,173. Our lab has also previously demonstrated that 
IGFBP-1 hyperphosphorylation is indicative of decreased IGF-I bioavailability in vitro 
by demonstrating a link between increased IGFBP-1 phosphorylation and decreased IGF-
1R autophosphorylation in HepG2 cells172. Phosphorylated IGFBP-1 secreted by HepG2 
cells displays a 6-fold higher affinity for IGF-I compared to non-phosphorylated 
IGFBP-173, and hyperphosphorylated IGFBP-1 species derived from human plasma 
displays approximately 10-fold greater binding affinity for IGF-I151. Interestingly, 
IGFBP-1 phosphorylation does not affect its propensity for IGF-II binding153.  
Sites of IGFBP-1 phosphorylation 
Mass spectrometry has helped identify five phosphorylation sites on IGFBP-1 
(Ser95, Ser98, Ser101, Ser119, Ser169)158. The phosphorylation status of IGFBP-1 at 
Ser101, Ser119 and Ser169 has been associated with altered IGF-I affinity73,190,191and 
IGF-I bioactivity in vitro172.Jones et. al. demonstrated that site-directed mutagenesis 
of Ser101 to un-phosphorylatable Ala101 decreases IGFBP-1 affinity for IGF-I 3-
fold183. By mutating phospho-acceptor residues to un-phosphorylatable Ala residues 
in HepG2 cells, our team has demonstrated that phosphorylation of IGFBP-1at 
Ser101, Ser119 and Ser169 variably affects IGF-I bioavailability, with most 
pronounced effects when IGFBP-1 was mutated to Ser101Ala and Ser119Ala172. 
Ser101, Ser119 and Ser169 are sensitive to phosphorylation in vitro in response to 
leucine restriction and are associated with potent increases in IGF-I affinity (up to 30-
fold) upon phosphorylation190.Our lab has previously demonstrated an increase in 
pSer101, pSer119 and pSer169 in amniotic fluid171 and umbilical cord plasma173 from 
FGR babies as well as in fetal hepatocytes from a baboon model of FGR173.  
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Figure 1.1.IGFBP-1 sequesters IGF-I from its cell surface receptor. Phosphorylated 
IGFBP-1 sequesters IGF-I with greater affinity. 
1.3.5 Total and phosphorylated IGFBP-1 in normal and growth-
restricted pregnancies 
Total IGFBP-1 and fetal growth 
Several groups have linked FGR with increased fetal IGFBP-156,93,95,103,112,160,192,194-196 
FGR infants have been shown to have increased perigestational cord blood93,95,160,194 and 
post-natal circulating195,196 IGFBP-1. Elevated IGFBP-1 in maternal plasma95,197 and 
placental tissues112,113 are also inversely related to infant birth weight. A study on 
discordant twins (one FGR and one AGA infant) demonstrated increased IGFBP-1 in 
FGR infants compared to their AGA siblings, a difference that was not observed in twin 
pairs who experienced concordant growth56. This finding suggests that altered IGFBP-1 
levels in FGR are likely due to environmental, rather than genetic, influences. 
Additionally, transgenic over-expression of IGFBP-1 in murine fetuses decreased fetal 
birth weight by 18%175, suggesting a causative relationship between IGFBP-1 and 
restricted fetal growth. HepG2 cells cultured in leucine concentrations observed in 
nutrient-restricted rats had significantly induced IGFBP-1 mRNA and protein 
expression198. Further, Bajoria et. al. reported that fetal IGFBP-1 production was elevated 
in FGR infants where amino acid supply was reduced56. The negative correlation between 
IGF-I 
6-10-fold greater affinity 
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fetal amino acid uptake and IGFBP-1 production suggests that increased IGFBP-1 
synthesis may be a fetal response to decreased amino acid availability.  
IGFBP-1 phosphorylation and fetal growth 
Fetal liver contains an abudance of phosphorylated IGFBP-1 throughout the gestational 
period162. Conversely, IGFBP-1 phosphorylation in the maternal compartment appears to 
be temporally regulated. Amniotic fluid IGFBP-1 circulates primarily unphosphorylated 
in early pregnancy with singly and multiply phosphorylated IGFBP-1 present in 
decreasing concentrations158, although the exact proportions of total to unphosphorylated 
IGFBP-1 have not been classified. However, as pregnancy progresses, the relative 
abundance of highly phosphorylated IGFBP-1 species increases in maternal plasma162, 
placenta162 and amniotic fluid168.  
The partially and highly phosphorylated IGFBP-1 isolated from cord plasma likely 
originates in the fetal liver169. Fetal IGF-I levels continue to rise throughout pregnancy 
while IGFBP-1 levels, once peaked, typically remain consistent for the remaining 
gestational period72. It is likely that IGFBP-1 phophorylation is a cellular mechanism 
employed to fine-tune IGF-I bioavailability, and that increased phosphorylation of 
IGFBP-1 rather than its total secreted levels is the principal regulator of IGF-I 
bioavailability in latter gestation. 
Altered IGFBP-1 phosphorylation is associated with fetal abnormalities165,171,173,174,189,199. 
Phosphorylated IGFBP-1 is elevated in cord plasma of growth restricted babies relative to 
babies who are appropriate for gestational age (AGA)165, with an accompanied decreased 
proportion of non-phosphorylated IGFBP-1 in these infants. Further, amniotic fluid from 
FGR pregnancies also displays an altered phospho-isoform profile for IGFBP-1compared 
to amniotic fluid from healthy pregnancies191. IGFBP-1 hyperphosphorylation at 
specific phosphosites (Ser101, Ser119 and Ser169) was previously detected by our 
team in amniotic fluid171 and umbilical cord plasma173 from FGR pregnancies. Our 
team also previously reported that hyperphosphorylation of IGFBP-1 at pSer101 and 
pSer169 in amniotic fluid is most dramatically increased in FGR171, but that 
hyperphosphorylation at Ser119 most potently induces IGFBP-1 affinity for IGF-I191. 
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In addition, we recently reported IGFBP-1 hyperphosphorylation at pSer101, 
pSer119, and pSer169 in umbilical cord plasma of FGR babies as well as fetal 
baboon hepatocytes from nutrient-restricted mothers173. In contrast, in human 
amniotic fluid, a decreased ratio of highly phosphorylated to lowly phosphorylated 
IGFBP-1 isoforms is linked with stimulated fetal growth200. 
In summary, the literature suggests that diminished amino acid supply to the fetus during 
gestation is a key factor in FGR onset, and that IGFBP-1 hyperphosphorylation leads to 
decreased IGF-I bioavailability. However, the signaling mechanisms involved in 
signaling amino acid deficiency to increased fetal hepatic IGFBP-1 phosphorylation are 
presently unknown. Herein, we explore candidate nutrient-sensing signaling pathways for 
their potential role in modulating hepatic IGFBP-1 secretion and phosphorylation in 
amino acid deprivation. 
1.4 Nutrient-sensing signaling pathways 
Nutrient deprivation is an environmental stressor, requiring an adaptive cellular response 
to optimize organismal outcomes. Upon nutritional stress, the organism typically defends 
overall homeostasis by reducing cell growth and survival and promoting energy 
conservation201. The mechanistic target of rapamycin (mTOR) and Amino Acid Response 
(AAR) are key sensors of nutrient (amino acid) availability in several cell types202,203 
including the liver203. Here, we highlight the functions of these two signaling pathways in 
the context of their possible roles in modulating amino acid deprivation-induced IGFBP-
1 hyperphosphorylation in HepG2 cells, a model for fetal hepatocytes204-208. 
1.4.1 Mechanistic Target of Rapamycin (mTOR) 
1.4.1.1 The two mTOR complexes 
mTOR exists in two, ubiquitinously expressed209, functional complexes, mTOR Complex 
1 (mTORC1) and mTOR Complex 2 (mTORC2). The two complexes are composed of 
both unique and shared proteins. mTOR is the catalytic component common to both 
complexes210, which also share DEP domain-contain mTOR-interacting protein 
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(DEPTOR), mammalian lethal with Sec13 protein 8 (mLST8), and Tti1–Tel2211-213.  
DEPTOR is an endogenous inhibitor of both complexes213 and Ttil-Tel2 regulates 
complex formation for both mTORC1 and mTORC2211. mLST8 is critical to mTORC2 
function214. Further, each complex is associated with a unique, key functional protein that 
responds to external stimuli and accordingly phosphorylates downstream effectors210. 
mTORC1 is associated with regulatory-associated protein of mammalian target of 
rapamycin (raptor)215 and mTORC2 with rapamycin-insensitive companion of 
mammalian target of rapamycin (rictor)214. Raptor has been implicated in amino acid 
sensing and sub-cellular localization of mTORC1216. Similarly, rictor phosphorylates 
downstream mTORC2 effectors210, recruits substrates214, and confers structural stability 
to mTORC2217. 
The two complexes are differently regulated with independent and overlapping cellular 
functions210. Both complexes are sensitive to inhibition by rapamycin, though mTORC2 
requires higher treatment doses and durations173,214. mTORC1 is endogenously inhibited 
by tuberous sclerosis 1 and 2 (TSC1-TSC2 complex) in response to a variety of stress-
stimuli. When activated, mTORC1 phosphorylates and activates eukaryotic translation 
initiation factor 4E (4E-BP1) and p70-ribosomal S6 Kinase 1 (p70-S6K), which proceed 
to modulate cell growth and proliferation210. mTORC2 phosphorylates downstream 
effectors protein kinase C-α (PKCα) and AKT and has been typically implicated in 
maintaining the actin cytoskeleton, although recently has also been demonstrated to play 
a role in cell proliferation, survival, and morphology217 and in the regulation of lipid 
homeostatis218. 
1.4.1.2  mTOR as a cellular nutrient sensor 
mTOR signaling is sensitive to fluctuations in nutritional status210,219, although the 
mechanisms by which mTOR senses nutrient availability have not been completely 
elucidated. In particular, mTOR has been proposed to respond to fluctuations in nutrient 
status via mTORC1, whereas mTORC2 is proposed to not be directly involved in cellular 
energy sensing217. Various factors have been discovered to be necessary for amino acid 
sensing by mTOR, suggesting that nutrient sensing by the signaling complex is highly 
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dynamic. Sancak et. al. demonstrated that sufficient amino acid availability is absolutely 
necessary for mTOR activity and involves the Rag family of proteins216. Amino acids 
promote RagA/B complex association with GTP216. These GTP-bound complexes 
subsequently associate with raptor and translocate to the lysosomal membrane where they 
interact with Ragulator, an essential component for amino acid sensing by mTORC1209.  
Further, Hardie et. al. suggested that cellular energy sensing by mTORC1 occurs via 
AMP-dependant kinase (AMPK)220. Adequate nutrient availability is sensed by AMPK, 
which subsequently phosphorylates and deactivates TSC1-TSC2 complexes and activates 
mTORC1220. Kim et. al. proposed that nutrient deprivation increases the stability of the 
mTORC1:raptor complex, sequestering mTORC1 in an inactive complex and inhibiting 
its kinase ability221. It is likely that all these components interplay in a dynamic 
mechanism to modulate mTOR activity under various nutritional cues. 
Amino acid insufficiency leads to decreased phosphorylation of downstream mTOR 
effectors222. mTOR activity is especially sensitive to circulating  BCAAs. BCAAs 
stimulate mTOR activity in multiple cell types223 including murine hepatocytes as 
indicated via increased phosphorylation of p70-S6K and 4E-BP1224,225. mTORC1 
activation is critically dependant on sufficient amino acid availability, especially on 
cellular leucine status226. mTOR signaling is a key component of leucine-stimulated 
protein synthesis in catabolic conditions227. Although mTORC2 has been proposed to be 
insensitive to amino acid status228, the complete regulation and functions of mTORC2 
have not been extensively classified210. Inhibition of mTOR activity by amino acid 
deprivation is reversed by the re-introduction of amino acids into the culture media229. 
Finally, mTOR nutrient sensing in the placenta has been implicated in FGR onset230-232. 
1.4.1.3 mTOR signaling as a potential link between nutrient 
deprivation and decreased fetal growth in FGR 
Placental mTOR nutrient sensing has been implicated in FGR onset230,231 and is 
particularly sensitive to activation by amino acids233. mTOR has been proposed as a key 
regulator of the placental expression of amino acid transporters that are critical to EAA 
transfer to the fetus32,230,231. Further, mTOR signaling is diminished in placentas from 
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maternal nutrient restricted (MNR) rats32, MNR baboons234 and in human FGR 
pregnancies230,235. Kavitha et. al. recently demonstrated, in MNR baboons, that mTOR 
and IGF-I activity inhibition led to a decrease in placental nutrient transporters and 
decreased offspring growth234. The role of mTOR signaling in the fetal compartment in 
FGR has been not as well established. Promisingly, our team has recently reported 
decreased mTOR activity in baboon hepatocytes from MNR pregnancies173. Further, 
Teodoro et. al. reported that BCAA supplementation reversed growth restriction in an 
induced murine model of FGR by activating the fetal hepatic mTOR signaling pathway45.  
In addition, mTOR signaling is necessary and sufficient for insulin-mediated 
inhibition of Igfbp1 gene expression236-238. Conditioned cell media from mTORC1- 
and mTORC2-silenced trophoblast cells induced IGFBP-1 secretion and 
phosphorylation in cultured HepG2 cells239, and our lab has recently linked 
decreased mTOR activity with increased IGFBP-1 protein secretion and 
phosphorylation173. However, whether mTOR is the mechanistic link between amino 
acid deprivation and hepatic IGFBP-1 hyperphosphorylation has yet to be 
determined. 
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Figure 1.2. Model for IGFBP-1 phosphorylation by various components of the mTOR 
signaling components. 
1.4.2 The Amino Acid Response (AAR) 
Amino acid deprivation in mammalian cells activates a collection of intracellular 
signaling responses, collectively known as the Amino Acid Response (AAR), which lead 
to the induction of a stress-responsive transcriptional program240. The AAR is an 
evolutionarily conserved, adaptive cellular response to decreased circulating amino acids 
and is part of the Integrated Stress Response (ISR), which is initiated by multiple stress-
sensing kinases upon distinct environmental stimuli. General control non-derepressible 2 
(GCN2) is the specific sensor for the AAR. GCN2 functions exclusively to initiate an 
amino acid restriction-specific stress response and its activity is initiated upon reduced 
intake of essential amino acids or diminished intracellular synthesis of non-essential 
amino acidsvia sensing excess intracellular uncharged tRNAs241. Subsequent 
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GCN2phosphorylation of eukaryotic initiation factor 2 (eIF2a) initiates the AAR, leading 
to reduced global protein translationand a concurrent increase in the translation of pre-
existing stress-responsive mRNAs, most notably Activating Transcription Factor 4 
(ATF4). ATF4 is a transcription factor that then proceeds to up-regulate the transcription 
of several stress-responsive proteins. Overall protein translation is curtailed in favour of 
the up-regulation of a host of stress-responsive genes that serve to restore cellular 
homeostatis242. 
1.4.2.1 General control non-derepressible 2 (GCN2) is the AAR 
nutrient sensor 
GCN2 is a serine/threonine kinase and a universally conserved sensor of cellular nutrient 
status from yeast (GCN4 homologue)243 to mammalian systems. Among the four ISR 
kinases, GCN2 is uniquely sensitive to fluctuations in amino acid availability244. Within 
the AAR, GCN2 is the only identified sensor of amino acid depletion245. Deprivation of 
even a single amino acid is sufficient to induce GCN2 activity246. Activated GCN2 
subsequently initiates stress-responsive downstream signaling pathways via 
phosphorylation of eIF2α (Ser51)203,241,247-249. 
Structurally, GCN2 contains a catalytic eukaryotic kinase domain that is well-conserved 
among all eukaryotic kinases250,251. Of the twelve sub-domains, catalytic subunits IV and 
V are the least conserved among eukaryotes250,251. However, there is significant sequence 
homology in the V domains between the eIF2α kinases, conferring substrate specificity to 
this kinase family252. GCN2 also contains C-terminal ribosome binding/dimerization, 
pseudo-kinase(regulatory), histidyl-tRNA (HisRS)-related, and N-terminal RWD 
domains that are not structurally conserved among the eIF2α kinases. 
GCN2 typically circulates in its inactive form246 in loose association with 80S ribosomes 
or actively translating polysomes253. Uncharged tRNAs, which accumulate as a result of 
reduced essential amino acid intake or non-essential amino acid synthesis, preferentially 
bind the HisRS domain over charged tRNAs245. tRNA binding leads to GCN2 
dimerization254 and subsequent autophosphorylation at Thr898255, causing kinase 
activation. tRNA binding is facilitated by the binding of a GCN1/GCN20 protein 
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complex to the RWD domain256,257 and by certain C-terminal lysine residues on GCN2256, 
conferring additional sensitivity to the nutrient sensor. There are two reports of GCN2 
binding to viral RNA258,259, however, eIF2α is the only currently established target for 
GCN2 phosphorylation in mammalian systems.  
The role of GCN2 in amino acid sensing is widely acknowledged. GCN2+/GCN2+ mice 
displayed decreased hepatic and adipose mass in response to leucine starvation, whereas 
GCN2-/GCN2- mice livers were not affected in size but rather displayed pronounced 
steatosis260. GCN2-/GCN2- mice do not avoid essential amino acid-deprived diets unlike 
their wild-type counterparts261,262 and have decreased rates of survival263. GCN2 is also 
sensitive to glucose deficiency264,265. 
GCN2 phosphorylation of eIF2α occurs in a MEK/ERK dependant manner266 (discussed 
further in section 1.4.2.3), which subsequently proceeds to initiate a stress-responsive 
transcriptional program via the increased translation of pre-existing ATF4 mRNAs and 
concurrent decrease in overall protein translation241. Increased GCN2 and eIF2α (pSer51) 
phosphorylation and ATF4 expression are therefore indicators of AAR pathway 
activation. 
1.4.2.2 AAR propagation via eukaryotic initiation factor 2 alpha 
(eIF2α) phosphorylation and ATF4 expression 
eIF2 is a heterotrimer of α, β, and γ subunits248,257 and participates in mRNA translation 
by mediating Met-tRNA binding to the ribosome227,267. The process of translation 
initiation by eIF2 is GTP dependant 268,269. eIF2γ is the main docking site for GTP/GDP, 
and eIF2β catalyzes eIF2-GDP conversion to eIF2-GTP. eIF2α is the enzyme’s 
regulatory subunit268,269. Phosphorylation of eiF2α at Ser51 increases its affinity for 
eIF2β251, thereby sequestering eIF2β-GDP in its inactive complex. Consequently, eIF2β 
is unable to catalyze the nucleotide exchange, reducing the functional capacity of the 
translation factor270. 
eiF2α is phosphorylated by four distinct stress-responsive kinases, rendering it the 
convergence point for the ISR242,271. eIF2α is exclusively phosphorylated by the four ISR 
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kinases in vivo, and sequence determinants remote from Ser51 have been proposed to 
confer this specificity268. The phospho-acceptor site (Ser51) on the alpha subunit is 
buried within a hydrophobic pocket preventing its phosphorylation by other in vivo 
kinases268,269. Kinase binding to eIF2α induces a conformational change that projects 
Ser51 into the active site, allowing its phosphorylation268,269.  
In mammalian cells, in addition to GCN2, eIF2α is also phosphorylated by the three other 
ISR kinases depending on the particular stressor: heme-regulated inhibitor kinase (HRI), 
double-stranded RNA-activated protein kinase (PKR), and PKR-like endoplasmic 
reticulum (ER) kinase (PERK). The transcriptional program elicited by eIF2α 
phosphorylation reduces global translation in favor of up-regulating gene products 
involved in cellular stress-management244. In a study by Dang et. al., 2.5% of total 
murine hepatic mRNA was down-regulated by eIF2α phosphorylation272. 
PERK is a component of the Unfolded Protein Response (UPR) that is activated under 
endoplasmic reticular (ER) stress242,271 and has been most commonly investigated 
alongside GCN2 in regards to the transcriptional program that is elicited upon cellular 
stress. ATF4 induction, characteristic of eIF2α phosphorylation, which is intitiated by 
PERK elicits an overlapping transcriptional program with that of up-regulated ATF4 by 
GCN2 activation, suggesting that ATF4 is a critical signaling convergence point from 
cellular stress derived from amino acid insufficiency and from oxidative stress273. A 
comprehensive analysis of the gene profiles elicited by GCN2 and PERK in murine 
hepatocytes indicates that although some overlap exists in the programs elicited by GCN2 
and PERK, each cellular stressor has a vastly distinct overall affect on the hepatic 
transcriptome272. The stress response elicited by AAR activation is therefore likely 
affected by a multitude of factors downstream of GCN2 and is not specific to ATF4. 
Specific attenuation of the AAR is therefore best accomplished via direct manipulation of 
GCN2. 
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Figure 1.3. Overview of signaling components of the Amino Acid Response (AAR) as a 
component of the Integrated Stress Response (ISR). 
1.4.2.3 Involvement of MAPKs in the AAR 
The Mitogen-Activated Protein Kinase (MAPK) family of serine/threonine kinases is 
widely conserved among eukaryotic species, and encompasses a three-tier system of 
kinases. MAPKs are phosphorylated upstream by MAPK kinases (MKKs), which in turn 
are phosphorylated by MEK Kinases (MKKKs)274. MKKs are dual specificity kinases 
that phosphorylate Thr-X-Tyr motifs on their respective MAPKswhich in turn 
phosphorylate their own downstream targets, many of which are transcription factors275. 
There are four subfamilies of the MAPK signaling cascades in mammalian cells, each of 
which is involved in unique and overlapping intracellular functions274. Each subfamily 
contains several MAPKs, MEKs, and MKKs, serving as multiple integration points for 
various intracellular signals. One signaling arm (MEK1/2/ERK1/2) in particular is critically 
involved in cell growth and proliferation; the MAPKs in this cascade are known as ERK1 
and ERK2, and this signaling arm will herein be referred to as MEK/ERK. An overview 
of the various components of the MEK/ERK signaling cascade is illustrated in Figure 1.3. 
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Various Growth Factors 
 
 
 
 
 
Cell growth and differentiation 
Figure 1.4. Schematic representation of the mitogenic (MEK/ERK) pathway including 
all potential MKKKS, MKKs, and MAPKs 
The literature purports that MEK/ERK signaling is necessary for AAR propagation245,266. 
Inhibiting MEK/ERK signaling is therefore a strategy for attenuating the AAR. However, 
the role of MEK/ERK in cell growth and proliferation274 suggests it may independently 
modulate IGFBP-1 secretion and phosphorylation. Inhibition of MEK/ERK signaling has 
been shown to decrease IGFBP-1 secretion in the human endometrium276 and secretion of 
both IGF-I and IGFBP-1 in rat hepatocytes 277,278. MEK/ERK signaling has also been 
implicated downstream of IGFBP-1 in modulating mitogenesis in the liver279. Various 
studiesreport differential involvements of MEK/ERK signaling in IGFBP-1 regulation280-
282. However, its explicit role in the secretion and phosphorylation of IGFBP-1 in nutrient 
restriction, and whether these effects occur via the AAR, are unknown. 
1.4.2.4 Potential role of the AAR in IGFBP-1 regulation under 
nutrient restriction in FGR 
Decreased transfer of EAAs from the mother to fetus is observed in FGR22,283,284, and the 
extent to which fetal amino acid transfer is restricted is correlated with FGR severity283. 
An important study by Strakovsy et. al. demonstrated that the AAR is activated in 
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placentas of rats fed nutrient-restricted diets during gestation, which also led to stunted 
growth of neonates285. More recently, increased eIF2α phosphorylation has been detected 
in placentas from human FGR pregnancies235. Considering that the AAR is an adaptive 
cellular response to restricted amino acids, and that FGR results from a maladaptive 
physiological response to decreased nutrient availability, it is extremely likely the AAR is 
implicated in FGR onset.  
The amino acid-specific, and AAR-mediated, regulation of IGFBP-1 has been 
demonstrated at the transcriptional and translational levels. IGFBP-1 expression is 
induced downstream of ATF4 in murine hepatocytes286. Further, in vitro 287and in vivo288 
studies support this observation by demonstrating that dietary amino acid restriction in 
rats leads to induced hepatic IGFBP-1 mRNA expression288. Conversely, murine IGF-I 
gene expression is down-regulated by amino acid restriction289. Amino acid restriction-
induced hepatic IGFBP-1 mRNA is dependent on specific regions in the IGFBP-1 
promoter (IRE, GRE)290, subsequently named the Amino Acid Response Unit 
(AARU)291. Increased IGFBP-1 species in response to amino acid deprivation is 
accomplished in part by mRNA stabilization287 in addition to increased transcription.  
Upstream stimulatory factors 1 and 2 (USF-1, USF-2) have been identified as potential 
transcription factors in protein restriction-induced IGFBP-1 transcription 291. USF-1 and -
2 are ubiquitously expressed and up-regulated in protein restricted conditions291, 
suggesting that regulation of total IGFBP-1 output may be under the control of the AAR 
via stress-induced up-regulation of various downstream transcriptional factors. 
Interestingly, Averous et. al. demonstrated that primary hepatocytes derived from mice 
deficient for GCN2 were still able to induce IGFBP-1 transcription under leucine 
restriction287. Together, the literature suggests that the AAR is partly involved in 
modulatingIGFBP-1 expression; however, the involvement of the AAR in the translation 
and post-translational regulation of IGFBP-1 has not been classified. 
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1.5 Kinases involved in the regulation of IGFBP-1 
phosphorylation 
Phosphorylation of IGFBP-173, IGFBP-3292 and IGFBP-5184 has been unequivocally 
demonstrated, while other IGFBPs display potential phosphorylation sites140. IGFBP-1 is 
likely phosphorylated by intracellular kinase(s) prior to its secretion293. Consensus 
sequence analysis and in vitro studies indicate that IGFBP-1 is a potential substrate for 
protein kinase CK2, protein kinase C (PKC) and protein kinase A (PKA)140,168,188,293. 
Here, we review these three potential kinases for their potential involvement in IGFBP-1 
phosphorylation under leucine deprivation.  
1.5.1 Protein Kinase CK2 
1.5.1.1 Structure and Function 
CK2 is a constitutively active, ubiquitous serine/threonine kinase with over 300 potential 
targets294,295 including IGFBP-1293. Ubiquitinously expressed in mammalian cells296 , 
CK2 exists in a tetrametric form with two identical regulatory (β) subunits297,298 and two 
catalytic subunits (α and/or α')298-302. CK2 characteristically phosphorylates Ser or Thr 
residues located in close proximity to acidic amino acids140,297,303 (consensus sequence: S-
X-X-D/E) (Table 1.1). However, this minimal consensus sequence has been shown to be 
neither necessary304 nor sufficient305 for phosphorylation by CK2, suggesting that other 
structural determinants are involved in potentiating phosphorylation by CK2.  
Differing only in their C-terminal domains, CK2a and CK2a' catalytic domains are 90% 
identical306 and exhibit highly similar in vitro enzymatic properties307. CK2β is highly 
conserved among species with identical sequence homology in birds and 
mammals296,308,309. CK2 has been found to be localized in the cytoplasm as well as 
multiple intracellular organelles310, functioning as both an endokinase310 and 
ecktokinase310,311. CK2 subunits each target different substrates312,313 and are individually 
implicated in robust regulatory cellular functions296. CK2 activity is responsive to various 
stress stimuli in mammalian cells314-318. 
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1.5.1.2 CK2 phosphorylation of IGFBP-1 
CK2 phosphorylates IGFBP-1 in HepG2293 and endometrial stromal cells188. IGFBP-1 
phosphorylation sites (Ser101, Ser119, Ser169) exist in proximity to acidic amino acids, 
characteristic of the CK2 consensus recognition motif 319,140(Table 1.1). However, 
whether or not IGFBP-1 is a true CK2 substrate has not been conclusively demonstrated. 
Previously in our lab, inhibition of CK2 activity via combined siRNA silencing of CK2α, 
CK2α’ and CK2β or selective CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) 
decreased IGFBP-1 phosphorylation in HepG2 cells173. Additionally, our team has shown 
that CK2 activity and IGFBP-1 phosphorylation are concomitantly elevated in growth-
restricted fetal baboon hepatocytes from nutrient-restricted mothers173. Previous work 
from our lab also showed that CK2 is a key regulator of IGFBP-1 phosphorylation 
(pSer101, pSer119, pSer169) downstream of mechanistic target of rapamycin (mTOR) 
signaling173. Whether CK2 mediates IGFBP-1 phosphorylation in amino acid deprivation 
remains to be established. 
1.5.2 Protein Kinase C (PKC) 
1.5.2.1 Structural and functional basis for inhibition 
PKC is another indiscriminate protein kinase and is activated intracellularly by second 
messenger diacylgycerol320. The role of PKC in IGFBP-1 phosphorylation has not been 
established. Although PKC is a potential kinase for IGFBP-1 phosphorylation140, based 
on the PKC consensus sequencewhich requires surrounding basic residues to the 
phospho-acceptor site140, Ser101, Ser119 and Ser169 on IGFBP-1 are not likely sites for 
direct phosphorylation by PKC. However, PKC has been shown to be pivotal in the 
regulation of IGF-I bioactivity through uncharacterized mechanisms321-327. 
PKC is widely expressed in mammalian tissues. PKC consists of a regulatory N-domain 
and catalytic C-domain, and 4 conserved and 5 variable regions in its primary structure. 
11 PKC isoforms (α, βI, βII , γ, δ, ε, θ , η, ζ , √, λ) have been identified with minor 
structural and functional differences328. PKC isoforms α, βI, βII and γ are considered 
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conventional isotypes (cPKCs) and share conserved (C1 and C2) modules in their 
regulatory domains328. Novel PKCs (nPKCs) consist of the δ, ε, θ and η isotypes and lack 
the C2 subunit, whereas atypical PKCs (aPKCs - ζ , √ and λ) lack both C2 and integral 
structural components of C1 rendering them insensitive to activation by diacylglycerols 
(DAGs) and phorbol esters328. The isoforms are variably regulated by intra- and extra-
cellular stimuli329 and the expression of certain isoforms is restricted to specific cell 
types: γ to the central nervous system, θ to the skeletal muscle and hematopoietic cells, 
and β to the pancreatic, adrenal and neuronal tissue329. There is also evidence for 
differential sub-cellular localization of the various PKC isoforms329. The PKC isoform 
profile of HepG2 cells has not been exclusively classified, although certain PKC isoforms 
have been specifically implicated in various stress-related responses in HepG2 cells330,331. 
PKC has been implicated in multiple diseases phenotypes, and the specific roles of 
individual isoforms are emerging in the literature330.The development of pharmacological 
tools to elucidate the stimuli- and cell-specific roles of the various PKC isoforms is a 
current topic of investigation328. 
Staurosporine is the most widely used chemical inhibitor against PKC. Although its 
effects are potent, it has demonstrated cross-reactivity with other kinases including 
protein kinase A (PKA)332. On the other hand, a less potent derivative of staurosporine, 
Bisindolylmaleimide (BIS), is a very specific PKC inhibitor for all PKC isoforms332. 
1.5.2.2 PKC as a nutrient-sensitive kinase and its possible role in 
FGR 
PKC activity is sensitive to fluctuations in nutrient availability. PKC integrates signals 
downstream of mTOR in an amino acid-sensing pathway and certain PKC subunits 
(α,δ,ε) are regulated by mTOR in amino acid-dependant manner. PKC functions 
downstream of mTOR to stimulate mitogenic protein synthesis333 including leucine-
induced DNA synthesis as assessed in cultured chicken hepatocytes334. Nishitani et. 
al. demonstrated that leucine-mediated glucose uptake occurs via PKC signaling335. 
However, leucine supplementation in rats stimulates hepatic PKC activity as well as 
redistribution of the kinase from the hepatocellular membrane to the cytosol through 
mTOR-independent mechanisms336, suggesting that PKC is also independently 
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sensitive to nutrient supply. Further, PKC signaling is abrogated in certain nutritional 
disorders. For example, hepatic PKCα signaling participates in nutrient transport and 
its function is implicated in obesity and diabetes mellitus II337. PKC activity was 
attenuated in the pancreas338 and skeletal muscle339 of rats subjected to reduced protein 
intake during gestation.  
Finally, there is some evidence for the involvement of PKC in FGR onset. One study 
demonstrates an altered expression profile of the various PKC isoforms in placentas from 
murine FGR pregnancies during the third trimester340. Artificially-induced hypoxia 
potentiated PKCα activity in human umbilical venous endothelial cells from normal 
pregnancies to comparable levels seen in the same cells derived from FGR pregnancies341 
and hepatic PKCζ expression is increased in FGR rats342. Together, these studies 
implicate a possible role for altered PKC signaling in FGR onset. 
1.5.2.3 Interactions between PKCand the IGF/IGFBP signaling 
axis 
Various isoforms of PKC have been implicated in modulating the cellular actions of IGF-
I in a variety of tissues. While PKCα up-regulates IGF-I bioactivity in microtubes321, 
PKCζ modulates IGF-I-stimulated macrophage differentiation322 and along with PKCβ, 
PKCη, and PKCε, plays an essential role in IGF-I-mediated migration of vascular smooth 
muscle cells, DNA synthesis and gene expression323. PKCζ signaling modulates IGF-I 
bioactivity in vascular smooth muscle cells324 and PKCθ has been shown to be critical in 
IGF-1R mediated oncogenic cell proliferation325. PKCζ modulates the effect of growth-
inducing hormones (e.g. insulin) on downstream mitogenic protein synthesis and cell 
cycle progression327. Inhibition of pan-PKC with BIS inhibited both IGF-I-stimulated 
early cell differentiation and later cell proliferation in messenchymal cells326. Induction of 
pan-PKC activity stimulates HepG2 cell proliferation343. 
There is evidence for PKC regulation of the IGFBPs. Multiple PKC isoforms have been 
implicated in regulating IGFBP-2 and IGFBP-3 secretion by thyroid cells344-346. PKCα 
phosphorylates IGFBP-3, inducing its degradation347. Further, pan-PKC inhibition 
induces IGFBP-5 synthesis348 and secretion349,350 and IGFBP-4 secretion349 in multiple 
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cell types. There is also some support for the role of PKC in the regulation of IGFBP-
1output. For example, a study by Kachra et. al. in rat hepatocytes revealed that glucagon 
inhibited IGFBP-1 mRNA expression via activation of PKC signaling351. Further, PKC 
plays a role in both the up- and down- regulation of IGFBP-1 secretion in vitro at the 
protein level, depending on the parameters of the exposure to the inhibitors352,353.  
The role of PKC in post-translational regulation of IGFBP-1 has not been classified. 
Given the nutritional sensitivity of PKC, its role in the regulation of IGF-I bioactivity and 
IGFBP-1 expression, and its dynamic interactions with members of the IGFBP family of 
proteins, we considered it a valuable kinase to assess for its role in the elusive signal 
transduction pathway modulating IGFBP-1 phosphorylation under leucine deprivation. 
1.5.3 Protein Kinase A (PKA) 
1.5.3.1 Structural and functional basis for inhibition 
PKA is a multifunctional, ubiquitously expressed, intracellular kinase with a wide variety 
of protein targets320,354, and is activated by secondary messenger cyclic AMP 
(cAMP)320,354. PKA is a heterotetrameric kinase, with two catalytic subunits containing 
dimerization and regulatory subunit-binding domains as well as binding sites for the 
kinase’s substrate and for ATP, the kinase’s phosphate source. cAMP binding to the 
homodimeric regulatory subunits causes its dissociation and consequent activation of the 
catalytic subunits. PKI (5-24) is a highly potent, competitive inhibitor of PKA. PKA 
residues Tyr235 and Phe239 on the regulatory subunits structurally integrate with Phe10 
of PKI, preventing substrate (cAMP) binding and subsequent activation of PKA355. 
1.5.3.2 PKA as a nutrient-sensitive kinase 
Hepatic PKA activity is sensitive to fluctuations in nutrient availability356-359. PKA 
signaling is potently decreased in murine livers after offspringwere fed low-protein 
diets357,358. Further, murine pancreatic PKA expression is reduced by nutrient 
restriction360. Decidualization of human endometrial stromal cells during human 
pregnancy occurs in a PKA-dependant mechanism361 and the increased IGFBP-1 
production characteristic of this process is also dependant on PKA signaling361-363. 
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Finally, altered PKA signaling has been implicated in fetal brain development in 
FGR364,365. 
1.5.3.3 Interactions between PKA and the IGF/IGFBP signaling 
axis 
PKA has been implicated in modulating systemic IGF-I mitogenic actions in multiple cell 
types366-368. For example, PKA regulates IGF-I-stimulated osteoclast-like cell 
formation369, and PKA inhibition prevents IGF-I stimulated early chondrocyte cell 
proliferation and differentiation326. PKA kinase activity stimulates the IGF-I promoter370. 
The majority of studies linking PKA and the IGFBPs focus on PKA-regulation of IGFBP 
expression and synthesis in multiple cell types. PKA activation prevents chondrocytic 
IGFBP-3 and IGFBP-4 expression and secretion371 as well as antagonizes IGFBP-4 and 
IGFBP-5 secretion in the murine ovaries348. Conversely, PKA stimulation induces 
IGFBP-5 expression350. Importantly, induction of PKA activity stimulates IGFBP-1 
promoter activity372, mRNA372 expression and protein372,373levels in HepG2 cells. PKA 
activation modulates glucagon-stimulated IGFBP-1 expression in rat hepatocytes351. 
Conversely, PKA inhibition attenuates cAMP-stimulated IGFBP-1 synthesis. 
Promisingly, one study188 links PKA to IGFBP-1 phosphorylation in endometrial stromal 
cells. 
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Table 1.1. Surrounding peptide sequence of the three IGFBP-1 phosphosites and 
consensus sites for CK2, PKC and PKA 
Peptide Surrounding peptide sequencea 
IGFBP-1(E97-S101-L110) ESPEpSTEITEEELL 
IGFBP-1(D111-S119-E121) DNFHLMAPpSEE 
IGFBP-1(A165-S169-K175) A QETpSGEEISK 
Kinase Consensus siteb 
CK2 S/T-X-X-D/E 
PKC S/T-X-R/K 
PKA R/K-R/K-X-S/T 
a Abu Shehab M et. al. Site specific phosphorylation of insulin-like growth factor binding protein-1 (IGFBP-1) for 
evaluating clinical relevancy in fetal growth restriction. J Proteome Res. 2009;8(11):5325-5335. 
b Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol. 
1997;128(1-2):1-5 
 
1.5.4 IGFBP-1 de-phosphorylation 
Westwood et. al. proposed that IGFBP-1 dephosphorylation is another regulatory 
mechanism by which cells can stimulate IGF-I bioactivity by releasing the growth factor 
from sequestration151,166. Alkaline phosphatase (ALP) was recently identified as the 
phosphatase which de-phosphorylates IGFBP-1 in vitro167 and in vivo374to decrease its 
propensity for IGF-I binding167. During pregnancy, placental ALP de-phosphorylates 
IGFBP-1 in order to increase IGF-I bioavailability374. Therefore, dephosphorylation of 
IGFBP-1 may be an additional mechanism by which cells modulate IGF-I bioavailability 
in FGR. 
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1.6 Experimental models  
1.6.1 Leucine deprivation as a model for nutrient restriction 
BCAAs are the key stimulators of global protein synthesis227. Supplementation of 
murine hepatocytes with EAAs, but particularly the BCAAs, maximally induces 
plasma protein synthesis, as indicated by induction of albumin and tranferrin 
secretion375. BCAA repletion alone is sufficient to maximally induce protein 
synthesis in skeletal muscle376. Leucine, along with isoleucine and valine, is a BCAA 
and one of the nine EAAs in humans. Leucine accounts for more than 20% of human 
dietary protein 223. Administration of BCAAs, but specifically leucine, has mitogenic 
effects in the liver, such as the synthesis of hepatocyte growth factor, as well as in 
hepatocellular regeneration377. In addition to its structural role in protein synthesis, 
leucine has one of the most potent roles in intracellular signaling compared to other 
essential amino acids223.  
Studies of placental nutrient transfer in FGR have focused on trans-placental leucine 
transport, which is potently and consistently decreased in FGR22,46,47,378. Assessment of 
venous umbilical samples indicates that leucine and phenylalanine most rapidly cross 
the placenta from the mother to the fetus47, and that leucine transport is particular 
heightened after 20 weeks gestation in human pregnancies48.Oral administration of 
leucine augments protein synthesis in multiple tissue and cell types379,380, however, 
does not affect global protein synthesis in the liver379,381. Rather, hepatic leucine 
administration induces the expression of specific mRNAs and significantly activates 
mTOR signaling263,381. 
There is strong evidence in the literature suggesting that leucine is unique in its 
ability to stimulate protein synthesis to the maximal level comparable to a mixture of 
all EAAs227,376in vivo. In previous in vitro studies in our lab, leucine deprivation 
reliably triggered IGFBP-1 hyperphosphorylation at Ser101, Ser119 and Ser169 in 
HepG2 cells190. 
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1.6.2 HepG2 cells as a model for fetal hepatocytes 
As described previously (Section 1.3.2), fetal liver is the primary source of fetal 
circulating IGFBP-1. In vitro, HepG2 cells are an ideal, widely-used model for human 
fetal hepatocytes 204-208. They express a transcriptome and secretome206,382,383 most 
similar to human fetal hepatocytes. HepG2 cells induce IGFBP-1 mRNA expression 
when limited for leucine without affecting the expression of IGF-I198. Previous work in 
our lab demonstrated that, in a HepG2 cell culture model, leucine deprivation-induced 
phosphorylation of IGFBP-1 led to up a 21-fold increase in affinity for IGF-I in 
vitro190. Further, our lab has recently demonstrated that changes in IGFBP-1 secretion 
and phosphorylation in HepG2 cells are reflected in primary baboon hepatocytes173, 
which have served a successful, physiologically relevant model in the study of regulation 
of IGFBP-1 phosphorylation in FGR173,384. Therefore, it is justified to use HepG2 cells to 
study the mechanisms underlying leucine deprivation-induced fetal hepatic IGFBP-1 
phosphorylation. 
1.7 Scope of Thesis 
The fetal response to decreased nutrient (amino acid) supply likely involves multiple 
signaling pathways in an effort to optimize fetal health. A maladaptive molecular 
response to amino acid restriction is detrimental to fetal outcomes53. The signaling 
mechanisms linking amino acid deficiency to decreased cell growth and proliferation in 
FGR have not been elucidated. As described previously, the bioavailability of IGF-I is a 
key determinant of its ability to stimulate fetal cell growth and proliferation; IGFBP-1 
phosphorylation (Ser101, Ser119 and Ser169) is an indicator of decreased IGF-I 
bioavailability and is increased in FGR. The mechanisms regulating IGFBP-1 secretion 
and phosphorylation under amino acid deprivation, which is a keycontributing factorto 
FGR onset, remain to beestablished. The overall objective of this study is to shed light on 
the molecular mechanisms by which fetal growth is regulated under amino acid 
deprivation by studying the signaling pathways modulating leucine deprivation-induced 
IGFBP-1 phosphorylation in vitro. The central hypothesis is that leucine deprivation-
induced IGFBP-1 phosphorylation is modulated via down-regulation of the mTOR 
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signaling cascade and up-regulation of the AAR pathway. Further, we predict that 
IGFBP-1 phosphorylation under leucine restriction is modulated by multiple protein 
kinases (CK2, PKC, PKA). The specific aims encompassed in this thesis are three-fold: 
Aim 1: Determine the role of mTOR signaling in mediating leucine deprivation-induced 
IGFBP-1 secretion and phosphorylation (pSer101, pSer119 and pSer169) (Chapter 2). 
Aim 2: Establish whether the AAR is involved in modulating leucine deprivation-
induced IGFBP-1 secretion and phosphorylation (pSer101, pSer119 and pSer169) and 
whether this occurs in a MEK/ERK-dependant manner (Chapter 2). 
Aim 3:Surveypotential kinases that may be involved in regulating IGFBP-1 
phosphorylation (pSer101, pSer119 and pSer169) under leucine deprivation (Chapter 3). 
 
 
 
 
 
 
 
 
 
Figure 1.5. Proposed model for total and phospho-IGFBP-1 regulation by mTOR, AAR, 
and the kinases CK2, PKC and PKA under fetal amino acid deprivation 
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In Chapters 2 and 3, we analyze changes in IGFBP-1 secretion and phosphorylation in 
HepG2 cell media after treatments which have manipulated various molecular 
components of the mTOR and AAR signaling pathways or protein kinases CK2, PKC 
and PKA in both regular (leucine plus) or leucine minus conditions. Changes in IGFBP-1 
secretion and phosphorylation are linked to concomitant changes in the activity of 
downstream pathway components. Identifying signaling pathways involved in leucine 
deprivation-mediated IGFBP-1 phosphorylation in vitro will provide the foundation for 
future in vivo studies aimed at contributing insight into the pathophysiology of FGR.  
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Chapter 2 
2 Total and phosphorylated IGFBP-1 in leucine deprivation: 
roles for the mTOR and AAR signal transduction pathways 
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Malkani N, Jansson T, and Gupta MB. IGFBP-1 phosphorylation in response to leucine 
deprivation is mediated by the AAR pathway. Mol Cell Endocrinol. 2015.  
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2.1 Introduction 
Fetal Growth Restriction (FGR) arises from a heterogeneous group of factors and 
although its etiology is multi-factorial, FGR is primarily a result of placental 
insufficiency, i.e. the inability of the placenta to effectively deliver nutrients and oxygen 
to the fetus1,2. FGR infants fail to achieve their full growth potential after suffering 
nutritional deprivation3 and are at an increased risk for perinatal mortality4. FGR affects 
~5 to 7% of all pregnancies5. FGR babies born under the 10th percentile for estimated 
birth weight are predisposed to greater risks of childhood and adult metabolic, 
cardiovascular, and neurological complications4,6,7. The mechanisms by which the fetus 
signals nutrient deficiency to attenuating fetal growth are not well understood.  
Insulin-like growth factor I (IGF-I), synthesized mainly by the fetal liver, is a key 
regulator of fetal growth. Fetal serum IGF-I levels are significantly reduced in the 
growth-restricted fetuses8. IGF binding protein-1 (IGFBP-1) primarily secreted by the 
fetal liver9 is the key fetal circulating IGFBP during gestation10. Elevated fetal circulating 
IGFBP-1 and decreased IGF-I levels are strongly correlated with FGR onset11-13. IGFBP-
1 functions by binding IGF-I and sequestering it from its receptor, IGF-1R, consequently 
preventing it from transducing mitogenic signals14-16. Phosphorylation of IGFBP-1 
increases the binding affinity of IGFBP-1 for IGF-I17 and sequesters IGF-I thereby 
resulting in its decreased bioavailability16,18-20. 
Human FGR fetuses often have decreased fetal circulating levels of essential amino 
acids, such as leucine21-24. In our laboratory, we have previously demonstrated that 
leucine deprivation triggered hyperphosphorylation of IGFBP-1 in HepG2 cells at 
discrete sites, which markedly increased the affinity of IGFBP-1 for IGF-I, and inhibited 
IGF-I-dependent cell growth25. Although modest increases in IGFBP-1 phosphorylation 
were found in HepG2 cells cultured under lower leucine concentrations (70 and 140 μM 
leucine), leucine deprivation (0 µM leucine) distinctly increased IGFBP-1 
phosphorylation compared to HepG2 cells cultured with leucine (450 µM leucine)25. 
Furthermore, we have recently demonstrated that IGFBP-1 phosphorylation was 
increased at three different sites (Ser101, Ser119, and Ser169) in human umbilical cord 
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plasma from FGR pregnancies and in liver from baboon FGR fetuses26. These data 
indicate that increased phosphorylation of IGFBP-1 at specific sites plays an important 
role in FGR pathogenesis.   
FGR is characterized by decreased amino acid availability2,27, which activates the Amino 
Acid Response (AAR)28 and inhibits mechanistic target of rapamycin (mTOR) 
signaling29,30. The AAR signaling pathway is highly responsive to changes in amino acid 
availability28. Amino acids, oxygen and growth factor signaling activate mTOR 
signaling30-33. mTOR integrates nutrient and mitogenic signals to regulate cell growth and 
cell division34. mTOR exists in two complexes, mTOR Complex 1 (mTORC1) and 2, 
with the protein raptor associated to mTORC1 and rictor associated to mTORC235,36. 
Activated mTORC1 phosphorylates 4E-BP1 and p70-S6K and promotes protein 
translation34,37. mTORC2 phosphorylates Akt and PKCα and regulates cell metabolism 
and survival36,37. Oxygen, growth factor and amino acids, particularly leucine and 
arginine, activate mTORC1 signaling32,38-41. mTORC1, in particular, is inhibited by the 
binding of rapamycin although longer treatments and higher doses of rapamycin have 
also been shown to inhibit mTORC226,37. 
We have previously shown using HepG2 cells and baboon fetal hepatocytes in vitrothat 
inhibition of mTOR signaling resulted in increased IGFBP-1 phosphorylation at the three 
specific sites26. In addition using a baboon model of FGR in the same study we also 
identified that increased site-specific IGFBP-1 phosphorylation in FGR is linked with an 
inhibition of the mTOR and stimulation of protein kinase CK2. However, the 
mechanisms underlying IGFBP-1 hyperphosphorylation specifically in conditions of 
amino acid deprivation remain to be established.  
The AAR pathway is activated under conditions of cellular nutrient stress28,42-47. General 
control non-derepressible 2 (GCN2) is the key sensor of cellular nutrient status, which is 
activated upon sensing excess uncharged cytoplasmic tRNAs45,46. Leucine deprivation 
activates and phosphorylates GCN2 at pThr898 which subsequently phosphorylates 
eukaryotic initiation factor 2 (eiF2) at pSer51 of the alpha subunit (eiF2α)47. 
Phosphorylated eiF2α (pSer51), which is increased in abundance in FGR48, proceeds to 
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inhibit eIF2B activity and therefore overall global protein synthesis while concurrently 
promoting the translation of certain stress-responsive mRNAs, including activating 
transcription factor 4 (ATF4)45,47. ATF4 is a critical stress-responsive transcription factor, 
which, when synthesized, promotes the transcription of several growth-arresting genes49. 
eiF2α (pSer51) phosphorylation and total ATF4 expression levels are therefore functional 
readouts of AAR activity. The role of the AAR signal transduction pathway in regulating 
IGFBP-1 phosphorylation has, to our knowledge, not previously been investigated.  
In this study, we hypothesized that inhibition of mTOR signaling and AAR activation 
increase IGFBP-1 secretion and phosphorylation at specific sites in response to amino 
acid deprivation. We used HepG2 cells as a model for human fetal hepatocytes50-54 to 
investigate the mechanisms linking mTOR and AAR signaling with IGFBP-1 
phosphorylation under leucine deprivation. We studied the secretion and phosphorylation 
of IGFBP-1 in HepG2 cells in response to mTOR inhibition (rapamycin) or AAR 
inhibition (U0126). Alternatively, cells were transfected with siRNA targeting 
raptor+rictor or DEP domain-containing mTOR-interacting protein (DEPTOR) (to inhibit 
or activate mTORC1 and C2, respectively)37, and ERK1/2 and/or GCN2 (to inhibit ERK-
mediated AAR)45,55 in cells cultured with or without leucine. Finally, we verified that 
changes in IGFBP-1 phosphorylation under leucine deprivation altered IGF-I bioactivity 
by employing our previously established IGF-1R autophosphorylation assay26,56 which 
supported the functional significance of our findings. 
2.2 Methods 
2.2.1 Cell culture 
Human hepatocellular carcinoma cells (HepG2), purchased from ATCC (Mananassas, 
VA), were cultured in Dulbecco’s modified Eagle medium with nutrient mixture F-12 
(DMEM/F-12) supplemented with 10% fetal bovine serum (FBS) (Invitrogen Corp., 
Carlsbad, CA) at 37°C in 20% O2 and 5% CO2  as we described previously
25,26.  
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2.2.2 Leucine deprivation 
HepG2 cells were treated in specialized DMEM/F12 selectively deprived and restored of 
specific amino acids and were incubated in the specialized media either deprived of (0 
μM) or supplemented with (450 µM) leucine as we  described in our previous study25.  
Cells were further incubated in leucine plus or leucine deprived media during rapamycin 
(100 nM), U0126 (10 μM), or TBB (1 μM) treatments or following transfection with 
siRNA. Cell media and cell lysate were collected following 24 hour (chemical 
treatments) or 72 hour (siRNA treatments) exposure to the specialized media. 
2.2.3 Inhibitor treatments 
HepG2 cells were plated in 12-well culture dishes until cultures reached 75% confluence 
then starved for 6 hours in 2% FBS (DMEM/F12) prior to treatments with chemical 
inhibitors. Based on previous dose-dependency data, HepG2 cells were treated post-6 
hour starvation for 24 hours using 100 nM rapamycin, 1 μM TBB as we reported 
previously26 or treated with 10 μM U0126 after assessment via dose-dependency 
experiments. Following treatments, cell media and cell lysate were prepared as we 
described26 and stored at -80°C. 
2.2.4 RNA interference silencing 
HepG2 cells were plated at 65% confluence in 12-well culture plates. Silencing using 
siRNA against raptor+rictor, DEPTOR, GCN2 (Sigma-Aldrich, St Louis, MO, USA) or 
ERK (Cell Signaling Technologies, Beverly, MA, USA) in HepG2 cells was achieved 
using transfection with 100 nM siRNA and 5 μL Dharmafect transfection reagent 4 
(Thermo Scientific, Rockford, IL, USA) in regular, serum free DMEM/F12. To 
simultaneously ensure maximal silencing and maximize cell survival, the transfected cell 
media was replaced after 24 hours with specialized leucine plus or leucine deprived 
media and studied after 72 hours (96 hours following transfection). Western immunoblot 
analysis was used to determine the efficiency of target silencing. 
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2.2.5 Cell viability assay 
We tested the effect of leucine deprivation, TBB and U0126 treatments on cell viability 
using the Trypan Blue exclusion assay to ensure these treatments did not sacrifice cell 
viability. Following leucine deprivation and U0126 treatments, cells were trypsinized and 
re-suspended in 10% FBS media. Cell suspensions were diluted 1:1 with 0.4% Trypan 
blue and counted with the Countess Automated Cell Counter (Life Technologies, 
Carlsbad, CA). A measure of live/total cells was used as an indicator of cell survival. 
2.2.6 SDS-PAGE and Western Blotting 
Equal amounts of cell lysate protein (35-50 μg) were separated by SDS-PAGE to 
determine total expression and phosphorylation of p70-S6K (Thr389), Akt (Ser473), 
ERK (Thr202/pTyr204), eiF2α (Ser51), GCN2 (Thr898), and IGF-1Rβ (Tyr1135), as 
well as total expression levels of siRNA target proteins, ATF4 and β-actin (Appendix A; 
Supplementary Table 1). IGFBP-1 secretion and phosphorylation (Ser101, Ser119 and 
Ser169) by HepG2 cells were determined using equal volume of cell media (30-40 μL). 
Nitrocellulose membranes from immunoblot analyses were shaken with 5% skim milk or 
5% BSA diluted in Tris-buffered saline (TBS) plus 0.1 % Tween-20 and blocked for 1 
hour. All primary antibodies were obtained from Cell Signaling Technologies (Beverly, 
MA, USA) with the exception of monoclonal antihuman IGFBP-1 (mAb 6303) (Medix 
Biochemica, Kauniainen, Finland), total and phospho GCN2 (Abcam, Cambridge, MA, 
USA)pre-validatedcustom phosphosite-specific IGFBP-1 polyclonal antibodies targeting 
pSer101, pSer119, and pSer169 (generated at YenZyme Antibodies LLC, San Francisco, 
CA, USA). Primary antibodies were all used at a dilution of 1:1000, and peroxidase-
labelled goat-anti mouse or goat-anti rabbit antibodies (1:10000, BioRad Laboratories 
Inc.) were used as secondary antibodies. Band intensities were determined using 
densitometry in Image Lab (Beta 3) software (BioRad). 
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2.2.7 Validation of custom phosphosite-specific IGFBP-1 antibodies 
In our previous study56, four IGFBP-1 mutants with single amino acid substitutions 
(Ser98Ala, Ser101Ala, Ser119Ala and Ser169Ala) were generated that disrupted IGFBP-
1 phosphorylation. We used these well-characterized mutants and wild-type (positive 
control) IGFBP-1 and performed western blots using our custom phosphosite-specific 
IGFBP-1 antibodies (pSer101, 119 and pSer169) as primary antibodies in order to 
validate their specificity. The data shown in the Figure 356 using pSer101 and pSer169-
specific antibodies clearly validate that the pS101 antibody only recognized IGFBP-1 
when Ser101 was phosphorylated and pSer169 antibody when Ser169 was 
phosphorylated. The validity of the IGFBP-1 antibody specific to pSer119 was similarly 
reported in a subsequent study in Supplementary Figure 726. The Ser119Ala mutant only 
reacted with IGFBP-1 on immunoblot when phosphorylated at Ser119, validating the 
specificity of respective antibody. In addition, we used human amniotic fluid (AF) as an 
additional positive control. We had previously confirmed for IGFBP-1 phosphorylation at 
Ser101, Ser119 and Ser169 residues in amniotic fluid56-58. To include appropriate 
negative controls, we utilized alkaline phosphatase (ALP)-treated amniotic fluid, wild-
type and mutant IGFBP-1 samples to demonstrate diminished reactivity with IGFBP-1 
following ALP treatments56-59. These data unequivocally demonstrate that our custom 
phosphosite-specific IGFBP-1 antibodies are highly specific to only phosphorylated 
forms of IGFBP-1 at their respective sites. 
2.2.8 IGF-I receptor activation assay 
P6 cells (a gift from Dr. R. Baserga, Thomas Jefferson University, Philadelphia, PA), are 
immortalized mouse embryonic fibroblast cells (a BALB/c3T3 cell line) that over-
express human IGF-1R but do not express IGF-I60. Therefore, they are a widely 
established model for the assessment of IGF-1R activation under IGF-I addition61,62. We 
have tested the validity of P6 cells under conditions of variable IGFBP-1 phosphorylation 
previously in our laboratory26,56. P6 cells were cultured in DMEM/F12 with sodium 
pyruvate supplemented with 10% FBS.  
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The P6 cell bioassay was performed in FBS-free conditions as we described previously56. 
Aliquots of HepG2 cell media from various treatments containing equal concentrations of 
IGFBP-1 were buffer-exchanged to P6 cell media using Amicon Ultra-
0.5 mL Centrifugal Filter Units (Millipore, Darmstadt, Germany) per manufacturer 
instructions. Samples were subsequently incubated with rhIGF-I (25 ng/mL) for two 
hours at room temperature. P6 cells were treated for 10 minutes with the P6 media 
containing IGFBP-1/IGF-I complexes. Cells were subsequently lysed and samples were 
separated using SDS-PAGE gels and immunoblot analysis was performed to asses IGF-
1R autophosphorylation using phosphosite-specific IGF-1Rβ (Tyr1135) primary 
antibody. 
2.2.9 Data presentation and statistics 
Data was analyzed using GraphPad Prism 5 (Graph Pad Software Inc., CA). Three 
replicates were analyzed for each treatment condition, including the control treatment.  
For each quantified protein, the mean density of the control sample bands was assigned 
an arbitrary value of 1, and averaged densitometry values for each treatment were 
expressed relative to this mean. We employed One-way analysis of variance with 
Dunnet’s Multiple Comparison Post-Test and expressed results as the mean ± Standard 
Error of Measurement (SEM). Significance was accepted at *p<0.05. n=3. 
2.3 Results 
2.3.1 Rapamycin and/or leucine deprivation inhibit mTOR signaling 
First, we assessed changes in mTORC1 and C2 signaling in response to leucine 
deprivation and rapamycin as a pharmacological mTOR inhibitor. Based on our previous 
dose dependencydatafor leucine deprivation in HepG2 cells25, we cultured HepG2 cells in 
media with leucine (450 μM) or deprived of leucine (0 μM). Cells were cultured with or 
without rapamycin (100 nM). We assessed changes in mTORC1 and C2 signaling 
activity in response to leucine deprivation and/or rapamycin by investigating changes in 
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phosphorylation of downstream effectors p70-S6K (Thr389) and Akt (Ser473) as 
functional readouts of mTORC1 and C2 activity, respectively.  
As evidenced in Figure 2.1A-B, we noted a significant decrease in mTORC1 and C2 
activity by leucine deprivation, rapamycin treatment, and leucine deprivation and 
rapamycin combined, indicated by decreased phosphorylation (-60%) of p70-S6K 
(Thr389) and Akt (Ser473) (-65-70%) under these three treatments. These data 
demonstrate that both mTORC1 and C2 activity are significantly inhibited by rapamycin. 
In addition, leucine deprivation inhibited mTORC1 and C2 activity to the same extent as 
rapamycin with no additive effect when the two treatments were combined (Figure 2.1A-
B), supporting that the degrees to which mTORC1 and C2 were inhibited were not 
significantly different between treatments.  
2.3.2 mTOR inhibition increases IGFBP-1 secretion but not IGFBP-1 
phosphorylation in leucine deprivation 
To test our hypothesis that mTOR signaling is responsible for changes in IGFBP-1 
secretion and phosphorylation in amino acid limitation, we first investigated the effects of 
rapamycin and leucine deprivation on IGFBP-1 secretion and phosphorylation in HepG2 
cells singly and combined. To examine these changes, we resolved equal volumes of 
HepG2 cell media from rapamycin-treated cells with leucine (450 μM) or in leucine 
deprived (0 μM) conditions (Figure 2.1C-F). As demonstrated in Figure 2.1C, IGFBP-1 
secretion was increased (+400%) both in leucine deprivation and rapamycin and these 
effects were not additive when both treatments were combined. To investigate whether 
this effect was consistent with IGFBP-1 phosphorylation, we used custom phosphosite-
specific IGFBP-1 antibodies against pSer101, pSer119 and pSer169 (Figure 2.1D-F). We 
demonstrated that while rapamycin consistently induced IGFBP-1 phosphorylation 
(Ser101, +400%, Ser119, +200% and Ser169, +400%), leucine deprivation increased 
IGFBP-1 phosphorylation beyond that seen by rapamycin treatment alone (Ser101, 
+1000%, Ser119, +500% and Ser169, +1200%) (Figure 2.1D-F). Further, there was no 
additive effect on IGFBP-1 phosphorylation at any of the three sites in combined leucine 
deprivation and rapamycin treatment compared to leucine deprivation alone (Figure 
2.1D-F), suggesting that mTOR signaling does not induce IGFBP-1 phosphorylation in a 
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parallel mechanism, but rather contributes partially to IGFBP-1 phosphorylation induced 
by leucine deprivation. Together, these findings strongly suggest that while leucine 
deprivation inhibited mTOR signaling to the same extent as rapamycin, changes in 
IGFBP-1 phosphorylation under nutrient deprivation are only in part regulated by mTOR 
signaling. While mTOR inhibition was sufficient to induce total IGFBP-1 secretion to the 
same extent as leucine deprivation, IGFBP-1 phosphorylation due to leucine deprivation 
is only partially regulated by mTOR signaling. These data suggest that mTOR signaling 
and leucine deprivation function in a common mechanism to induce total IGFBP-1 
secretion, additional mechanisms are involved in regulation of IGFBP-1 phosphorylation. 
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Figure 2.1. The effect of leucine deprivation and rapamycin on mTORC1+C2 
activity and IGFBP-1 secretion and phosphorylation.A representative immunoblot of 
HepG2 cell lysate (35 μg per lane) assayed for A. S6K (Thr389) phosphorylation and B. 
Akt (Ser 473) phosphorylation. A representative western immunoblot of HepG2 cell 
media (40 μL per well) displaying C. total IGFBP-1 secretion and D-F. IGFBP-1 
phosphorylated at Ser101, Ser119, and Ser169 in control, leucine deprivation, rapamycin, 
and combined leucine deprivation+rapamycin treatments. Values are displayed as mean + 
SEM. *p<0.05, **p=0.001-0.05, ***p <0.001 versus control; One-way analysis of 
variance, Dunnet’s Post-Test. n=3. C: Control, 450 μM leucine. LD: Leucine deprivation, 
0 μM leucine. R: Rapamycin (100 nM), 450 μM leucine. R:LD: Rapamycin (100 nM), 0 
μM leucine. 
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2.3.3 Inhibition of mTOR signaling by raptor and rictor silencing 
confirms that mTOR induces IGFBP-1 secretion, but not 
phosphorylation during leucine deprivation 
For selective inhibition of mTOR complexes, we employed an RNAi strategy to silence 
both raptor and rictor in leucine or leucine deprived conditions with HepG2 cells. 
Primarily, we confirmed efficient silencing of both raptor (-45 to 50%) and rictor (-50%) 
(Appendix A; Supplementary Figure2.1A-B). Raptor+rictor silencing successfully 
inhibited mTORC1 activity as seen by reduced (-50%) phosphorylation of p70-S6K 
(Thr389) to a similar extent as leucine deprivation or combined leucine deprivation and 
raptor+rictor silencing (Figure 2.2A). Similarly, mTORC2 activity was reduced to a 
similar extent in leucine deprivation, raptor+rictor silencing and combined leucine 
deprivation and raptor+rictor silencing as assessed by a reduction (-50%) in 
phosphorylation of Akt  (Ser473) (Figure 2.2B). We therefore confirmed the ability of 
raptor+rictor silencing to effectively inhibit mTORC1 and C2 signaling. 
Next, we sought to assess whether raptor+rictor silencing translated to changes in 
IGFBP-1 secretion and phosphorylation. We demonstrated that raptor+rictor silencing 
induced total IGFBP-1 secretion (+350%) to levels comparable to leucine deprivation 
with or without raptor+rictor silencing (+400%), and that combined raptor+rictor 
silencing and leucine deprivation had no additive effect on IGFBP-1 secretion compared 
to leucine deprivation alone (Figure 2.2C). As expected, raptor+rictor silencing induced 
IGFBP-1 phosphorylation at all three sites (Ser101, +400%, Ser119, +200% and Ser169, 
+400%) but was unable to achieve the phosphorylation induced in the presence of leucine 
deprivation (Ser101, +2000%, Ser119,  +1100% and Ser169, +2300%) (Figure 2.2D-F). 
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2.3.4 Activation of mTORC1 and C2 signaling by DEPTOR silencing 
attenuates leucine deprivation-induced IGFBP-1 secretion but 
not phosphorylation 
To further study changes in IGFBP-1 secretion and phosphorylation under mTOR 
signaling, we selectively activated the mTOR pathway using siRNA against DEPTOR, an 
endogenous inhibitor against mTORC1 and C2 activity. To maximize cell viability, 
serum free DMEM/F12 media containing transfection reagent was aspirated immediately 
following the 24 hour transfection period. Cell media were subsequently replaced with 
DMEM with (450 μM) or without (0 μM) leucine for an additional 72 hours. We first 
confirmed that our RNAi approach efficiently reduced (-50%) DEPTOR expression 
(Appendix A; Supplementary Figure 2.1C). Analysis of cell lysates was used to examine 
changes in phosphorylation of downstream mTOR effectors (Figure 2.2A-B). DEPTOR 
silencing successfully induced p70-S6K (pThr389) phosphorylation (+250%) (Figure 
2.2A) and Akt (pSer473) phosphorylation (+300%) (Figure 2.2B) regardless of leucine 
status, supporting that constitutive activation of the mTOR pathway induces mTORC1 
and C2 signaling downstream of leucine deprivation.  
We proceeded to test whether mTOR activation was able to prevent changes in IGFBP-1 
secretion and phosphorylation caused by leucine deprivation. Activating mTOR signaling 
by DEPTOR silencing successfully attenuated leucine deprivation-induced IGFBP-1 
secretion (+400%) (Figure 2.2C) but was unable to prevent leucine deprivation-induced 
phosphorylation of IGFBP-1 at all three sites (Figure 2.2D-F). Since mTORC1 and C2 
inhibition induced total IGFBP-1 secretion only to the same extent as leucine deprivation, 
and since mTORC1 and C2 activation completely prevents this induction, we assert that 
mTOR signaling is the key mechanism implicated in IGFBP-1 secretion, but not 
phosphorylation, induced by leucine deprivation. 
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Figure 2.2. The effect of raptor+rictor or DEPTOR silencing on IGFBP-1 secretion 
and phosphorylation in leucine deprivation.A representative western immunoblot of 
HepG2 cell lysates (35 μg per lane) displaying A. S6K (Thr389) phosphorylation and B. 
Akt (Ser473) phosphorylation.  A representative western immunoblot of C. total IGFBP-
1 secretion and D-F. IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 in equal 
amounts (40 μL per well)of cell media of scrambled, raptor+rictor, DEPTOR siRNA with 
and without leucine deprivation in HepG2 cells. Values are displayed as mean + 
SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-way analysis of 
variance; Dunnet’s Multiple Comparison Test; n=3.Sc: Scrambled siRNA, 450 μM 
leucine. Sc:LD: Scrambled siRNA, 0 μM leucine (Leucine Deprivation). RR: 
Raptor+Rictor siRNA, 450 μM leucine. RR:LD: Raptor+Rictor siRNA, 0 μM leucine. D: 
DEPTOR siRNA, 450 μM leucine. D:LD: DEPTOR siRNA, 0 μM leucine. 
30 kDa pIGFBP-1
(Ser169)
 30 kDa 
pIGFBP-1
(Ser119)
 
Sc Sc:LD RR RR:LD D D:LD
0
5
10
15
20
R
e
la
ti
v
e
 I
G
F
B
P
-1
 p
h
o
s
p
h
o
ry
la
ti
o
n
 (
S
e
r1
1
9
)
(a
rb
it
ra
ry
 u
n
it
s
)
Sc Sc:LD RR RR:LD D D:LD
0
10
20
30
R
e
la
ti
v
e
 I
G
F
B
P
-1
 p
h
o
s
p
h
o
ry
la
ti
o
n
 (
S
e
r1
6
9
)
(a
rb
it
ra
ry
 u
n
it
s
)
*
*
* 
* 
E 
* *
*
* 
* 
F 
*
*
* *
*
* 
*
*
* 
*
*
* 
91 
 
 
 
2.3.5 Inhibition of AAR (MEK/ERK) signaling attenuates the amino 
acid response triggered by leucine deprivation 
To investigate stress-responsive pathways other than mTOR that may be involved in 
regulating IGFBP-1 phosphorylation under leucine deprivation, we inhibited AAR 
signaling, which is activated under cellular amino acid deprivation42,46,63. To chemically 
inhibit AAR signaling, we used AAR (MEK1/2) inhibitor U0126 (10 μM) since MEK 
signaling is necessary for GCN2-mediated eiF2α phosphorylation (pSer51) and 
subsequent propagation of the AAR55. We tested the effects of U0126 on leucine-
mediated IGFBP-1 secretion and phosphorylation.  
GCN2 was activated, as indicated by an increase in phosphorylation of GCN2 (Thr898), 
under leucine deprivation (+200%) regardless of MEK status (Figure 2.3A). Leucine 
deprivation also induced MEK activity proportionate to GCN2 as indicated by increased 
ERK phosphorylation (Thr202/Tyr204) (+200%), which was on the contrary decreased in 
the presence of U0126 (-50%) regardless of leucine status (Figure 2.3B).  
Figures 2.3C-D indicate that leucine deprivation and subsequent GCN2 activation further 
stimulate the AAR as evidenced by an increase in eiF2α (Ser51) phosphorylation 
(+150%) and total ATF expression (+200%) in leucine deprived samples. However, AAR 
(MEK/ERK) inhibition with U0126 was successful in preventing leucine deprivation-
induced AAR propagation downstream of GCN2. We concluded this because in the 
presence of the inhibitor, leucine deprivation was unable to induce eiF2α phosphorylation 
(Ser51) and ATF4 expression beyond control values (Figure 2.3C-D). Together, these 
data advocate the importance of MEK/ERK signaling in AAR propagation and confirm 
that chemical inhibition of AAR (MEK1/2) is sufficient in attenuating the AAR cascade.  
2.3.6 AAR (MEK/ERK) inhibition prevents leucine deprivation-induced 
IGFBP-1 secretion and phosphorylation 
We assessed whether attenuation of the AAR results in changes in downstream IGFBP-1 
secretion and phosphorylation. Total IGFBP-1 secretion was induced (+200%) in leucine 
deprivation and reduced (-50%) in the presence of U0126, regardless of leucine status 
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(Figure 2.3E). IGFBP-1 phosphorylation was strongly induced (Ser101, +700%, Ser119, 
+250% and Ser169, +900%) under leucine deprivation and reduced (-50%) at all three 
sites regardless of leucine status when AAR (MEK/ERK) was inhibited (Figure 2.3F-H). 
Importantly, the presence of inhibitor did not allow leucine deprivation to induce IGFBP-
1 secretion (Figure 2.3E) or phosphorylation at any of the three phosphosites (Figures 
2.3F-H). To validate changes in IGFBP-1 secretion and phosphorylation, we performed 
the Trypan Blue exclusion assay and demonstrated no significant change in post-
treatment cell viability between treatment conditions (Appendix A; Supplementary 
Figure 2). 
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Figure 2.3. Effect of pharmacological AAR inhibitor U0126 (MEK1/2) on IGFBP-1 
secretion and phosphorylation.A. Representative western immunoblot of HepG2 cell 
lysates (50 μg per lane) tested for GCN2 (Thr898) phosphorylation. A representative 
western immunoblot of HepG2 cell lysates (35 μg per lane) display B. ERK 
(Thr202/Tyr204) phosphorylation and C. eiF2α (Ser51) phosphorylation and in leucine 
deprivation and U0126 treatments. D. Representative western immunoblot of total ATF4 
expression (50 μg per lane). Representative western immunoblots indicating E. total 
IGFBP-1 secretion and F-H. IGFBP-1 phosphorylation at Ser101, Ser119, and Ser169.in 
HepG2 cell media in control, leucine deprivation, U0126, and leucine deprivation+U0126 
treatments. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 
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0.001 versus control; One-way analysis of variance; Dunnet’sMultipleComparisonTest; 
n=3.C: Control, 450 μM leucine. LD: Leucine deprivation, 0 μM leucine. U: U0126 (10 
μM), 450 μM leucine. U:LD: U0126 (10 μM), 0 μM leucine.
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2.3.7 siRNA silencing of ERK (to inhibit ERK-mediated AAR) 
prevents leucine deprivation-induced IGFBP-1 secretion and 
phosphorylation 
To determine that changes in IGFBP-1 secretion and phosphorylation under leucine 
deprivation and inhibition by U0126 were specific and that effects were targeted, in a 
subset of experiments, cells were treated with siRNA against ERK to attenuate ERK-
mediated AAR signaling. First, we validated ERK silencing efficiency by assessing cell 
lysates for total ERK expression (-45%) (Appendix A; Supplementary Figure 3). GCN2 
phosphorylation (Thr898) was induced by leucine deprivation (+200%) regardless of 
ERK status (Figure 2.4A). Although leucine deprivation triggered AAR signaling, it was 
not stimulated downstream of GCN2 in cells where ERK was silenced as seen by a lack 
of induction in eiF2α phosphorylation (Ser51) and ATF4 expression, which were 
otherwise both triggered (+200%) in leucine deprivation (Figure 2.4B-C). 
We examined whether ERK silencing (to inhibit ERK-mediated AAR) was able to 
attenuate IGFBP-1 secretion and phosphorylation in HepG2 cells. IGFBP-1 secretion and 
phosphorylation at all three sites (Ser101, Ser119, and Ser169) was not significantly 
different from control values in the presence or absence of leucine when ERK was 
silenced (Figures 2.4D-G), supporting our finding that IGFBP-1 secretion and 
phosphorylation under leucine deprivation is mediated by the AAR in a MEK/ERK 
dependant mechanism. 
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Figure 2.4. Effects of ERK siRNA on IGFBP-1 secretion and phosphorylation. 
Representative western immunoblots of HepG2 cell lysates (50 μg per lane) treated with 
scrambled or ERK siRNA with or without leucine deprivation displayingA. GCN2 
(Thr898) phosphorylation,B.eiF2α (Ser51) phosphorylation andC. total ATF expression. 
A representative western immunoblot of D.total IGFBP-1 secretion and E-G. IGFBP-1 
phosphorylation at Ser101, Ser119 and Ser169 in equal amounts of cell media of HepG2 
cell media treated with scrambled or ERK siRNA with and without leucine deprivation. 
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus 
control; One-way analysis of variance; Dunnet’sMultipleComparisonTest; n=3.Sc: 
Scrambled siRNA, 450 μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine (Leucine 
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Deprivation). ERK: ERK1/2 siRNA, 450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM 
leucine. 
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2.3.8 AAR inhibition via GCN2 silencing and ERK inhibition (to inhibit 
ERK-mediated AAR) act in a common mechanism to regulate 
IGFBP-1 secretion and phosphorylation in leucine deprivation 
To investigate that MEK/ERK inhibition-mediated regulation of IGFBP-1 secretion and 
phosphorylation functions in accordance with the AAR, we inhibited AAR signaling via 
GCN2 silencing in tandem with MEK/ERK signaling and assessed changes in 
downstream AAR effectors and IGFBP-1 secretion and phosphorylation. We used siRNA 
to knockdown GCN2 to prevent AAR-sensing, separately and together with ERK siRNA. 
We first confirmed GCN2 (-50%) and ERK (-50%) knockdown efficiency using cell 
lysates (Appendix A; Supplementary Figure 4A-B). GCN2 and ERK silencing, separately 
and together, prevented AAR propagation downstream of GCN2 as seen by a lack of 
increase in eiF2α phosphorylation (Ser51) and ATF4 expression in leucine deprivation by 
cells silenced for GCN2 and/or ERK, both of which were otherwise induced (+200%) by 
leucine deprivation (Figure 2.5A-B). Silencing of either or both proteins also attenuated 
the induction of IGFBP-1 secretion and phosphorylation in leucine deprivation (Figure 
2.5C-F). Interestingly, there was no additional reduction in IGFBP-1 secretion or 
phosphorylation in leucine plus or leucine deprived samples when both pathways were 
inhibited simultaneously (Figure 2.5C-F) suggesting that MEK/ERK signaling and the 
AAR function in a common mechanism to regulate both IGFBP-1 secretion and 
phosphorylation in leucine deprivation. 
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Figure 2.5. Effects of ERK and/or GCN2 silencing on IGFBP-1 secretion and 
phosphorylation. A. eiF2α (Ser51) phosphorylation and B. total ATF4 expression in 
HepG2 cell lysates silenced with GCN2 and/or ERK siRNA with or without leucine 
deprivation. A representative western immunoblot of C. total IGFBP-1 secretion and D-
F. IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 in equal amounts (40 μL per 
lan)e of cell media of HepG2 cells treated with scrambled, ERK, GCN2, or combined 
ERK+GCN2 siRNA with and without leucine deprivation.) treated with scrambled, ERK, 
GCN2, or ERK+GCN2 siRNA with or without leucine deprivation.Values are displayed 
as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-way 
analysis of variance; Dunnet’sMultipleComparisonTest; n=3. Sc: Scrambled siRNA, 450 
μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine (Leucine Deprivation). GCN2: 
GCN2 siRNA, 450 μM leucine. GCN2:LD: GCN2 siRNA, 0 μM leucine. ERK: ERK1/2 
siRNA, 450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM leucine. G:E: GCN2+ERK1/2 
siRNA, 450 μM leucine. G:E:LD: GCN2+ERK1/2 siRNA, 0 μM leucine. 
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2.3.9 IGFBP-1 phosphorylation induced by leucine deprivation is 
mediated by CK2 
We have hereby established that the AAR is responsible for mediating total IGFBP-1 
secretion as well as IGFBP-1 phosphorylation in leucine deprivation, and that mTOR 
signaling partially regulates IGFBP-1 phosphorylation but is the key mechanistic link 
between nutrient deprivation and total IGFBP-1 secretion. Based on previous data from 
our lab26 that CK2 mediates mTOR-induced IGFBP-1 phosphorylation, we investigated 
whether CK2 is also involved in leucine deprivation-mediated IGFBP-1 phosphorylation. 
We inhibited CK2 signaling using CK2 inhibitor TBB (1 µM) as previously26 in leucine 
plus or leucine deprived media. Following treatments, evaluation of HepG2 cells 
indicated intact cellular morphology, and Trypan Blue exclusion assay demonstrated that 
TBB treatments did not significantly alter the vitality of HepG2 cells (Appendix A; 
Supplementary Figure S5), supporting that normal cell physiology was intact post-
treatment.  
Leucine deprivation significantly induced total IGFBP-1 secretion (+250 to 300%) 
regardless of whether they were treated with TBB, suggesting that CK2 is not involved in 
regulating total IGFBP-1 secretion during leucine deprivation (Figure 2.6A). However, 
similar to MEK/ERK- dependent AAR inhibition, TBB prevented the phosphorylation of 
IGFBP-1 at all three sites as seen by an overall reduction (-60%) of IGFBP-1 
phosphorylation (Ser101, Ser119 and Ser169) in TBB-treated cells and no significant 
increase in phosphorylation in leucine deprived versus leucine plus samples when both 
are treated with TBB (Figure 2.6B-D). Therefore, since inhibition of CK2 activity 
attenuated leucine deprivation-induced IGFBP-1 phosphorylation without affecting total 
IGFBP-1 secretion, we assert that CK2 may potentially be the major kinase responsible 
for IGFBP-1 phosphorylation under conditions of leucine deprivation. 
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Figure 2.6. Effect of CK2 inhibition on IGFBP-1 secretion and phosphorylation. A. 
A representative blot of equal volumes of HepG2 cell media (40 μL per lane) treated with 
leucine plus (control), leucine deprivation, TBB (1 μM), or leucine deprivation+TBB. B-
D. Representative western immunoblots of equal volumes of HepG2 cell media assessed 
for IGFBP-1 phosphorylation at Ser101, Ser119, and Ser169. Values are displayed as 
mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way 
analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM 
leucine. LD: Leucine deprivation, 0 μM leucine. TBB: TBB (1 μM), 450 μM leucine. 
TBB:LD: TBB (1 μM), 0 μM leucine. 
105 
 
 
 
 
 
2.3.10 Increases in IGFBP-1 phosphorylation due to leucine 
deprivation inhibit IGF-I bioactivity 
To assess whether changes in IGFBP-1 phosphorylation under leucine deprivation 
effectively regulate IGF-I bioactivity, we employed an IGF-1 receptor (IGF-1Rβ) 
autophosphorylation assay in P6 cells to test for IGF-1Rβ (Tyr1135) 
autophosphorylation26,56 as an indicator of IGF-I bioactivity during leucine deprivation. 
When P6 cells were incubated with 25 ng/mL IGF-I only (positive control), we observed 
a drastic increase in IGF-1R phosphorylation (Tyr1135) (+2500%) compared to P6 cells 
without IGF-I (negative control) (Figure 2.6), demonstrating the ability of IGF-I to 
stimulate IGF-1Rβ autophosphorylation in P6 cells. P6 cells were also treated with IGF-I 
plus post-treatment HepG2 cell media (leucine plus or leucine deprivation). The amount 
of leucine plus or leucine deprivation media used in the treatment was adjusted for total 
IGFBP-1 and buffer-exchanged to P6 cell media as described above (Section 2.3.6) to 
ensure that changes in IGF-1Rβ phosphorylation were not due to differences in media 
composition.  
When P6 cells were incubated with IGFBP-1 from HepG2 cells with 450 µM leucine 
(basal) media+IGF-I (control), a significant reduction in IGF-1R autophosphorylation 
was observed (-40%) compared to P6 cells incubated with IGF-I only. This suggests that 
basal levels of IGFBP-1 secreted by HepG2 cells were able to sequester bioavailable 
IGF-I and subsequently reduce IGF-1R signaling. On the other hand IGF-I induced IGF-
1Rβ phosphorylation was almost completely abolished (-90%) when HepG2 cell media 
from leucine deprivation (0 µM leucine) was used. These data suggest that IGF-1Rβ 
phosphorylation was inhibited due to the presence increase in IGFBP-1 phosphorylation 
due to leucine deprivation (Figure 2.6). Considering equal concentration of total IGFBP-1 
from HepG2 cell media incubated with IGF-I was used to activate IGF-1R in P6 cells for 
each of the treatments, these data support that the hyperphosphorylation of IGFBP-1 in 
leucine deprivation effectively inhibits IGF-I bioactivity through reduced IGF-1Rβ 
autophosphorylation (pTyr1135). 
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Figure 2.7. The effect of leucine deprivation-induced IGFBP-1 phosphorylation on 
IGF-1R autophosphorylation.HepG2 cells were treated in leucine plus (450 μM Leu) or 
leucine deprived (0 μM Leu) for 24 hours. Equal concentrations of IGFBP-1 in HepG2 
cell media were mixed with P6 media (serum free) and human recombinant IGF-I (25 
ng/mL) for 2 hours to allow IGFBP-1 to sequester IGF-I. Ten minute exposure to P6 cells 
allowed the induction of IGF-I-mediated IGF-1Rβ autophosphorylation (Tyr1135). A 
representative western immunoblot of cell lysates (50 μg per lane) from P6 cells over-
expressing IGF-IR. Blots were assessed for IGF-IR autophosphorylation (Tyr1135). 
Increased IGFBP-1 phosphorylation due to leucine deprivation results in significantly 
decreased IGF-1R activation. Values are displayed as mean + SEM. *p< 0.05, **p= 
0.001-0.05, ***p < 0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. – IGF-I: Negative control, no IGF-I, no 
IGFBP-1. +IGF-I: Positive control, 25 ng/mL IGF-I, no IGFBP-1. 450 μM leucine + 
IGF-I: IGFBP-1 from HepG2 cell media with leucine plus 25 ng/mL IGF-I. 0 μM leucine 
+ IGF-I: IGFBP-1 from HepG2 cell media without leucine plus 25 ng/mL IGF-I. 
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2.4 Discussion 
In this study, we use HepG2 cells, to show for the first time that the AAR regulates 
IGFBP-1 secretion and phosphorylation at Ser101, Ser119 and Ser169 in amino acid 
deprivation. Although mTOR inhibition induced IGFBP-1 secretion in leucine 
deprivation, it failed to increase IGFBP-1 phosphorylation to the levels induced by 
leucine deprivation alone. Activation of mTOR validated these findings, suggesting that 
mTOR regulates IGFBP-1 secretion but not IGFBP-1 phosphorylation in leucine 
deprivation. However, when the AAR was blocked, it prevented both IGFBP-1 secretion 
and phosphorylation in response to leucine deprivation. These findings are consistent 
with our hypothesis that mTOR inhibition and AAR activation increase IGFBP-1 
secretion and phosphorylation independently in response to amino acid deprivation. This 
study provides a novel understanding of the mechanisms modulating IGF-I 
bioavailability and potentially fetal growth under reduced amino acid availability in FGR. 
Nutrient deprivation is a leading cause of FGR2,27, a perinatal disorder which increases 
the risks of both severe childhood and adult metabolic and neurological complications. 
IGF-I is the key regulator of fetal growth beginning at ~16-20-weeks gestation64,65 and its 
altered circulating levels during gestation are correlated with fetal growth 
complications66-68. IGF-I bioavailability is strongly influenced by the phosphorylation 
status of IGFBP-169. Previous literature reports 59,70,71 including ours26,57,58 indicate strong 
association of IGFBP-1 phosphorylation with altered fetal growth. Mimicking hypoxia 
and leucine deprivation in HepG2 cells, the two key conditions associated with human 
FGR in vivo, we have previously demonstrated site-specific hyperphosphorylation of 
IGFBP-1 in vitro25. Furthermore, our previous data have also shown that increase in 
phosphorylation of IGFBP-1 at specific sites (Ser101, Ser119 and Ser169) in human 
amniotic fluid to be associated with increased binding affinity for IGF-I in FGR57. These 
data provided strong rationale to determine the mechanistic details of how IGFBP-1 
phosphorylation is controlled in restriction of fetal growth such as due to lack of nutrient 
availability in FGR. 
108 
 
 
 
 
FGR is characterized by decreased amino acid availability2,21,27,72 which is known to 
activate the AAR44,63 and inhibit the mTOR signaling pathway29,41. We investigated the 
two regulatory pathways (AAR and mTOR), to determine the mechanism linking reduced 
nutrient availability to IGFBP-1 secretion and phosphorylation and consequently, reduced 
IGF-I bioavailability and downstream IGF-I bioactivity via assessing changes in IGF-1R 
autophosphorylation.  
We utilized HepG2 cells in this study as a well-established model for human fetal 
hepatocytes50-54. The HepG2 and fetal hepatocyte transcriptomes54,73,74 and 
secretomes38,50,53,75 are highly similar. Moreover, we have shown that HepG2 cells are 
also highly responsive to hypoxia and leucine deprivation25. In addition we have tested 
the validity of our data with IGFBP1 using well-characterized76 fetal primary baboon 
hepatocytes26 
The mTOR pathway modulates cell growth and function in response to changes in the 
levels of growth factors, such as IGF-I and nutrients, and is down-regulated under 
reduced cellular energy states29,30,37,40,41. Our results with pharmacological inhibitor 
(rapamycin) and RNAi based inhibition of mTORC1 and C2 signaling have previously 
demonstrated induced IGFBP-1 secretion and phosphorylation in HepG2 cells26. In the 
present study, our new findings demonstrated that while mTOR signaling plays a vital 
role in regulating IGFBP-1 secretion, interestingly, leucine deprivation impinges on 
additional mechanisms to produce its downstream stress response on IGFBP-1 secretion 
and phosphorylation. 
Dietary protein restriction significantly induces hepatic IGFBP-1 mRNA expression in 
rats77 and is consistently reduced in human circulation in conditions of reduced nutrient 
intake78,79. It has also been reported that leucine deprivation is sufficient in inducing 
maximal IGFBP-1 mRNA expression compared to the individual or combined restriction 
of any other essential amino acid80. It is well established that the AAR signal transduction 
pathway is activated by limitation or imbalance of essential amino acids40,42-47. It has also 
been previously shown that deprivation of a single essential amino acid, leucine, is 
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sufficient to induce AAR activation via GCN2 phosphorylation43. To our knowledge the 
role of AAR in regulation of IGFBP-1 phosphorylation has however not yet been 
investigated. 
In concordance with literature reports55, we showed that leucine deprivation activated the 
AAR, as expected, and that this effect was attenuated downstream of GCN2 when 
MEK/ERK was inhibited. Attenuating the AAR via MEK/ERK and/or GCN2 
inhibition/silencing clearly prevented induction of both IGFBP-1 secretion and 
phosphorylation due to leucine deprivation; this importantly shows that the mitogenic 
MEK/ERK cascade mediates leucine deprivation-induced IGFBP-1 secretion and 
phosphorylation via its interactions with the AAR pathway. This cross-talk is vital in 
transducing the AAR and elucidating downstream changes in IGFBP-1 secretion and 
phosphorylation, suggesting that MEK/ERK-dependant AAR signaling is the key 
mechanism involved in fetal hepatic IGFBP-1 phosphorylation, and consequently, 
regulation of IGF-I bioavailability. Since inhibition of the AAR was sufficient to 
attenuate this response, we assert that IGFBP-1 secretion and phosphorylation is 
regulated primarily by the AAR in a MEK-dependant manner while mTOR contributes a 
significant role in regulation of IGFBP-1 secretion. It is unclear whether the AAR and 
mTOR signaling function in common or parallel mechanisms to regulate IGF-I 
bioavailability and bioactivity. In light of our findings, we propose a model where lack of 
amino acid availability inhibits hepatic mTOR signaling while simultaneously inducing 
the AAR pathway, leading to an increase in IGFBP-1 phosphorylation and decreased 
fetal cell growth and proliferation (Figure 2.8). 
 
 
110 
 
 
 
 
 
 
Figure 2.8. Proposed model of fetal growth regulation in FGR. Amino acid limitation 
causes a decrease in mTOR signaling which leads primarily to an increase in IGFBP-1 
secretion. A concurrent induction in the AAR pathway signals an increase in IGFBP-1 
secretion and phosphorylation, to regulate IGF-I bioavailability and decreased 
downstream fetal growth. 
Although increased total IGFBP-1secretion is a strong indicator of reduced IGF-I 
bioavailability, we assert that the pathogenesis of FGR is due primarily to phosphosite-
specific changes in IGFBP-1 phosphorylation, supported by our earlier data that show 
increases (30-300-fold) in IGF-1 affinity to be linked with marked increases in distinct 
site-specific IGFBP-1 phosphorylation (Ser101, Ser119, Ser169)25. 
Notably, not all serine residues in our study due to leucine deprivation appear to be 
equally prone to phosphorylation and this reflects an additional level of complexity of the 
regulation of IGF-I bioavailability. For example, it is possible that different types of 
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cellular stresses, such as leucine deprivation versus hypoxia, have distinct effects on IGF-
I bioavailability mediated by different patterns of IGFBP-1 serine phosphorylation25. 
Although the true biological significance of the variable degree of phosphorylation at the 
different serine residues in response to leucine deprivation remains to be established, we 
speculate that induction of phosphorylation at Ser119 under leucine deprivation in this 
study possibly acts through synergistic interactions with doubly or multiply 
phosphorylated residues which may result in the high affinity of IGFBP-1 for IGF-I.  
These synergistic multi-site interactions were not tested in our previous study56 or 
elsewhere in the literature. Such interactions would require further experimental evidence 
through structure-functional and quantitative mass spectrometry (MRM MS) studies. In 
addition, we expect that the relatively weaker induction of phosphorylation at Ser119 
compared to Ser101 and Ser169 under leucine deprivation also reflects the functional 
characteristics and substrate preference of the protein kinases responsible for 
phosphorylating respective serine residues. 
The three phosphorylated Ser residues in IGFBP-1 are surrounded by acidic amino acids, 
making them conducive to phosphorylation by CK269,81. CK2 has been suggested to be a 
kinase that could phosphorylate IGFBP-1 in vitro82. However, we have recently 
demonstrated that inhibition of CK2 by pharmacological inhibitor TBB or targeting CK2 
holoenzyme using RNAi prevented phosphorylation of IGFBP-1 in HepG2 cells in 
culture26. In the current study we further indicate that CK2 is involved in IGFBP-1 
phosphorylation under leucine deprivation implicating CK2 as a potential kinase 
regulating increased IGFBP-1 phosphorylation under nutrient deprivation. Whether CK2 
is the key kinase linking the AAR signaling pathway in fetal liver to IGFBP-1 
phosphorylation under leucine deprivation is currently not known.  
In conclusion, our findings in this study are consistent with the possibility that the AAR 
signaling is involved in pathogenesis of FGR. Levels of essential amino acids are reduced 
in FGR fetuses83-86. We have shown, for the first time, that activation of the AAR in the 
fetal liver may constitute a key mechanism linking decreased amino acid availability to 
decreased IGF-I bioavailability and reduced fetal growth in FGR. To test this hypothesis, 
animal models relevant to human FGR, such as our established baboon model of FGR26, 
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will be useful. Because of the inaccessibility of the human fetus, implications for the 
diagnosis and treatment of FGR are not immediately apparent. However, the decidua 
constitutes the primary source of IGFBP-1 in the maternal circulation during 
pregnancy87,88, and maternal IGFBP-1 phosphorylation is increased in FGR 
pregnancies89. If phosphorylation of decidual IGFBP-1 is regulated by the AAR and 
mTOR signaling pathways, our findings may be used in future to develop approaches for 
diagnosis and intervention in FGR. 
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Chapter 3 
3 Exploring the kinases involved in leucine deprivation-mediated IGFBP-1 
phosphorylation 
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3.1 Introduction 
Fetal Growth Restriction (FGR) predisposes infants to severe childhood and adult 
morbidities1,2, making it an important area for investigation. Affecting 5-7% of 
pregnancies3, FGR commonly results from insufficient in utero availability of nutrients, 
such as oxygen and essential amino acids, to the fetus due to either maternal malnutrition 
or inadequate placental nutrient transfer from mother to fetus4-6. The fetal response to 
perigestational nutrient deficiency can lead to restricted growth, although the molecular 
mechanisms by which this occurs are largely unknown. The insulin-like growth factors 
(IGF-I and IGF-II) are critical factors in fetal growth and development across species7-10. 
Knockout studies of IGF-I and IGF-II in mice demonstrate that both IGFs are crucial to 
fetal growth and development11, and that deficits in IGF-II lead to pathological placental, 
embryonic, and organ development as well as fetal demise12,13. IGF-II provides a 
continuous stimulus for growth14and exists in the fetal serum in far greater concentrations 
(3-10 fold) than IGF-I14,15. However, as gestation progresses, fetal development becomes 
increasingly dependent on IGF-I16, whose function is acutely sensitive to physiological 
and environmental cues, such as nutritional stress14,17. In human studies, fetal IGF-I 
levels in particular have been consistently positively associated with fetal size and birth 
weight18-21, and its fetal circulating levels are decreased in growth restricted human 
fetuses8,19,21-23. IGF-Binding Protein 1 (IGFBP-1) secreted from the fetal liver24, the 
predominant fetal circulating IGFBP in pre-natal life25-28, is a potent inhibitor of IGF-I 
bioavailability in vitro and in vivo29-33and functions by sequestering IGF-I from its cell-
surface cognate receptor (IGF-1R), preventing downstream cell growth and 
proliferation34. Phosphorylated IGFBP-1 isolated from HepG2 cell media, an in vitro 
model for fetal hepatocytes35-39 as well as phosphorylated IGFBP-1 from human plasma 
demonstrates a 6-10 fold greater affinity for IGF-I compared to the non-phosphorylated 
isoform29,40.The phosphorylation status of fetal IGFBP-1 during pregnancy has been 
associated with fetal growth abnormalities41-44. Importantly, our team has recently 
detected elevated levels of phosphorylated IGFBP-1 (pSer101, pSer119, pSer169) in 
umbilical cord plasma45 from FGR babies.  
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Previous work in our lab has established that FGR is associated with fetal IGFBP-1 
hyperphosphorylation42,45, making it crucial to identify the molecular mechanisms which 
mediate amino acid deprivation-induced IGFBP-1 phosphorylation, which, to date, have 
not been extensively classified. Leucine depletion stimulates IGFBP-1 phosphorylation 
(pSer101, pSer119, pSer169) in HepG2 cells46which we recently demonstrated to be 
linked to the activation of the Amino Acid Response (AAR) (Chapter 2). The specific 
kinases which phosphorylate IGFBP-1 at Ser101, Ser119, and Ser169 in leucine 
deprivation, however, have not been reported.  
Initialstudies of the kinases whichphosphorylate IGFBP-1 were conducted in human 
endometrial stromal cells derived from pregnant women and cultured in vitro47. Due to 
the proximity of IGFBP-1 phospho-serines to acidic residues conducive to 
phosphorylation by CK2, and based on the elevated presence of PKA substrate, cAMP, in 
stromal cells47, IGFBP-1 was isolated from cell media from cultured stromal cells and 
incubated with purified protein kinase CK2 or protein kinase A (PKA). Both kinases 
induced phosphorylation of previously non-phosphorylated IGFBP-1 indicating that CK2 
and PKA can phosphorylate IGFBP-1 in vitro47. However, the direct exposure of CK2 or 
PKA to IGFBP-1 when the protein and kinases are co-incubated is not reflective of 
intracellular conditions; thus, the kinases which phosphorylate IGFBP-1 when co-
incubated with the substrate do not necessarily represent the kinases which are triggered 
intracellularly to phosphorylate IGFBP-1 with high affinity in either regular or nutrient 
restricted conditions. Additionally, the distinct IGFBP-1 residues that were 
phosphorylated by these kinases were not reported. The proximity of acidic amino acids 
(Aspartic Acid (D), Glutamic Acid (E)) to residues Ser101, Ser119, and Ser169 on 
IGFBP-1 make them conducive to direct phosphorylation by CK2 (Table 3.1). Ser101 
and Ser169 are proximal to structured regions on the IGFBP-1 molecule that contain the 
IGF-I-binding domain, whereas Ser119 is contained within the unstructured linker region 
that is unique to each IGFBP48. A subsequent study by Ankrapp et. al. demonstrated that 
partially purified CK2 from HepG2 cell extracts phosphorylated recombinant human 
IGFBP-1 produced by CHO cells in vitro at Ser101 and Ser16949. The functional 
relevance of CK2 in phosphorylating IGFBP-1 within live cells, however, was not 
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established. CK2 is a pleiotropic kinase with over 300 potential substrates50; therefore, to 
establish CK2 as the key, specific kinase implicated in IGFBP-1 phosphorylation in live 
cells, it was necessary to specifically inhibit CK2 using both pharmacological and siRNA 
approaches and to measure subsequent IGFBP-1 phosphorylation, a strategy which was 
recently undertaken in our laboratory in HepG2 cells45.  
The recent demonstration by our team that pharmacological (TBB) and siRNA inhibition 
of CK2 reduces IGFBP-1 phosphorylation in live, cultured HepG2 cells in addition to the 
demonstration that hepatic CK2 activity is elevated in growth-restricted baboon offspring 
from mothers who received restricted diets during gestation45, provides strong rationale 
for our investigation as to whether CK2 is a direct mechanistic link between amino acid 
depletion and IGFBP-1 phosphorylation.  
PKA activity is also sensitive to fluctuations in nutrient availability51-56 and reduction in 
its activity has been linked to total IGFBP-1 mRNA and protein expression in HepG2 
cells57,58. Similarly, overall protein kinase C (PKC) activity is decreased in nutrient 
deficiency59-63, and has been linked to elevated IGFBP-1 protein secretion in HepG2 
cells64. However, whether PKA and PKC are linked to IGFBP-1 phosphorylation, in 
either regular leucine or leucine-deprived conditions, has not been reported. PKC exists 
in a variety of isotypes comprising of conventional PKCs (cPKCs: α, βI, βII and γ), novel 
PKCs (nPKCs: δ, ε, θ and η) and atypical PKCs (aPKCs: ζ, ν and λ)65 all of which are 
dynamically regulated by a variety of intra- and extra-cellular stimuli66. The placental 
PKC isoform profile is altered in mice with induced FGR67,68 although the exact function 
of each isoform is unknown. Neither PKA nor PKC contain consensus sequence sites for 
the direct phosphorylation of the IGFBP-1 protein at Ser101, Ser119 or Ser169 (Table 
3.1) despite PKA being implicated as an IGFBP-1 kinase when the purified kinase was 
co-incubated with the substrate in vitro47. It is possible that PKA and PKC phosphorylate 
IGFBP-1 at additional Ser or Thr residues for which it shares consensus sequence sites 
(Table 3.1). IGFBP-1 was previously shown to be phosphorylated at Ser95 and Ser98, 
suggesting that additional IGFBP-1 residues in addition to Ser101, Ser119 and Ser169 
which are hyperphosphorylated in FGR45,69, may also be prone to phosphorylation70. 
PKC or PKA may indirectly modulate IGFBP-1 phosphorylation (Ser101, Ser119 and 
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Ser169) in HepG2 cells via phosphorylation at discrete IGFBP-1 residues for which it 
shares consensus sequences (Table 3.1), or via up-stream signaling networks which 
induce CK2 activity. For example, both kinases have been implicated down-stream of 
mechanistic target of rapamycin (mTOR signaling) and may function in a common 
signaling mechanism to modulate IGFBP-1 phosphorylation by mTOR, which was 
previously demonstrated to mediate IGFBP-1 phosphorylation via CK245. 
In this study, we sought to elucidate the roles of CK2, PKC, and PKA in modulating 
IGFBP-1 phosphorylation (Ser101, Ser119 and Ser169) in leucine-deprived HepG2 cells, 
which have been validated as an in vitro model for human fetal hepatocytes35-39. We 
hypothesized that CK2 activity is induced by leucine deprivation and is directly linked to 
IGFBP-1 phosphorylation (Ser101, Ser119 and Ser169) in HepG2 cells. We focused on 
IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 because these sites have been 
demonstrate to modulate IGFBP-1 affinity for IGF-I42,46,71,72 and have been shown by our 
team to be hyperphosphorylated in FGR45,69. Further, based on the down-regulated 
activity of the PKCs and of PKA in nutrient restriction which has been demonstrated in 
multiple cell types in vitro51-53,59-63, we hypothesized a possible link between PKC and 
PKA and IGFBP-1 phosphorylation in leucine deprivation. Due to the fact that Ser101, 
Ser119 and Ser169 do not fall in the consensus sequences for PKC or PKA, we predict 
that any identified links between PKC or PKA and IGFBP-1 phosphorylation will be 
indirect and inflicted via CK2.  
To examine the mechanistic links between CK2, PKC and PKA and IGFBP-1 
phosphorylation in leucine deprivation, we inhibited CK2, PKC or PKA in regular media 
(450 µM leucine, equivalent to standard DMEM/F12) and in leucine deprived (0 µM 
leucine, to ensure maximal IGFBP-1 phosphorylation46 conditionsand studied changes in 
IGFBP-1 secretion and phosphorylation (pSer101, pSer119 and pSer169) by western 
immunoblot analyses of conditioned cell media. To down-regulate overall PKC signaling, 
we used non-isoform discriminate PKC inhibitor Bisindolylmaleimide (BIS) and pan-
PKC siRNA, which targets all cPKCs and nPKCs in addition to aPKCζ, and aPKCν. We 
attribute functional significance to our findings using our established45,71 IGF-1R 
autophosphorylation assay.Whereas direct exposure of purified IGFBP-1 to CK2 or PKA 
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demonstrated an ability for the two kinases to phosphorylate IGFBP-1in vitro in earlier 
studies47,49, it was not previously studied whether the direct, intracellular inhibition of 
these kinases would alter IGFBP-1 phosphorylation in regular (leucine plus) or in 
leucinedeprived conditions. These previous investigations did not adequately demonstrate 
that CK2 or PKA were linked to IGFBP-1 phosphorylation in live cells; thus, the direct 
inhibition of candidate kinases (CK2, PKA, PKC) for IGFBP-1 phosphorylation in 
HepG2 cells in this study sought to confirm whether the kinases are essential to leucine 
deprivation-mediated IGFBP-1 phosphorylation in vitro. To our knowledge, we provide 
the first report of the relative effects of inhibiting CK2, PKA or PKC in modulating 
leucine deprivation-induced IGFBP-1 phosphorylation (pSer101, pSer119, and pSer169) 
in HepG2 cells, which conclusively illustrate the functional roles of the kinases in 
modulating IGFBP-1 phosphorylation in leucine restriction which have not been 
previously reported. Identifying the specific intracellular kinases that are linked to 
IGFBP-1 phosphorylation in leucine deprivation in cultured HepG2 cells is important to 
provide insight into the signaling mechanisms that mediate IGFBP-1 phosphorylation in 
leucine deprivation. 
Table 3.1. IGFBP-1 peptide sequence (45-180) and possible phosphorylation sites for 
CK2, PKC and PKA. 
IGFBP-1 peptide 
sequence (45-
180) 
45ACGVApT50ARCARGLpS58CRALPGEQQPLHALTRGQGACVQESDASAP
HAAEAGSPESPEpS101TEITEEELLDNFHLMAPpS119EEDHSILWDAISTYDG
SKALHVTNIKKWKEPCRIELYRVVESLAKAQETpS169GEEISKFYLPN180 
Kinase 
consensus 
sequences: 
CK2: pS/T-X-X-D/E                    
pS101TEITEEE 
pS119EED 
pS169GEE 
PKC: pS/T-X-R/K                              
pT50AR 
pS58CR 
PKA: R/K-R/K-X-pS/T            NIL 
IGFBP-1 residues phosphorylated in HepG2 cells in response to leucine deprivation46 and in FGR umbilical 
cord plasma45 (Ser101, Ser119 and Ser169) are likely sites for phosphorylation by CK2. Conversely, PKC 
and PKA are not likely to directly phosphorylate IGFBP-1 at these sites.  
CK2 
CK2 
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3.2 Methods 
3.2.1 Cell culture 
Human hepatocellular carcinoma (HepG2) cells were purchased from ATCC 
(Mananassas, VA). HepG2 cells were cultured in DMEM/F-12 supplemented with 10% 
FBS (Invitrogen Corp., Carlsbad, CA). Cultures were incubated in 20% O2 and 5% CO2 
and maintained at 37°C.  
3.2.2 Leucine deprivation 
HepG2 cell treatments were conducted in specialized DMEM/F12 previously deprived 
and restored of specific amino acids46. Cells were incubated in this specialized media 
supplemented with 450 µM leucine to mimic leucine concentrations in regular 
DMEM/F12 as a control (leucine plus) or in media that was not supplemented with 
leucine (0 μM leucine; leucine minus) to ensure maximum induction of IGFBP-1 
phosphorylation as previously46. The concentrations of all other amino acids were 
consistent between the two sets of media.  
3.2.3 Inhibitor treatments 
HepG2 cells were plated in 12-well plates and grown to ~75% confluence. After 
starvation in 2% FBS (DMEM/F12) for 6 hours, cell media was replaced with specialized 
leucine plus or leucine minus media containing the various inhibitors. Concentrations for 
BIS (7.5 µM) and PKI 5-24 (PKI) (100 nM) treatments were determined based on dose-
dependency treatments (Appendix C).  Phosphorylation of CREB (Ser133) was used to 
assess changes in PKA activity. TBB was used at a concentration of 1 μM as reported 
previously71. HepG2 cells were incubated with the inhibitors for 24 hours, after which 
cell media and lysates were prepared as previously71. 
3.2.4 RNA interference (RNAi) silencing 
HepG2 cells were plated in 12-well culture plates and grown to 60% confluence. 5 μL 
Dharmafect transfection reagent 4 (Thermo Scientific, Rockford, IL, USA) was used to 
transfect 100 nM siRNA against CK2α, CK2α’, CK2β (SMARTpool, Thermo Scientific, 
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Rockford, IL, USA) or pan-PKC (against PKC isoforms α, β, βII, γ, δ, ε, η, θ, ζ, and ν) 
(Santa Cruz Biotechnology, Dallas, TX, USA) in serum free DMEM/F12 for 24 hours to 
ensure maximal silencing efficiency. Transfection media containing the transfection 
reagent was removed 24 hours post-transfection. HepG2 cells were subsequently 
incubated with specialized leucine plus or leucine minus media for an additional 72 
hours. Western immunoblot analysis of CK2α, CK2α’ and CK2β demonstrated effective 
silencing of CK2 subunits, whereas immunoblot analysis of PKCδ and PKCε together 
represented effective silencing of pan-PKC. 
3.2.5 Cell viability assay 
To ensure that leucine deprivation and/or chemical BIS did not compromise cell viability, 
we employed a trypan bBlue exclusion assay. This confirmed that decreases in IGFBP-1 
phosphorylation were not attributable to compromised cell vitality due to exposure to the 
treatment stimuli. Following leucine deprivation and/or TBB or BIS treatments, cells 
were re-suspended in serum-free DMEM/F12. Cell suspensions were diluted 1:1 with 
0.4% trypan blue and counted using the Countess Automated Cell Counter (Life 
Technologies, Carlsbad, CA). Cell survival was determined as a ratio of live/total cells. 
3.2.6 SDS-PAGE and Western Blotting 
Equal amounts of cell lysate protein (40-50 μg) were separated by SDS-polyacrylamide 
gel electrophoresis to determine total expression of CK2α, CK2α’, CK2β, PKCδ, PKCε, 
CREB, IGF-1Rβ, and phosphorylation of CREB (pSer133), IGF-1Rβ (pTyr1135). 
IGFBP-1 secretion and phosphorylation at Ser101, Ser119 and Ser169 by HepG2 cells 
was determined by western immunoblot of equal volumes of cell media (40-50 μL). Cell 
lysates blots were probed with β-actin primary antibody and bands were used for 
normalization. Equal loading of conditioned cell media was verified using fibrinogen 
antibody (Appendix D).  
To block non-specific protein binding on nitrocellulose membranes, we incubated blots 
with 5% skim milk diluted in Tris-buffered saline with 0.1 % Tween-20 (TBST) for 1 
hour at room temperature. Alternatively, blots for monoclonal IGFBP-1 were blocked 
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with 5% Bovine Serum Albumin in TBST and blots for total CK2α, CK2α’ or CK2β 
were blocked in Odyssey Blocking Buffer (LI-COR Biosciences, Bad Homburg, 
Germany). Monoclonal anti-human IGFBP-1 (mAb 6303) was obtained from Medix 
Biochemica (Kauniainen, Finland) and custom IGFBP-1 polyclonal antibodies against 
pSer101, pSer119, and pSer169 were generated at YenZyme Antibodies LLC, San 
Francisco, CA, USA. The custom phosphosite-specific antibodies against pSer101 and 
pSer169 have been previously validated in the context of non-phosphorylatable IGFBP-1 
mutants71. The specificity of phosphosite-specific pSer119 antibody was subsequently 
validated in the same manner45. Anti-fibrinogen primary antibody was purchased from 
Sigma Aldrich (St. Louis, MO, USA) and antibodies against CK2α, CK2α’ and CK2β 
were a kind gift from Dr. D.Litchfield, Western University, London, ON. Remaining 
primary antibodies were obtained from Cell Signaling Technologies (Beverly, MA, 
USA). All primary antibodies were diluted to 1:1000 with the exception of β-actinwhich 
was diluted to 1:3000. Peroxidase-labeled goat-anti mouse or goat-anti rabbit secondary 
antibodies were obtained from BioRad Laboratories Inc., and used at a concentration of 
1:10000. Densitometric analyses of bands were conducted using Image Lab (Beta 3) 
software. 
3.2.7 IGF-1 receptor (IGF-1R) activation assay 
P6 cells are an immortalized BALB-c3T3 mouse embryo fibroblast cell line derived to 
over-express IGF-1R56. We cultured P6 cells in DMEM/F12 with sodium pyruvate, 
supplemented with 10% FBS. Post-treatment conditioned HepG2 cell media containing 
variable concentrations of total and phosphorylated IGFBP-1 were aliquoted to contain 
equal amounts of total IGFBP-1. In addition to leucine plus and leucine minus 
conditioned HepG2 cell media which was previously used to assess IGF-1R 
autophosphorylation in P6 cells (Chapter 2), we used leucine plus and leucine minus 
conditioned media from HepG2 cells which had been incubated with TBB or BIS. In 
order to ensure that changes in IGF-1Rβ phosphorylation are caused by differential 
degrees of IGFBP-1 phosphorylation rather than total circulating IGFBP-1 or differences 
in media composition between treatments, media aliquots were buffer-exchanged to 
serum-free P6 cell media (DMEM/F12, with sodium pyruvate) using Amicon Ultra-
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0.5 mL Centrifugal Filter Units (Millipore, Darmstadt, Germany) per manufacturer 
instructions. Buffer-exchanged conditioned media were subsequently incubated with 
rhIGF-I (25 ng/mL) for two hours at room temperature. P6 cells in 12-well plates were 
grown to 75% confluency. For treatment, P6 cells were incubated with prepared media 
aliquots for 10 minutes. Following the incubation period, treatment media was aspirated. 
Equal amounts of total protein from post-treatment P6 cell lysates were separated using 
SDS-polyacrylamide gel electrophoresis. Western immunoblots were used to assess 
changes in IGF-1R autophosphorylation (pTyr1135) using phosphosite-specific IGF-1Rβ 
(pTyr1135). 
3.2.8 CK2 Activity Assay 
CK2 activity was measured in HepG2 cell extracts from treatments with leucine 
deprivation with and without CK2 inhibitor (TBB) or PKC inhibitor (BIS). As 
previously71,73, the synthetic peptide substrate DSD (RRRDDDSDDD)(100 µL) which 
was formerly described50 was used to assess CK2 activity. Phosphorus-32 (P32) was 
purchased from PerkinElmer (Waltham, MA, USA) and DSD peptide was a kind gift 
from Dr. David Litchfield. 
3.2.9 Data presentation and statistics 
GraphPad Prism 5 (Graph Pad Software Inc., CA) was used for all data analyses. In each 
independent experiment, the densitometric values for control bands were averaged, and 
this number was assigned an arbitrary value of 1. Densitometric values for each treatment 
were averaged among replicates and expressed relative to control. For assessment of 
statistical significance, we used one-way analysis of variance (ANOVA) with Dunnet’s 
Multiple Comparison Post-Test and expressed results as the mean ± Standard Error of 
Measurement (SEM). Significance was accepted at *p<0.05, **p=0.01-0.05, ***p<0.01. 
n=3. 
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3.3 Results 
3.3.1 Silencing of CK2α+α’+β subunits confirms that CK2 contributes 
to modulating IGFBP-1 phosphorylation but not secretion 
caused by leucine deprivation 
Based on our previous datawhich indicate that pharmacological CK2 inhibitor, TBB, 
prevents leucine deprivation-induced IGFBP-1 phosphorylation (Chapter 2), we used a 
targeted approach (RNAi) to silence the CK2 holoenzyme by siRNA against the three 
CK2 subunits (CK2α+α’+β) and assessed changes in total and phosphorylated IGFBP-1 
in leucine deprivation. The expression of CK2α and CK2α’ were reduced 45-55% and 
CK2β expression was reduced 50-55% (Appendix B; Supplementary Figure 3.1). We 
assessed whether CK2 silencing affected leucine deprivation-induced IGFBP-1 secretion 
and phosphorylation. Leucine deprivation induced IGFBP-1 secretion (+350%) 
regardless of CK2 status (Figure 3.1A). While leucine deprivation induced IGFBP-1 
phosphorylation (pSer101: +800%, pSer119: +300%, pSer169: +600%), leucine-deprived 
cells also silenced for the CK2 holoenzyme did not phosphorylate IGFBP-1 atany of the 
three sites. IGFBP-1 phosphorylation was not significantly elevated in HepG2 cells 
which were both CK2-silenced and leucine-starved compared to control (leucine plus, 
scrambled siRNA), confirming that leucine deprivation-induced phosphorylation, but not 
secretion, occurs in a CK2-dependent mechanism (Figure 3.1A-D). 
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Figure 3.1. The effect of CK2 holoenzyme (α+α’+β) silencing on leucine deprivation-
induced IGFBP-1 secretion and phosphorylation. Silencing of the CK2 holoenzyme 
attenuates IGFBP-1 phosphorylation induced by leucine deprivation. Representative 
western immunoblots of HepG2 cell media (50 μL per well) treated with scrambled 
siRNA, or siRNA against the CK2 holoenzyme (α+α’+β) in regular leucine plus or 
leucine deprived conditions as assessed for A. IGFBP-1 secretion and B. IGFBP-1 
phosphorylation at Ser101, Ser119 and Ser169. Values are displayed as mean + 
SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-way analysis of 
variance; Dunnet’s Multiple Comparison Test; n=3. Sc:450: Scrambled siRNA, 450 μM 
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leucine. Sc:0: Scrambled siRNA, 0 μM leucine. CK2:450 CK2 holoenzyme (α+α’+β) 
siRNA, 450 μM leucine. CK2:0: CK2 holoenzyme (α+α’+β) siRNA, 0 μM leucine. 
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3.3.2 Inhibition of PKC signaling with Bisindolylmalemide (BIS) 
supports that PKC contributes to the modulation of IGFBP-1 
phosphorylation caused by leucine deprivation 
We use pharmacological PKC inhibitor Bisindolylmalemide (BIS) (7.5 µM) in leucine 
plus or leucine minus conditions in HepG2 cells. A post-treatment Trypan Blue exclusion 
assay demonstrated that the vitality of HepG2 cells was not significantly affected by BIS 
treatments (Appendix B; Supplementary Figure 3.2), confirming that overt cell mortality 
did not contribute to observed changes in total and phosphorylated IGFBP-1 output by 
BIS. We assessed whether inhibition of PKC signaling translated to changes in IGFBP-1 
secretion and phosphorylation under leucine restriction. We demonstrated that leucine 
deprivation induced total IGFBP-1 (+250%) regardless of the presence of BIS (Figure 
3.2A). However, while leucine deprivation potently induced IGFBP-1 phosphorylation 
(pSer101: +800%, pSer119: +300%, pSer169: +600%) it was unable to achieve the same 
effect in the presence of the PKC inhibitor (Figure 3.2B-D). BIS-mediated inhibition of 
PKC signaling decreased IGFBP-1 phosphorylation at all three phospho-sites (pSer101: -
30%, pSer119: -40%, pSer169: -50%), and leucine deprivation-induced changes in 
IGFBP-1 phosphorylation were not significantly different from control in the presence of 
BIS (Figures 3.2B-D). These data suggest that PKC signaling is involved in mediating 
IGFBP-1 phosphorylation under conditions of leucine deprivation. 
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Figure 3.2. Effect of pharmacological pan-PKC inhibitor Bisindolylmaleimide (BIS) 
on IGFBP-1 secretion and phosphorylation.BIS prevents IGFBP-1 phosphorylation in 
leucine deprivation, demonstrated via representative western immunoblots of HepG2 cell 
media indicating A. total IGFBP-1 secretion and B. IGFBP-1 phosphorylation at Ser101, 
Ser119 and Ser169 in control, leucine deprivation, BIS, and leucine deprivation+BIS 
treatments. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 
0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. C:450 Control, 450 μM leucine. C:0: Leucine 
deprivation, 0 μM leucine. BIS:450: Bisindolylmaleimide (7.5 μM), 450 μM leucine. 
BIS:0: Bisindolylmaleimide (7.5 μM), 0 μM leucine. 
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3.3.3 Silencing of PKC confirms that PKC contributes to modulating 
IGFBP-1 phosphorylation caused by leucine deprivation 
To confirm PKC involvement in mediating IGFBP-1 phosphorylation in leucine 
deprivation, we utilized RNAi to specifically knockdown total PKC expression in HepG2 
cells. We utilized non-isoform specific siRNA against PKC (pan-PKC), which targets all 
conventional and novel PKC isoforms (cPKCs: α+βI+βII+γ and nPKCs: δ+ε+η+θ) as 
well as two out of three atypical PKC isoforms (aPKCs: ζ+ν). cPKCs and nPKCs contain 
slight structural differences but, unlike aPKCs, are both equally responsive to 
intracellular activation by diacylglycerols (DAGs) and phorbol esters65. We verified 
efficient PKC silencing via western immunoblot analysis of two representative PKC 
isoforms, nPKCδ and nPKCε, which are known to be down-regulated in nutrient 
deprivation61 and with known prominent expression in HepG2 cells74, as a distinct PKC 
isoforms profile has not been characterized. The expression of both PKCδ and PKCε 
were decreased 50% regardless of leucine status (Appendix B; Supplementary Figure 
3.3).  
We evaluated the effect of PKC silencing on leucine deprivation-induced IGFBP-1 
secretion and phosphorylation. Leucine deprivation induced IGFBP-1 secretion (+450%) 
regardless of PKC status (Figure 3.3A). Conversely, PKC silencing strongly attenuated 
the ability of leucine deprivation to induce IGFBP-1 phosphorylation, which was 
otherwise potently increased (pSer101: +1000%, pSer119: +500%, pSer169: +800%) 
(Figure 3.3B-D). IGFBP-1 phosphorylation was only moderately induced by leucine 
deprivation when PKC was silenced (pSer101: +400%, pSer119: +250%, pSer169: 
+300%). Therefore, silencing of PKC reduces IGFBP-1 phosphorylation in leucine 
deprivation at all three sites (pSer101: -60%, pSer119: -50%, pSer169: -70%). 
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Figure 3.3. Effects of pan-PKC siRNA on IGFBP-1 secretion and phosphorylation in 
leucine deprivation.RNAi-mediated inhibition of PKC mitigates leucine deprivation-
induced IGFBP-1 phosphorylation.A. A representative western immunoblot of total 
IGFBP-1 secretion in equal amounts (50 µL) of cell media treated with scrambled or 
ERK siRNA with and without leucine deprivation. B-D. Representative western 
immunoblots of HepG2 cell media (50 µL) treated with scrambled or pan-PKC siRNA in 
regular or leucine deprived and assayed for IGFBP-1 phosphorylation at Ser101, Ser119 
and Ser169. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p< 
0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3.Sc:450 Scrambled siRNA, 450 μM leucine. 
Sc:0: Scrambled siRNA, 0 μM leucine. PKC: PKC siRNA, 450 μM leucine. PKC:LD: 
PKC siRNA, 0 μM leucine. 
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3.3.4 Inhibition of PKA signaling does not affect IGFBP-1 
phosphorylation in nutrient deprivation 
To investigate whether PKA signaling is involved in regulating IGFBP-1 phosphorylation 
under leucine deprivation, we used selective PKA inhibitor, PKI (100 nM), in HepG2 
cells in leucine plus or leucine minus conditions. We first verified that PKA signaling is 
sensitive to leucine deprivation by demonstrating an increase in Creb (Ser133) 
phosphorylation (+200%), which was subsequently reduced (-75%) in the presence of 
PKI (Figure 3.4A) regardless of leucine status. Figures 3.4B-E indicate that leucine 
deprivation increased IGFBP-1 secretion (+300%) and phosphorylation (pSer101: 
+1000%, pSer119: +500%, pSer169: +750%) whether or not PKA was inhibited. These 
data suggest that PKA inhibition is unable to attenuate IGFBP-1 phosphorylation 
(pSer101, pSer119, pSer169) induced by leucine deprivation, and that PKA does not 
modulate hepatic IGFBP-1 secretion phosphorylation under leucine deprivation. 
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Figure 3.4. Effects of PKI (5-24) inhibition of PKA on leucine deprivation-induced 
IGFBP-1 secretion and phosphorylation.Leucine deprivation induced and PKI 
treatment reduced PKA activity, which was not associated with IGFBP-1 
phosphorylation in leucine deprivation. Representative western immunoblots of HepG2 
cell media indicating A. total and phosphorylated Creb (Ser133) as an indicator of PKA 
activity and B-E. IGFBP-1 secretion and phosphorylation at Ser101, Ser119 and Ser169 
in control, leucine deprivation, PKI, and leucine deprivation+PKI treatments. Values are 
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-
way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM 
leucine. LD: Leucine deprivation, 0 μM leucine. PKI: PKI (5-24) (100 nM), 450 μM 
leucine. PKI:LD: PKI (5-24) (100 nM), 0 μM leucine. 
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3.3.5 CK2 or PKC kinase inhibition prevents decrease in IGF-I 
bioactivity due to IGFBP-1 hyperphosphorylation 
We predicted that prevention of leucine deprivation-induced IGFBP-1 phosphorylation 
by CK2 or PKC inhibition effectively restores IGF-I bioactivity. To asses this, we 
employed our IGF-1 receptor (IGF-1Rβ) autophosphorylation assay in P6 cells to test for 
IGF-1R (pTyr1135) autophosphorylation (Figure 3.5), which we used as a measure of 
IGF-I bioactivity. We assessed IGF-1Rβ autophopshorylatio (pTyr1135) after exposure 
of the P6 cells to conditioned HepG2 cell media from the various inhibitor treatments. P6 
cells over-express IGF-1R but do not express IGF-I56. Addition of 25 ng/mL IGF-I only 
to P6 cell media (positive control) caused a drastic increase in IGF-1R (pTyr1135) 
phosphorylation (a; +2700%) compared to P6 cells incubated in media not supplemented 
with IGF-I (negative control) (Figure 3.5), proving that IGF-I addition successfully 
induces IGF-1R activity in P6 cells. We considered the IGF-1R autophosphorylation 
induced by the addition of IGF-I only (positive control) as 100% activation of the 
receptor. 
P6 cells were also treated with IGF-I (25 ng/mL) in tandem with conditioned media from 
HepG2 cells. Firstly, basal phospho-IGFBP-1 levels (from treatments with 450 µM 
leucine and no inhibitors) was used as a control for the comparison of IGF-1R 
autophosphorylation to other treatments (lane 3). Next, we used HepG2 conditioned cell 
mediafrom cellsthat had been previously deprived of leucine and/or treated with chemical 
ihibitors against CK2 (TBB) or PKC (BIS). The varied volumes of conditioned cell 
media from each treatment used in the assay were adjusted to contain equal amounts of 
total IGFBP-1, ensuring that changes in IGF-1Rβ autophosphorylation in treated P6 cells 
are caused by changes in the degree of phosphorylated IGFBP-1. 
As expected, basal phospho-IGFBP-1 levels (from treatments with 450 µM leucine) 
reduced IGF-1Rβ autophosphorylation (pTyr1135) (b; -45%), regardless of the presence 
of inhibitors, compared to when P6 cells were treated with IGF-I only (positive control) 
(Figure 3.5). The reduction in IGF-1R autophosphorylation by this treatment served as an 
additional positive control for the comparison to pIGFBP-1 levels from other treatments. 
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Further, the elevated phospho-IGFBP-1 in leucine-deprived HepG2 cell media almost 
completely abolished IGF-1Rβ autophosphorylation (pTyr1135) when no inhibitor was 
present in the conditioned cell media (c; -90%) (Figure 3.5). When IGFBP-1 
phosphorylation had been prevented by CK2 inhibition (TBB) or PKC inhibition (BIS) in 
HepG2 cell and the conditioned cell media incubated with P6 cells, IGF-1R activity in P6 
cells remained at basal levels.  
Therefore, when either CK2 or PKC was inhibited (with TBB or BIS, respectively), 
leucine deprivation was unable to decrease IGF-I bioactivity (Figure 3.5). These data 
provide strong evidence that the hyperphosphorylation of IGFBP-1 in leucine deprivation 
attenuates IGF-I bioactivity via diminished IGF-1Rβ autophosphorylation (pTyr1135) 
(Figure 3.5), and that this effect is prevented by CK2 or PKC inhibition. These findings 
are summarized in Table 3.2. 
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Figure 3.5. The effects of CK2 and PKC inhibition of IGFBP-1 phosphorylation on 
IGF-1R autophosphorylation.CK2 or PKC inhibition mitigates leucine deprivation-
induced reduction of IGF-I bioactivity. HepG2 cell media samples were aliquoted to 
contain equal concentrations of IGFBP-1 and buffer-exchanged to serum-free P6 media 
(DMEM/F12 with pyruvate). Aliquots were then incubated with human recombinant 
IGF-I (25 ng/mL) for 2 hours to allow IGFBP-1 binding to IGF-I, followed by a ten 
minute exposure to P6 cells to allow induction of IGF-I-mediated IGF-1Rβ 
autophosphorylation (Tyr1135). The representative western immunoblot of post-
treatment P6 cell lysates (50 μg per lane) assessed for IGF-IRβ autophosphorylation 
(Tyr1135) indicates that leucine deprivation-stimulated IGFBP-1 phosphorylation 
reduced IGF-1R activation, but was unable to elicit this effect in the presence of BIS or 
TBB. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. 
– IGF-I: Negative control, no IGF-I, no IGFBP-1. +IGF-I: Positive control, 25 ng/mL 
IGF-I, no IGFBP-1. C:450: Control, 450 μM leucine. C:0: Leucine deprivation, 0 μM 
leucine. TBB:450: TBB (1 μM), 450 μM leucine. TBB:0: TBB (1 μM), 0 μM leucine. 
BIS:450: Bisindolylmaleimide (7.5 μM), 450 μM leucine. BIS:0: Bisindolylmaleimide 
(7.5 μM), 0 μM leucine. 
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Table 3.2. Summary of various treatments on P6 cells and consequent changes in IGF-
1Rβ autophosphorylation (Tyr1135) as a measure of IGF-I bioactivity. 
Sample Treatment 
Relative IGF-1R 
(Tyr1135) 
autophosphorylation 
Significance Conclusion 
1 -IGF-I P6 CM only 
Baseline IGF-1R 
phosphorylation 
arbitrarily set at 1 
(negative control) 
  
2 +IGF-I P6 CM + IGF-I 
+2700% (positive 
control) 
p<0.001 vs negative 
control 
IGF-I induces IGF-1R 
autophosphorylation 
3 C:450 
*HepG2 CM from leucine 
plus (450 µM) treatment + 
IGF-I 
+1500% (positive 
control) 
p<0.001 vs positive 
control (lane 2) 
Basal pIGFBP-1 levels 
reduce IGF-1R 
autophosphorylation 
compared to when 
there is no IGFBP-1 
present (lane 2) 
4 C:0 
*HepG2 CM from leucine 
minus (0 µM) treatment + 
IGF-I 
+250% 
p<0.001 vs C:450 
(positive control, 
lane 3) 
Leucine deprivation 
reduces IGF-1R 
autophosphorylation 
compare to basal 
pIGFBP-1 levels 
5 TBB:450 
*HepG2 CM from leucine 
plus (450 µM) and TBB  
treatment + IGF-I 
+1500% 
p<0.001 vs positive 
control, n.s. vs C:450 
(positive control, 
lane 3) 
IGFBP-1 
phosphorylation 
prevented by TBB did 
not cause a further 
reduction of IGF-1R 
autophosphorylation in 
leucine deprivation 
6 TBB:0 
*HepG2 CM from leucine 
minus (0 µM) and TBB 
treatment + IGF-I 
+1200% 
p<0.001 vs positive 
control, n.s. vs C:450 
(positive control, 
lane 3) 
7 BIS:450 
*HepG2 CM from leucine 
plus (450 µM) and BIS 
treatment + IGF-I 
+1400% 
p<0.001 vs positive 
control, n.s. vs C:450 
(positive control, 
lane 3) 
IGFBP-1 
phosphorylation 
prevented by BIS did 
not cause a further 
reduction of IGF-1R 
autophosphorylation in 
leucine deprivation 
8 BIS:0 
*HepG2 CM from leucine 
minus (0 µM) and BIS 
treatment + IGF-I 
+1000% 
p<0.001 vs positive 
control, n.s. vs C:450 
(positive control, 
lane 3) 
A tabular summary of various treatments on P6 cells and their effect on IGF-1R 
autophosphorylation (Tyr1135). Addition of IGF-I stimulated IGF-1R phosphorylation. 
All *HepG2 samples contained varied CM volumes that were aliquoted for equal total 
IGFBP-1. Leucine deprivation (4) reduced IGF-1R autophosphorylation to a greater 
extent than leucine plus samples (3) only when TBB or BIS were not present (6, 8). 
CM=conditioned media; *HepG2 CM were buffer-exchanged to P6 cell media prior to 
treatment. One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. 
n.s.=not significant.  
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3.3.6 Inhibition of CK2 (TBB) or PKC (BIS) signaling attenuates 
leucine deprivation-induced CK2 activity 
Utilizing a well-established CK2 activity assay75 as previously45, we assessed the effect 
of leucine deprivation on CK2 activity in HepG2 cell lysates. Leucine deprivation 
increased CK2 activity (+300%) whereas CK2 inhibitor TBB, reduced CK2 activity (-
50%) despite leucine status (Figure 3.6). As anticipated76, PKC inhibitor (BIS) did not 
affect CK2 activity in basal conditions; however, BIS completely obstructed the ability of 
leucine deprivation to induce CK2 activity. We thereby demonstrated that leucine 
deprivation-mediated induction of CK2 activity is PKC-dependent. These data suggest 
that PKC contributes to IGFBP-1 phosphorylation via activating CK2 in leucine 
deprivation, implicating the two kinases in a common mechanism regulating IGFBP-1 
phosphorylation in leucine deprivation. 
 
 
 
 
 
 
 
Figure 3.6. Effects of various inhibitor treatments on CK2 activity.A CK2 activity 
assay demonstrates that leucine deprivation induces CK2 activity, an effect that is 
attenuated by BIS. TBB decreases CK2 activity regardless of leucine status. Values are 
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-
way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C:450: Control, 450 
μM leucine. C:0: Leucine deprivation, 0 μM leucine. TBB:450: TBB (1 μM), 450 μM 
leucine. TBB:0: TBB (1 μM), 0 μM leucine. BIS:450: Bisindolylmaleimide (7.5 μM), 
450 μM leucine. BIS:0: Bisindolylmaleimide (7.5 μM), 0 μM leucine. 
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3.4 Discussion 
In this study, we demonstrate that CK2 and PKC, but not PKA, are involved in mediating 
IGFBP-1 phosphorylation (Ser101, Ser119, Ser169) caused by leucine deprivation in 
HepG2 cells. Inhibition of CK2 or PKC attenuated IGFBP-1 phosphorylation (pSer101, 
pSer119, pSer169) elicited by leucine deprivation without affecting the induction of total 
IGFBP-1. Our findings are consistent with our hypothesis that CK2 and PKC modulate 
hepatic IGFBP-1 phosphorylation in response to leucine deprivation, but contradict our 
prediction that PKA is also implicated in this mechanism. Importantly, we demonstrate 
that inhibition of CK2 or PKC prevented leucine deprivation-induced decreases in IGF-I 
bioactivity via our established40 IGF-1R autophosphorylation assay, illustrating roles for 
both CK2 and PKC in modulating IGF-I bioactivity under amino acid (leucine) restriction 
in vitro. Importantly, we demonstrated that PKC inhibition attenuated leucine 
deprivation-stimulated CK2 activity without affecting CK2 activity in basal conditions, 
suggesting that PKC likely modulates IGFBP-1 phosphorylation by diminishing CK2 
activity in leucine deprivation (Figure 3.6, bar 2 vs. bar 4).  
This study is the first, to our knowledge, to demonstrate roles for both CK2 and PKC in 
modulating fetal hepatic IGFBP-1 phosphorylation in response to leucine deprivation. 
Since the majority of IGF exists in circulation bound to one of the IGFBPs77, fluctuations 
in the relatively low amount of free circulating IGF-I can have dramatic effects on its 
capacity to transduce cell growth and proliferation. As the predominant circulating fetal 
IGFBP during gestation28, the ability of IGFBP-1 to modulate IGF-I bioavailability is 
critical to fetal growth. In utero amino acid deprivation is a hallmark of FGR5,78, and 
acutely influences IGFBP-1 phosphorylation46 and IGF-I bioavailability17,79. IGFBP-1 
phosphorylation is increased in growth-restricted fetuses44, an occurrence specific to 
humans44,80. Reports from our laboratory have demonstrated that human FGR fetuses 
display elevated pIGFBP-1 (pSer101, pSer119 and pSer169) in cord serum45 and in 
amniotic fluid69. Since IGFBP-1 hyperphosphorylation is correlated with reduced IGF-I 
bioactivity in vitro and in vivo, such as determined through an IGF-1R phosphorylation 
assay previously in our lab71, the kinases and phosphatases which phosphorylate and de-
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phosphorylate IGFBP-1, respectively, in leucine deprivation are likely critical in 
modulating IGF-I bioavailability, and potentially contribute to FGR pathogenesis in vivo.  
In previous studies, CK247,49 and PKA47 were proposed to phosphorylate IGFBP-1 when 
the kinases were directly incubated with the purified substrate. However, whether these 
kinases are mechanistically linked to IGFBP-1 phosphorylation within live cells cannot 
be extrapolated from these studies, since other kinases may be elicited under various 
stimuli, such as nutritional stress, to be functionally relevant and impinge on IGFBP-1 
phosphorylation in these circumstances. By inhibiting our kinases of interest and 
measuring IGFBP-1 phosphorylation in conditioned cell media from the same cells, we 
identify direct links between these kinases and IGFBP-1 phosphorylation in live cells.  
We recently illustrated that CK2 is mechanistically linked to IGFBP-1 phosphorylation at 
Ser101, Ser119 and Ser169 by demonstrating decreased phosphorylated IGFBP-1 in 
conditioned cell media from HepG2 cells treated with TBB (CK2 inhibitor)45. Using a 
similar in vitro approach in the current study, we demonstrate that CK2 is a key 
mechanistic link between leucine deprivation and IGFBP-1 phosphorylation. Together 
with our previous45 observations that CK2 activity is elevated in growth-restricted 
baboon hepatocytes in vivo, our findings implicate CK2 as the likely kinase modulating 
IGFBP-1 phosphorylation under amino acid deprivation in FGR. PKA, on the other hand, 
has not been mechanistically linked to IGFBP-1 phosphorylation in live cells. 
Additionally, PKC has not been studied for its explicit role in regulating IGFBP-1 
phosphorylation despite possessing consensus sequence sites for multiple residues on the 
IGFBP-1 molecule (Table 3.1) and its altered expression in FGR placentas68. In addition 
to Ser101, Ser119 and Ser169 which have been demonstrated by our team to be 
hyperphosphorylated in FGR42,45,69, phosphorylation of IGFBP-1 at additional sites such 
as Ser95 and Ser98 which have been previously identified by us and by others46, 70,71 may 
be functionally relevant both independently and through synergistic interactions with 
Ser101, Ser119 and Ser169 in FGR.  
The three phosphorylated residues in IGFBP-1 (Ser101, Ser119, Ser169) in FGR are were 
identified by LC-MS/MS previously in our lab81, and are proximal to acidic amino acids 
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(Table 3.1) adjacent to structured IGF-I-binding (Ser101, Ser169) and in unstructured 
regulatory (Ser119) regions on the IGFBP-1 molecule48, making them conducive to direct 
phosphorylation by CK250,82. In particular, Ser119 and Ser169 contain exact consensus 
sequences for direct phosphorylation by CK2 (Table 3.1). Leucine deprivation induces 
CK2 activity, which likely leads to the kinase directly phosphorylating IGFBP-1 at 
Ser101, Ser119 and Ser169 in HepG2 cells, however, future CK2:IGFBP-1binding 
studies would clarify whether IGFBP-1 is a true CK2 substrate. On the other hand, 
IGFBP-1 is less likely to be directly phosphorylated by PKC at Ser101, Ser119 and 
Ser169, since direct phosphorylation by this kinase requires the proximity of basic amino 
acid residues to the phospho-acceptor site (consensus site: pS/T-X-R/K)82 (Table 3.1). It 
is possible that PKC regulates IGFBP-1 phosphorylation via upstream modulation of 
CK2 activity, since it was demonstrated here that BIS, a PKC-specific inhibitor, prevents 
CK2 induction by leucine deprivation without affecting CK2 activity in basal conditions, 
in concurrence with previous literature reports76(Figure 3.6). It is also possible that PKC 
phosphorylates IGFBP-1 at discrete sites, such as pT50AR and pS58CR (Table 3.1), with 
functional effects on IGFBP-1 activity, which can be investigated in future studies. This 
finding unequivocally links CK2 and PKC signaling in a common signaling network 
specifically in leucine deprivation. It is therefore likely that PKC-mediated IGFBP-1 
phosphorylation occurs via downstream interactions with CK2 in leucine deprivation. 
In our previous reports, phosphorylation at the various Ser residues in IGFB-1 elicited 
variable affects on IGFBP-1 affinity for IGF-I46, and mutations which rendered any of the 
three sites un-phosphorylatable potentiated IGF-I bioactivity, as determined via IGF-1R 
autophosphorylation in HepG2 cells71. However, the exact conformational changes on the 
IGFBP-1 molecule elicited by phosphorylation at Ser101, Ser119 and Ser169 that affect 
its affinity for IGF-I are unknown. It is likely that phosphorylation at Ser101, Ser119 and 
Ser169 function concomitantly to induce conformational changes which increase IGFBP-
1 affinity for IGF-I. To assess this hypothesis, future structural studies on CK2/IGFBP-1 
binding will be valuable. Overall PKC activity is reduced and the expression patterns of 
the various isoforms are altered in cellular nutritional stress59,60,83-85. The isoform-specific 
distribution and functions of PKC are not well understood. Unlike the cPKCs, nPKCs do 
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not contain the C2 regulatory domain; however, the functional relevance of this structural 
difference has not been established65. Comparatively, aPKCs lack the structural 
components of cPKCs and nPKCs that are required for their activation by diacylglycerols 
and phorbal esters, suggesting atypical intracellular regulation of the aPKCs65. Assaying 
the down-regulated expression of all PKCs silenced by siRNA against pan-PKC was not 
realistic in this study. Therefore, we verified efficient PKC knockdown using the 
expression levels of nPKCδ and nPKCε as representatives as measures of the efficiency 
of pan-PKC siRNA, as these isotypes have been established to be predominantly 
expressed in HepG2 cells and have demonstrated to be sensitive to nutritional status61,74. 
Down-regulation of overall PKC activity has been linked to total IGFBP-1 mRNA and 
protein expression64,86,87, although its effects on post-translational regulation of IGFBP-1 
have not been classified. We report for the first time that PKC is involved in modulating 
IGFBP-1 phosphorylation in leucine deprivation, and that PKC function is necessary for 
leucine deprivation to induce CK2 activity in vitro. The placentas of rats with 
glucocorticoid-induced FGR display an altered pattern of PKC isoform expression67. This 
suggests that PKC signaling is dynamically implicated in FGR although the exact role of 
PKC function is FGR has not been established. If PKC modulates CK2 activity in 
growth-restricting conditions in vivo, it is possible that PKC and CK2 are mechanistically 
linked to IGFBP-1 phosphorylation in FGR. 
Although PKA activity is associated with IGFBP-1 phosphorylation in endometrial 
stromal cells44, The inability of PKA inhibition to effectively prevent IGFBP-1 
phosphorylation in HepG2 cells confers specificity to CK2 and PKC in the mediation47 of 
leucine deprivation-stimulated phosphorylation of hepatic IGFBP-1. Therefore, CK2 and 
PKC, but not PKA, may be critical in modulating IGFBP-1 phosphorylation in the fetal 
compartment in FGR. Our results indicate that CK2 and PKC modulate leucine 
deprivation-induced IGFBP-1 hyperphosphorylation at all three sites (pSer101, pSer119 
and pSer169). Whether phosphorylation of Ser101, Ser119 and Ser169 is independently 
regulated or a collection of co-dependent phosphorylation events is a topic for future 
exploration. Similar to our previous results (Chapter 2), we have demonstrated here that 
leucine deprivation most potently stimulates IGFBP-1 phosphorylation at Ser101 and 
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Ser169. During pregnancy, placental alkaline phosphatase de-phosphorylates IGFBP-1 in 
order to increase IGF-I bioavailability88. Therefore, de-phosphorylation of IGFBP-1 may 
be an additional mechanism by which cells modulate IGF-I bioavailability in FGR. 
In conclusion, our present study identifies protein kinases CK2 and PKC as critical 
mediators of IGFBP-1 phosphorylation under nutrient (leucine) deprivation in vitro. 
Taken together with our previous studies45, we speculate that CK2 is the key modulator 
of IGFBP-1 phosphorylation in response to amino acid restriction in FGR. Our novel 
demonstration that PKC is also linked to IGFBP-1 phosphorylation in leucine deprivation 
in vitro, and that PKC inhibition attenuates leucine deprivation-induced CK2 activity, 
illustrates a potential role for PKC signaling in a combined signaling mechanism with 
CK2 in modulating IGF-I bioavailability in FGR. Since leucine deprivation-induced 
decreases in IGF-I bioactivity are prevented by inhibition of CK2 or PKC, our findings 
bare physiological relevance. In vivo, the targeted inhibition of CK2 or PKC activity to 
circumvent amino acid deprivation-induced loss of IGF-I bioactivity may be valuable. By 
linking CK2 and PKC in a common mechanism modulating IGFBP-1 phosphorylation in 
leucine deprivation in vitro, we are one step closer to unraveling the molecular 
mechanisms underlying in utero FGR. 
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Chapter 4 
4 Summary and Conclusions 
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4.1 Summary of Findings 
Amino acid (leucine) deprivation stimulated IGFBP-1 phosphorylation at Ser101, Ser119 
and Ser169 in all experiments conducted in HepG2 cells (Chapters 2 and 3), as 
anticipated from previous reports1. However, the molecular mechanisms modulating 
hepatic IGFBP-1 phosphorylation in leucine deprivation had previously remained elusive. 
Through selective manipulation of the mTOR and AAR signaling cascades (Chapter 2) as 
well as protein kinases CK2, PKC and PKA (Chapter 3) in leucine deprived conditions, 
we have successfully shed light on the signaling pathways linking reduced leucine supply 
to stimulated IGFBP-1 phosphorylation in vitro. These findings contribute insight to how 
nutrient deprivation leads to decreased fetal growth, by way of increased IGFBP-1 
phosphorylation, in FGR. 
In Chapter 2, we show that manipulation of hepatic amino acid-sensing mTOR and AAR 
pathways variably affected the ability of leucine deprivation to elicit IGFBP-1 
phosphorylation. Based on previous findings by our group that mTOR modulates IGFBP-
1 phosphorylation in baboon fetal hepatocytes from a primate model for FGR2, and 
considering that mTOR is critically involved in placental nutrient sensing and is highly 
sensitive to amino acid status3, we had initially hypothesized that mTORC1+C2 signaling 
was the primary mechanism by which IGFBP-1 phosphorylation is induced under leucine 
deprivation. We demonstrated that the fetal hepatic (HepG2) mTOR pathway was indeed 
down-regulated by leucine restriction, as expected; however, this was linked to only a 
partial induction of the IGFBP-1 phosphorylation otherwise caused by leucine 
deprivation. We concluded that mTOR signaling only partially modulated IGFBP-1 
phosphorylation under leucine deprivation because although leucine deprivation reduces 
mTORC1+C2 activity, it stimulates IGFBP-1 phosphorylation to a greater extent than 
mTORC1+C2 inhibition by itself. Importantly, although leucine deprivation and mTOR 
inhibition both separately induced IGFBP-1 phosphorylation to different extents, their 
effects were not cumulative when combined. This observation suggested that mTOR-
mediated induction of IGFBP-1 phosphorylation occurred in a common mechanism with 
leucine deprivation.  
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We verified our findings via constitutive activation of mTORC1+C2 by DEPTOR 
silencing, which resulted in the inability of leucine deprivation to inhibit mTORC1+C2 
activity. This prevented leucine deprivation from eliciting IGFBP-1 secretion; however, 
IGFBP-1 phosphorylation (Ser101, Ser119 and Ser169) was nevertheless induced by 
leucine deprivation. These observations confirmed that although mTOR is a key mediator 
of IGFBP-1 secretion under leucine restriction, there was a need to explore additional 
cellular mechanisms that the cell may rely on to induce IGFBP-1 phosphorylation under 
nutritional stress. 
The observation that alternate mechanisms in addition to mTOR are elicited by leucine 
deprivation to induce IGFBP-1 phosphorylation prompted the investigation of the AAR. 
The AAR is a specific cellular response to restricted amino acid availability4, and is 
known to be systemically involved in mediating the stress response to nutritional 
insufficiency to down-regulate overall cell growth and proliferation, making it a likely 
candidate for modulation of IGFBP-1 phosphorylation under leucine deprivation. Due to 
the commercial unavailability of specific pharmacological inhibitors against the AAR, 
our primary investigation of the AAR relied on its cross-talk with MEK/ERK signaling. 
MEK/ERK signaling is necessary for the propagation of the AAR by GCN25, the 
exclusive nutrient sensor to the AAR4. We chemically inhibited MEK/ERK signaling 
with pharmacological inhibitor U0126 in order to wholly mitigate the activity of this 
specific MKK/MAPK arm of the MKKK signaling cascade6. We successfully 
demonstrated that U0126 was able to attenuate the AAR downstream of GCN2 and that 
this fully obstructed the ability of leucine deprivation to induce IGFBP-1 phosphorylation 
(Ser101, Ser119 and Ser169). We confirmed and validated these findings with ERK1/2 
siRNA, which was conducted separately and combined with GCN2 siRNA in order to 
conclusively determine whether leucine deprivation-mediated IGFBP-1 phosphorylation 
occurs via the AAR. This led to our experiment where we silenced ERK1/2 and GCN2 in 
tandem, and proved that the ability of MEK/ERK to modulate IGFBP-1 phosphorylation 
under leucine deprivation is, in fact, due to its participation in the AAR.  
In Chapter 3, we surveyed various kinases speculated to modulate IGFBP-1 
phosphorylation for their ability to mediate IGFBP-1 phosphorylation in leucine 
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deprivation.The molecular mechanisms regulating IGFBP-1 phosphorylation, especially 
under nutrient depletion, are largely unexplored in the literature. CK2, PKC, and PKA 
have been suggested to phosphorylate IGFBP-17. Specifically, our sites of interest 
(pSer101, pSer119, pSer169) are likely to be directly phosphorylated by CK27 due to 
surrounding acidic amino acid residues to the phospho-acceptor sites. Recent success by 
our team in demonstrating that that CK2 modulates IGFBP-1 phosphorylation in HepG2 
cells and primary baboon hepatocytes2 motivated this investigation. We presupposed that 
inhibiting CK2, but not PKC or PKA, in leucine deprivation would attenuate leucine 
deprivation-induced IGFBP-1 phosphorylation and that this would extend our previous2 
observations that CK2 is the key kinase involved in IGFBP-1 phosphorylation in nutrient 
restricted conditions. First, using pharmacological inhibitor TBB against CK2, we 
demonstrated that CK2 inhibition obstructed the ability of leucine deprivation to induce 
IGFBP-1 phosphorylation. In these same samples, we verified that TBB reduced CK2 
activity regardless of leucine status, which otherwise stimulated CK2 activity. The ability 
of TBB to attenuate IGFBP-1 phosphorylation was independent of overall IGFBP-1 
secretion, since total IGFBP-1 output was elevated in leucine deprivation despite the 
presence of TBB. Follow-up siRNA experiments against CK2(α+α’+β) proved that CK2 
is essential for leucine deprivation to stimulate IGFBP-1 phosphorylation at all three sites 
(Ser101, Ser119 and Ser169).  
Chemical inhibition of PKA was unable to alter IGFBP-1 phosphorylation in HepG2 cells 
regardless of leucine status. However, PKC inhibition or silencing was demonstrated 
here, for the first time, to not only modulate hepatic IGFBP-1 phosphorylation but to also 
coordinate this event under leucine deprivation (Chapter 3). Unlikely to be a direct kinase 
for the phosphorylation of IGFBP-1 at our sites of interest (pSer101, pSer119 and 
pSer169)7, we assessed whether the ability of PKC to modulate IGFBP-1 phosphorylation 
was due to mechanistic cross-talk with CK2. Our CK2 activity assay verified that PKC 
inhibition with BIS prevented the ability of leucine deprivation to induce CK2 activity, 
although BIS did not affect CK2 activity under basal conditions, as expected8. The 
finding that CK2 likely phosphorylates IGFBP-1 downstream of PKC in leucine 
deprivation is the first report of potential interactions between PKC and CK2 in HepG2 
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cells. Finally, to attribute functional relevance to our findings, we used our previously 
established9 IGF-1R autophosphorylation assay to demonstrate that changes in phospho-
IGFBP-1 content in conditioned media variably affected IGF-I bioactivity. 
Table 4.1. Summary of various treatments on IGFBP-1 secretion and 
phosphorylation. 
Treatment  
Effect on 
intracellular 
signaling  
Figure 
Reference  
IGFBP-1 
Secretion  
IGFBP-1 
Phosphorylation  
Figure 
reference  
mTOR pathway  
Rapamycin  
mTORC1+C2 
inhibition  
Figures 
2.1A-B  
 No significant 
effect  
Figures 2.1C-F  
Raptor+Rictor 
siRNA  Figures 
2.2A-B  
Figures 2.2C-F  
DEPTOR 
siRNA  
mTORC1+C2 
activation   
AAR pathway  
U0126  
AAR pathway 
inhibition  
Figures 
2.3A-D  
  
Figures 2.3E-H  
ERK siRNA  
Figures 
2.4A-C  
Figures 2.4D-G  
GCN2 siRNA  
Figures 
2.5A-B 
Figures 2.5C-F  ERK+GCN2 
siRNA  
Kinase Treatments 
TBB 
CK2 inhibition 
Figure 3.7 
No 
significan
t effect 
 
Figures 3.1A-D 
CK2α+α’+β 
siRNA 
N/A Figures 3.2A-D 
BIS 
PKC inhibition 
N/A Figures 3.3A-D 
pan-PKC 
siRNA 
N/A Figures 3.4A-D 
PKI (5-24) PKA inhibition Figure 3.5A No significant effect Figures 3.5B-E 
mTOR signaling modulates IGFBP-1 secretion but not phosphorylation caused by leucine 
deprivation. The AAR regulates both IGFBP-1 secretion and phosphorylation in leucine 
deprivation. CK2 and PKC are key kinases involved in modulating IGFBP-1 
phosphorylation in leucine deprivation. 
163 
 
 
 
Loading controls for secretory proteins 
A recurring concern in this study, as well as in the literature, is a lack of a consistent 
loading control for western blots of secretory proteins in conditioned cell media. β-actin 
served as a reliable loading control for western blots of whole cell lysates throughout this 
study, however, treatment-dependent fluctuations in IGFBP-1 secretion and 
phosphorylation were determined with western blots using conditioned media from 
HepG2 cell cultures, which have not been previously demonstrated to secrete any protein 
in a consistent quantity irrespective of treatments. Reversible stains for total protein, such 
as Ponceau stains, are not well accepted tools for the detection of equal loading between 
lanes due to their lack of sensitivity and specificity of the bands being stained10,11. 
Proteins that are enriched in conditioned media compared to lysatesamples are specific to 
cell-type and may be used as quality controls for western blots12. To improve the validity 
of our western blots, we speculated as to which HepG2 secreted protein could serve as a 
reliable loading control. Based on the HepG2 secretome13, which indicates that 
fibrinogen is synthesized and secreted in high quantities by HepG2 cells13-15 we evaluated 
whether fibrinogen could serve as an effective loading control for western blots of our 
conditioned HepG2 cell media.  
Due to the observation that fibrinogen secretion remained consistent among treatments 
regardless of the presence of inhibitor, fibrinogen output served as a valuable tool to 
ensure equal loading among lanes (Appendix D; Supplementary Figure 4.4). A 
representative western blot of conditioned media from leucine plus, leucine minus, and 
combined leucine plus/minus treatments with the various inhibitors that affect IGFBP-1 
phosphorylation used in this study (TBB, BIS, PKI, U0126) was probed with primary 
antibody against pSer101 (IGFBP-1), total IGFBP-1, and fibrinogen. Fibrinogen 
secretion remained consistent among all treatments irrespective of inhibitor-induced 
fluctuations in IGFBP-1 secretion or phosphorylation. Therefore, we verified that the 
differences in IGFBP-1 secretion and phosphorylation elicited by inhibitor treatments are 
independent of total loaded conditioned media (Appendix D). 
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4.2 Extensions, Perspectives and Significance 
The bioinhibitory capacity of IGFBP-1 on IGF-I is widely acknowledged. For example, 
IGFBP-1 impedes IGF-I-dependent amino acid transport16 and DNA synthesis17,18. The 
capacity of phosphorylated IGFBP-1to bind and sequester IGF-I is greater than that of the 
un-phosphorylated isoform19,20, suggesting that IGFBP-1 hyperphosphorylation bears 
significant functional relevance in the context of IGF-I bioactivity. The extent to which 
leucine deprivation induced IGFBP-1 phosphorylation (up to 2500%) in this study far 
superseded the extent to which leucine deprivation induced overall IGFBP-1 secretion 
(maximum observed 500% induction), demonstrating the impact leucine restriction has 
on mitigating IGF-I bioactivity through regulating its binding protein. This observation 
justifies why the identification of the signaling mechanisms which link leucine 
deprivation to IGFBP-1 hyper-phosphorylation is absolutely critical in understanding the 
regulation of IGF-I bioactivity under amino acid restriction. 
The finding that mTOR mediates IGFBP-1 secretion but is only partially responsible for 
IGFBP-1 phosphorylation in leucine deprivation, combined with the observation that 
CK2 or PKC inhibition prevents IGFBP-1 phosphorylation without affecting its overall 
secretion in leucine deprivation, demonstrates that the molecular mechanisms elicited by 
leucine deprivation to regulate IGFBP-1 phosphorylation are independent of those which 
Figure 4.2. Schematic of established mechanistic links between leucine deprivation and total and 
phospho-IGFBP-1. 
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modulate its total secretion. This clear illustration of a bipartite mode of regulation for 
IGFBP-1 secretion compared to its phosphorylation under leucine restriction suggests 
that IGFBP-1 phosphorylation occurs as an independent cellular response to nutritional 
stress. This finding has functional relevance in FGR, which our team has 
previouslyassociated with hyperphosphorylated IGFBP-1 in both maternal22 and fetal2 
compartments. Linking CK2 and PKC – which were identified in this study to modulate 
IGFBP-1 phosphorylation in leucine deprivation – to the AAR will be valuable in 
elucidating the specific cellular response toamino acid deprivation to phosphorylate 
IGFBP-1in vitro. Identification of the signaling mechanisms modulating IGFBP-1 
phosphorylation in this study lays the groundwork forfuture investigation on the roles of 
these specific signaling mechanisms in modulating IGFBP-1 phosphorylation in amino 
acid deprivationin vivo. If IGFBP-1 phosphorylation is modulated in vivo by the same 
molecular components identified in this study, these pathways may serve as candidatesfor 
future studies aimed at identifying targets for manipulation to offset IGFBP-1 
phosphorylation in FGR.  
The ultimate goal of the AAR is to arrest anabolic activity in favour of energy 
preservation upon amino acid restriction23. Induced ATF4 expression is not exclusive to 
amino acid deprivation – in fact, ATF4 is a conjunction point for multiple stress-
responsive pathways such as the Unfolded Protein Response (UPR) and elicits stressor-
specific gene programs. The gene expression profiles elicited by ATF4 from the AAR 
(via GCN2 sensing) and UPR are mutually exclusive, although there is a significant 
degree of overlap23. The mechanism by which ATF4 discriminates between multiple 
upstream signals is not understood. Thus, our rationale for silencing GCN2 rather than 
eIF2α or ATF4 is the specificity of GCN2 to the AAR. Although the AAR was 
demonstrated to be indispensable in modulating IGFBP-1 phosphorylation in leucine-
deprived HepG2 cells (Chapter 2), it is likely that the AAR coordinates withadditional 
signaling mechanisms down-stream, including mTOR, in order to transduce its effects. It 
is possible that the AAR and mTOR signaling pathways impinge on each other 
downstream to modulate leucine deprivation-induced IGFBP-1 secretion and 
phosphorylation in a common mechanism. Indeed, the mTOR and AAR pathways exhibit 
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a knownconvergence point: DNA damage response 1 (REDD1). GCN2-mediated eiF2α 
phosphorylation induces REDD124, an essential component of the mTOR signaling 
cascade25, thereby coordinating the two pathwaysdownstream. Another mode of 
convergence may, in fact, be CK2, which has shown to interact with ATF426,27, possibly 
linking the nutrient-responsive kinase with the AAR. Future studies to elucidate the 
interaction between the AAR and mTOR pathways in vitro will provide further 
insight into the mechanisms modulating IGFBP-1 phosphorylation.  
Previous work by our lab2 has linked mTOR signaling and CK2 kinase activity in the 
regulation of hepatic IGFBP-1 phosphorylation. The studies presented here demonstrate 
that additional mechanisms to mTOR and CK2 are implicated in IGFBP-1 
phosphorylation in amino acid deprivation. The cellular response to nutritional stress is 
dynamic. For instance, the AAR (Chapter 2) and PKC (Chapter 3) were discovered, for 
the first time, to play pivotal roles in IGFBP-1 phosphorylation in leucine-restricted 
conditions in vitro. The ability of PKC to mediate IGFBP-1 phosphorylation at Ser101, 
Ser119, and Ser169 while simultaneously modulating CK2 activity in leucine deprivation 
illustrates a novel role for PKC in modulating IGFBP-1 phosphorylation. Together, our 
findings demonstrate that the regulation of IGF-I bioactivity via phosphorylation of its 
binding protein is dynamic and influenced by multiple signaling pathways. 
Combined with previous in vitro studies demonstrating that CK2 directly phosphorylates 
IGFBP-1 in HepG2 cells28 and past work in our lab which linked CK2 activity with 
IGFBP-1 phosphorylation in fetal hepatocytes from MNR baboon mothers2, our findings 
suggest that CK2 is the key kinase responsible for directly phosphorylating fetal hepatic 
IGFBP-1 in amino acid deprivation. The contribution of PKC to IGFBP-1 
phosphorylation had not been previously reported, although its role in regulating IGFBP-
1 at the transcriptional and translational level has been studied32-34. PKC does not contain 
consensus sequence sites for phosphorylation at IGFBP-1 at Ser101, Ser119 and Ser169, 
although it does contain consensus sequence sites for IGFBP-1 phosphorylation at Ser50 
and Ser58. It is possible that PKC-mediated phosphorylation at these discrete sites 
contributes to modulating IGFBP-1 affinity for IGF-I independently or through 
synergistic effects with Ser101, Ser119 and Ser169. Future studies employing mass 
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spectrometry will be valuable in assessing the phosphorylation of IGFBP-1 at these sites 
in leucine deprivation. Considering the greater likelihood that IGFBP-1 at Ser101, Ser119 
and Ser169 is phosphorylated by CK2 due to surrounding amino acid residues on IGFBP-
1, our finding that PKC modulates IGFBP-1 phosphorylation at these sites in leucine 
deprivation warranted exploration of the interaction between PKC and CK2 in leucine 
deprivation. Our CK2 activity assay which demonstrated that PKC inhibition attenuated 
leucine deprivation-induced CK2 activitysuggested that the effect of PKC on IGFBP-1 
phosphorylation (Ser101, Ser119 and Ser169) is likely due to an upstream link in a 
common signaling mechanism with CK2 in leucine deprivation. PKC and CK2are both 
implicated downstream of mTOR signaling, however, whether PKC directly modulates 
CK2 or whether other molecular components are implicated is not known. It is possible 
that CK2 activity is regulated downstream of PKC in leucine deprivation, and is an 
attractive area for future in vitro research in HepG2 cells.  
To reduce overall PKC signaling, we used pharmacological inhibitor BIS which inhibits 
all 12 PKC isoforms31or pan-PKC siRNA.It is possible that specific PKC isoforms, rather 
than overall PKC activity, are specifically implicated in CK2-mediated IGFBP-1 
phosphorylation. Future in vitro can be conducted in HepG2 cells to assess isoform-
specific roles of PKC in modulating IGFBP-1 in leucine deprivation using targeted 
RNAiagainst specific PKC isoforms.  
The mechanism by which pSer101, pSer119 and pSer169 elicit conformational 
changes on the IGFBP-1 molecule to contribute to increased affinity of IGFBP-1 for 
IGF-I is presently unknown. The complete 3D structure of IGFBP-1 has yet to be 
resolved35. Ser101 and Ser169 are proximal to structured, IGF-I binding regions in 
the quaternary protein structure while Ser119 is contained within the protein’s 
mobile linker region45. Covalent modifications at these sites likely cause 
conformational changes that influence IGFBP-1 interactions with IGF-I. It is notable 
that IGFBP-1 phosphorylation protects it from proteolytic cleavage36,thus increasing 
the compound’s half-life. The induction of phosphorylation at Ser101, Ser119 and 
Ser169 in leucine deprivation suggests that the collective contribution of 
phosphorylation at each of the three sites is essential in modulating IGF-I 
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bioavailability compared to phosphorylation at any site alone. Previously published 
data from our lab demonstrated that IGFBP-1 individually mutated at any of the three 
studied phospho-acceptor sites (Ser101Ala, Ser119Ala and Ser169Ala) affect the 
ability of IGFBP-1 to modulate IGF-I bioavailability9, validating the functional 
relevance of phosphorylation at these three sites. The existence of multiple 
phosphorylated IGFBP-1 residues highlights the importance of potential synergistic 
effects between the various phosphorylated residues. The observation that 
phosphorylation at Ser101, Ser119 and Ser169 was prone to inhibition by all 
biological and chemical treatments in this study suggests that the regulation of 
phosphorylation at each of the residues is implicated in a common signaling 
mechanism. It is ascertainable that phosphorylation of a particular phospho-site can 
lead, either directly or indirectly, to the phosphorylation of the other residues. 
Finally, future molecular modeling studies of phosphorylated IGFBP-1 may be 
valuable to demonstrate how the individual and combined phosphorylation of 
Ser101, Ser119 and Ser169 elicits conformational changes to IGFBP-1 structure to 
directly contribute to IGF-I affinity. 
Significance and Future Directions 
By elucidating the relative contributions of the mTOR and AAR signaling pathways and 
CK2, PKC, and PKA kinases in regulating IGFBP-1 phosphorylation under leucine 
deprivation, this study has contributed vital pieces to the understanding of IGFBP-1 
phosphorylation in vitro. Our findings provide justification for future investigation into 
the mechanistic links between the various molecular components shown here to modulate 
IGFBP-1 phosphorylation in leucine deprivation. For example, it is unknown whether 
PKC and CK2 mediated IGFBP-1 phosphorylation is coordinated downstream of the 
AAR in a common signaling mechanism. It is also yet to be determined the precise 
mechanism by which PKC modulates IGFBP-1 phosphorylation at three sites for which it 
does not share consensus sequences (Ser101, Ser119, Ser169). PKC may modulate 
IGFBP-1 phosphorylation through synergistic effects of phosphorylation at descrete 
residues or via direct modulation of CK2 activity. The next step would be to replicate 
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these findings in in vivo models, such as our lab’s established primary fetal baboon 
hepatocytes, in order to further attribute functional significance to our findings. 
Due to the variety of factors which contribute to fetal development43,44, the appropriate 
functioning of intracellular signaling mechanisms which modulate fetal growth is 
paramount to healthy fetal development. Several intracellular signaling pathways impinge 
on one another, and abrogation in any component of this molecular web can lead to 
altered fetal growth. Decoding the signaling pathways involved in IGFBP-1 
phosphorylation in amino acid-restricted conditions in vitro will provide clues as to the 
signaling mechanisms implicated in the pathogenesis of FGR in utero. The idea that adult 
morbidity has “developmental origins” has strong implications on public health and 
disease prevention37, and we hope that the findings from this study will set the 
groundwork for future studies aimed at elucidating the pathogenesis of FGR. 
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Supplementary Figure 2. 1. Efficiency of raptor+rictor and DEPTOR silencing. A 
representative immunoblot of HepG2 cell lysates (50 μg per lane) assayed for raptor, 
rictor, or DEPTOR expression following siRNA silencing. A-B. Raptor+rictor silencing 
significantly reduced the expression of raptor (-45-50%) and rictor (-50%) regardless of 
leucine status, but did not affect DEPTOR expression. C. DEPTOR expression was 
reduced (-50%) in HepG2 cells treated with siRNA against DEPTOR, but not against 
raptor+rictor. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 
0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. Sc: Scrambled siRNA, 450 μM leucine. 
Sc:LD: Scrambled siRNA, 0 μM leucine. RR: Raptor+Rictor siRNA, 450 μM leucine. 
RR:LD: Raptor+Rictor siRNA, 0 μM leucine. D: DEPTOR siRNA, 450 μM leucine. 
D:LD: DEPTOR siRNA, 0 μM leucine. 
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Supplementary Figure 2. 2. HepG2 cell vitality after treatment with U0126 (10 μM) 
for 24 hours. A graphical representation of cell vitality between leucine plus or leucine 
deprived with or without U0126 treatments. A Trypan Blue exclusion assay was 
performed to assess cell viability, presented here as a percentage of live cells/total cells 
normalized to viability in control samples (leucine plus, no inhibitor). Leucine 
deprivation and the U0126 inhibitor did not separately or together significantly affect cell 
survival. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. 
C: Control, 450 μM leucine. LD: Leucine deprivation, 0 μM leucine. U: U0126 (10 μM), 
450 μM leucine. U:LD: U0126 (10 μM), 0 μM leucine. 
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Supplementary Figure 2. 3. Efficiency of ERK silencing. A representative western 
immunoblot of total ERK expression in HepG2 cell lysates silenced with scrambled or 
ERK siRNA with or without leucine deprivation. Equal protein loading (50 μg per lane) 
was conducted. Total ERK expression was reduced (-40%) in cells treated with ERK 
siRNA, and remained unaffected in cells treated with scrambled siRNA. Values are 
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-
way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. Sc: Scrambled 
siRNA, 450 μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine. ERK: ERK1/2 siRNA, 
450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM leucine. 
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Supplementary Figure 2. 4. Efficiency of GCN2, ERK, and GCN+ERK silencing. 
Representative immunoblots of HepG2 cell lysates (50 μg per lane) assayed for GCN2 or 
ERK expression following siRNA silencing. A. GCN2 silencing significantly reduced the 
expression of GCN2 (-50%) regardless of leucine status when GCN2 was silenced alone 
or in combination with ERK, and was unaffected when only ERK was silenced. B. ERK 
expression was reduced (-40%) in HepG2 cells treated with siRNA against ERK whether 
or not GCN2 was also silenced. GCN2 silencing had no significant effect on ERK 
expression and this effect was consistent in leucine plus or leucine deprived samples. 
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus 
control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. Sc: 
Scrambled siRNA, 450 μM leucine. Sc:LD: Scrambled siRNA, 0 μM leucine. GCN2: 
GCN2 siRNA, 450 μM leucine. GCN2:LD: GCN2 siRNA, 0 μM leucine. ERK: ERK1/2 
siRNA, 450 μM leucine. ERK:LD: ERK1/2 siRNA, 0 μM leucine. GCN2:ERK: 
GCN2+ERK1/2 siRNA, 450 μM leucine. GCN2:ERK:LD: GCN2+ERK1/2 siRNA, 0 μM 
leucine. 
A 
B 
178 
 
 
 
 
Appendix A 
C LD TBB TBB:LD
0.0
0.2
0.4
0.6
0.8
1.0
1.2
C
e
ll
 V
it
a
li
ty
(a
rb
it
ra
ry
 u
n
it
s
)
 
 
Supplementary Figure 2. 5. HepG2 cell vitality after treatment with TBB (1 μM) for 
24 hours.A graphical representation of cell vitality between leucine plus or leucine 
deprived with or without TBB treatments. A Trypan Blue exclusion assay was performed 
to assess cell viability, presented here as a percentage of live cells/total cells normalized 
to viability in control samples (leucine plus, no inhibitor). Leucine deprivation and the 
TBB inhibitor did not separately or together significantly affect cell survival. Values are 
displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 versus control; One-
way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM 
leucine. LD: Leucine deprivation, 0 μM leucine. TBB: TBB (1 μM), 450 μM leucine. 
TBB:LD: TBB (1 μM), 0 μM leucine. 
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Supplementary Table 2. 1. Comprehensive overview of assayed proteins. 
Protein 
Fraction 
assayed 
Component 
tested 
Phosphosite(s) Indicates 
AAR pathway 
GCN2 
HepG2 
cell lysate 
Phosphorylation 
Thr898 
AAR pathway activation 
eIF2α Ser51 
ERK Thr202/Tyr204 
ATF4 Expression N/A 
mTOR pathway 
Raptor 
HepG2 
cell lysate 
Expression N/A 
siRNA silencing 
efficiency 
Rictor 
DEPTOR 
p70-S6K 
Phosphorylation 
Thr389 mTORC1 activity 
Akt Ser473 mTORC2 activity 
IGFBP-1 (total and phosphorylated) 
IGFBP-1 
HepG2 
cell media 
Secretion and 
Phosphorylation 
Ser101, Ser119, 
Ser169 
IGF-I bioactivity 
IGF-1Rβ 
P6 cell 
lysate 
Phosphorylation Tyr1135 
Other 
β-actin 
HepG2 
and P6 
cell lysate 
Expression N/A 
Equal protein loading of 
cell lysates 
A tabular representation of the various proteins assessed for expression and 
phosphorylation in this manuscript, fractions assayed, phosphosites, and implications in 
mTOR, AAR and IGFBP-1 regulation. 
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Supplementary Figure 3. 1. Efficiency of CK2α+α’+β silencing. Representative 
immunoblots of HepG2 cell lysates (50 μg per lane) demonstrateknockdown efficiencies 
of CK2α+α’+β subunits. CK2α, CK2α’and CK2β expression were decreased (-45-55%) 
regardless of leucine status in HepG2 cells treated with siRNA against all three CK2 
subunits. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.001 
versus control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=3. . 
Sc:450: Scrambled siRNA, 450 μM leucine. Sc:0: Scrambled siRNA, 0 μM 
leucine.CK2:450CK2 siRNA, 450 μM leucine. CK2:0: GCN2 siRNA, 0 μM leucine. 
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Supplementary Figure 3. 2. HepG2 cell vitality after treatment with BIS (7.5 μM) 
for 24 hours. A graphical representation of cell vitality between leucine plus or minus 
treatments with or without BISs. A Trypan Blue exclusion assay was conducted to assess 
cell viability, illustrated as the ratio of live to total cells. Values are normalized to 
viability in control samples (leucine plus, no inhibitor). BIS inhibitor did not compromise 
cell survival. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 
0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. C: Control, 450 μM leucine. LD: Leucine 
deprivation, 0 μM leucine. BIS: Bisindolylmaleimide (7.5 μM), 450 μM leucine. BIS:LD: 
Bisindolylmaleimide (7.5 μM), 0 μM leucine. 
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Supplementary Figure 3. 3. Efficiency of pan-PKC silencing. A representative 
immunoblot of HepG2 cell lysates (50 μg per lane) assayed for PKCδ and PKCε 
expression following siRNA silencing of pan-PKC. The expression of A. PKCδ and B. 
PKCε were both reduced (-50%) regardless of leucine status by pan-PKC siRNA in 
HepG2 cells.Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 
0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. Sc:450: Scrambled siRNA, 450 μM leucine. 
Sc:0: Scrambled siRNA, 0 μM leucine. PKC:450 pan-PKC siRNA, 450 μM leucine. 
PKC:0: pan-PKC siRNA, 0 μM leucine. 
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Supplementary Figure 4. 1. Dose-dependent changes in IGFBP-1 phosphorylation 
with U0126. A significant decrease in IGFBP-1 phosphorylation was seen at 16µM 
U0126 which remained consistent at approximately twice the inhibitor concentration (30 
µM). A middle concentration between 5µM and 16µM U0126 (10 µM) was used in 
subsequent experiments.Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-
0.05, ***p < 0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. 
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Supplementary Figure 4. 2. Dose-dependent changes in IGFBP-1 phosphorylation 
with Bisindolylmaleimide (BIS). A significant decrease in IGFBP-1 phosphorylation 
was seen at 10 µM BIS which remained consistent at twice the inhibitor concentration 
(20 µM). A middle concentration between 5µM and 10µM BIS (7.5 µM) was used in 
subsequent experiments.Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-
0.05, ***p < 0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. 
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Supplementary Figure 4. 3. Dose-dependent changes in IGFBP-1 phosphorylation 
with PKI (5-24). PKI did not reduce IGFBP-1 secretion (i) or phosphorylation (ii-iv) in 
basal conditions. Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p 
< 0.001 versus control; One-way analysis of variance; 
Dunnet’s Multiple Comparison Test; n=3. 
N.B. PKI (5-24) (IC50=22 nM)
ahas been used in concentrations up to 2 µM in HepG2 
cellsb. We used conservative doses of PKI to assess the ability of PKA to phosphorylate 
IGFBP-1. As PKI was unable to diminish IGFBP-1 phosphorylation in basal conditions 
at the assayed doses, we employed the maximal surveyed dose (100 nM) in our 
subsequent assessment of IGFBP-1 phosphorylation in leucine deprivation. 
ade Boer AR, Letzel T, Lingeman H, Irth H. Systematic development of an enzymatic phosphorylation assay compatible with mass 
spectrometric detection. Anal Bioanal Chem. 2005;381(3):647-655. 
bCitterio C, Jones HD, Pacheco-Rodriguez G, Islam A, Moss J, Vaughan M. Effect of protein kinase A on accumulation of brefeldin 
A-inhibited guanine nucleotide-exchange protein 1 (BIG1) in HepG2 cell nuclei. Proc Natl Acad Sci U S A. 2006;103(8):2683-2688. 
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Supplementary Figure 4. 4. Fibrinogen as a loading control in conditioned media. 
Representative aliquots (30 μL) of HepG2 cell media from leucine plus and leucine 
minus treatments, with and without the various inhibitors used in this study (TBB, PKI, 
BIS, U0126), were probed with primary antibody against fibrinogen. Fibrinogen 
secretion remained consistent among treatments regardless of total IGFBP-1 secretion 
and IGFBP-1 phosphorylation.  
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